



STATE OF MARYLAND

DHMH

Maryland Department of Health and Mental Hygiene
201 W. Preston Street • Baltimore, Maryland 21201

Martin O'Malley, Governor – Anthony G. Brown, Lt. Governor – Joshua M. Sharfstein, M.D., Secretary

JUN 21 2011

The Honorable Martin O'Malley
Governor
State of Maryland
Annapolis, MD 21401-1991

The Honorable Thomas V. Mike Miller, Jr.
President of the Senate
H-107 State House
Annapolis, MD 21401-1991

The Honorable Michael E. Busch
Speaker of the House
H-101 State House
Annapolis, MD 21401-1991

Re: HB 935 (Chap. 203) of the Acts of 2003 and Health-General Article, Section 13-1104 (e)
2010 Cigarette Restitution Fund Revised Cancer Report

Dear Governor O'Malley, President Miller and Speaker Busch:

Pursuant to Health-General Article, Section 13-1104 (e), Annotated Code of Maryland, the Department of Health and Mental Hygiene is directed to produce a biennial report on the cancers targeted under the Cigarette Restitution Fund Program's Cancer Prevention, Education, Screening, and Treatment Program. Enclosed is the revised Cigarette Restitution Fund (CRF) Program Cancer Report for 2010. This report includes the most currently available Maryland data on cancer incidence and mortality for 2007 and replaces the version issued in December 2010 as mortality data was not available at the time.

I hope you find this information useful. If you have questions about this report, please contact Ms. Courtney Lewis, Director, Center for Cancer Surveillance and Control at 410-767-0824.

Sincerely,

Joshua M. Sharfstein, M.D.
Secretary

Enclosure

cc: Carlessia A. Hussein, R.N., Dr.P.H.
Russell W. Moy, M.D., M.P.H.
Wynne Hawk, R.N., J.D.
Donna Gugel, M.H.S.
Courtney Lewis, M.P.H.
Sarah Albert, MSAR #2251

Toll Free 1-877-4MD-DHMH – TTY/Maryland Relay Service 1-800-735-2258

Web Site: www.dhmh.state.md.us



Maryland Department of Health and Mental Hygiene

Cancer Report 2010 Revised

Cigarette Restitution Fund Program

Cancer Prevention, Education, Screening and Treatment Program


Martin O'Malley
Governor
of Maryland

Anthony G. Brown
Lieutenant Governor
of Maryland

Joshua M. Sharfstein, M.D.
Secretary
Maryland Department
of Health and Mental Hygiene

Carlessia A. Hussein, R.N., Dr.P.H
Director
Cigarette Restitution Fund Program
DHMH

December 2010
Updated March 2011



2010 Cancer Report - Revised

Cigarette Restitution Fund Program

Cancer Prevention, Education, Screening and Treatment Program

Prepared by:

Carolyn F. Poppell, M.S.

Epidemiologist, Surveillance and Evaluation Unit
Center for Cancer Surveillance and Control

Maya King, M.P.H.

Research Analyst, Surveillance and Evaluation Unit
Center for Cancer Surveillance and Control

Carmela Groves, R.N., M.S.

Program Manager, Surveillance and Evaluation Unit
Center for Cancer Surveillance and Control

Diane M. Dwyer, M.D.

Medical Director
Center for Cancer Surveillance and Control

Kelly Sage, M.S.

Acting Director
Center for Cancer Surveillance and Control

Carlessia A. Hussein, R.N., Dr.P.H.

Director
Cigarette Restitution Fund Program



STATE OF MARYLAND

DHMH

Maryland Department of Health and Mental Hygiene

201 W. Preston Street • Baltimore, Maryland 21201

Martin O'Malley, Governor – Anthony G. Brown, Lt. Governor – Joshua M. Sharfstein, M.D. Secretary

JUN 21 2011

Dear Fellow Marylanders:

Cancer is the second leading cause of death in Maryland and in the nation. Over 26,000 Marylanders were diagnosed with cancer in the year 2007, and more than 10,000 died from cancer. Technical advances and improved resources have led to earlier diagnosis and better treatment of many cancers. As a result, rates of new diagnoses and rates of death from all cancers combined are declining for men and women overall, and more people diagnosed with cancer are surviving each year.

Cancer prevention and control under the Cigarette Restitution Fund Program (CRFP) are among the highest priorities for the Maryland Department of Health and Mental Hygiene. The CRFP focuses on these priorities and includes the Cancer Prevention, Education, Screening and Treatment Program. The primary goals are to reduce cancer mortality and to decrease health disparities in cancer. The Department is coordinating efforts of the CRFP through local health departments and other partnerships in order to reduce the burden of cancer.

The enclosed 2010 Cancer Report of the Cigarette Restitution Fund Program reviews total cancers and the seven specific cancer sites targeted by the Cancer Prevention, Education, Screening and Treatment Program: lung and bronchus, colon and rectum, female breast, prostate, oral, melanoma of the skin, and cervix. These cancers were selected based on proven interventions for prevention (lung and bronchus and melanoma of the skin) and early detection and treatment (colon and rectum, female breast, cervix, and oral), or the magnitude of the impact on incidence and mortality (prostate). This version of the report updates the December 2010 version to include the most recent mortality data.

Cancer prevention and control results from awareness and proactive behavior of all Marylanders. On behalf of the Maryland Department of Health and Mental Hygiene, I appreciate your efforts to control cancer.

Sincerely,

Joshua M. Sharfstein, M.D.
Secretary

Acknowledgments

The Maryland Department of Health and Mental Hygiene (DHMH), Center for Cancer Surveillance and Control (CCSC), is pleased to present the Cigarette Restitution Fund Program 2010 Cancer Report. Our hope is that individuals, groups, and agencies, such as local health departments, Statewide Academic Health Centers, community health coalitions, other community organizations, policy makers, and the citizens of Maryland, will benefit from the information in this report and will find this report useful.

We thank the following agencies and individuals for their contributions to and assistance with this document:

- Maryland Cancer Registry, CCSC, DHMH, for providing data for the tables and graphs. Kimberly S. Stern, M.H.A., C.T.R., provided data coordination and Jennifer Hayes, M.Ed., M.P.H., and Afaq Ahmad, M.D., M.P.H., C.T.R., provided special assistance by extracting incidence data.
- Office of Health Policy and Planning, Family Health Administration, DHMH, for maintaining a Web-based tool for accessing health and risk behavior data from the Maryland Behavioral Risk Factor Surveillance System. Helio Lopez, M.S., provided special assistance.
- University of Maryland, Baltimore, Department of Epidemiology and Public Health, for providing Maryland Cancer Survey data. Eileen Steinberger, M.D., M.S., provided special assistance.
- Information Resources Management Administration, DHMH, for developing county and regional maps. Jennifer English provided special assistance.
- Surveillance and Evaluation Unit, CCSC, DHMH, for coordinating and developing this report. Lorraine Underwood provided special assistance.

We thank all the individuals who contributed to the development and careful review of this document.

Dedication

We dedicate this report to all persons whose lives have been touched by cancer.

While this publication reflects numbers and statistics, we recognize that each number represents an individual and the impact that a cancer diagnosis places on them and their loved ones. We hope to make a difference for cancer survivors and the people in their lives so together they may face the many challenges related to cancer diagnosis and treatment.



Table of Contents

I. Executive Summary

A. Introduction	1
B. Major Highlights of the Report	2
C. Major Changes to this Report from the 2009 Cancer Report.....	4

II. All Cancer Sites

All Cancer Sites	5
------------------------	---

III. Targeted Cancers

A. Lung and Bronchus Cancer	21
B. Colon and Rectum Cancer.....	37
C. Female Breast Cancer.....	53
D. Prostate Cancer.....	69
E. Oral Cancer	85
F. Melanoma of the Skin	101
G. Cervical Cancer	117

IV. Appendices

Appendix A: Cigarette Restitution Fund Cancer Report Requirements	133
Appendix B: Cancer Report Format	137
Appendix C: Cancer Report Data Sources, References, and Data Considerations	141
Appendix D: Glossary.....	157
Appendix E: Maryland Population Estimates, 2007	163
Appendix F: U. S. Standard Population, 2000	167
Appendix G: Definitions of International Classification of Diseases (ICD) Codes Used for Cancer Incidence and Mortality	171
Appendix H: Maryland Cancer Incidence and Mortality Rates by Geographical Area, 2003-2007.....	175
Appendix I: Trends in Cancer Incidence and Mortality Rates in Maryland by Cancer Site, Race, and Year, 2003-2007	193
Appendix J: Trends in Cancer Stage of Disease at Diagnosis in Maryland by Cancer Site and Year, 2003-2007	199

I. Executive Summary

A. Introduction

This publication is the Cigarette Restitution Fund Program (CRFP) 2010 Cancer Report. The primary purpose of the Cancer Report, which is required biennially by Maryland law, is to assist local health departments and local community health coalitions under the CRFP in planning and implementing comprehensive cancer prevention, education, screening, and treatment programs. The data and the “Public Health Intervention” recommendations are intended to guide local health departments, Statewide Academic Health Centers, community health coalitions, other community organizations, and policy makers as they decide how to allocate limited resources (e.g., staff time, funding) for the maximum benefit, with the goal of reducing cancer mortality and eliminating racial disparities.

The CRFP was established in 2000 to provide for the distribution of funds received as a result of multi-state litigation against the tobacco industry. This program provided approximately \$11.5 million in Fiscal Year 2010 to combat cancer. The CRFP law established the Cancer Prevention, Education, Screening and Treatment (CPEST) Program within the Maryland Department of Health and Mental Hygiene (DHMH). The primary goal of the CPEST Program is to reduce mortality and morbidity rates for cancer and tobacco-related diseases in the State of Maryland.

The CRFP law requires DHMH to identify the types of cancers that may be targeted under the CPEST Program. In addition to overall cancers presented in this report, DHMH has selected seven targeted cancers; each is presented individually. The seven targeted cancer sites are: lung and bronchus, colon and rectum, female breast, prostate, oral, melanoma of the skin, and cervix. These cancers were selected because they can be prevented (lung and bronchus and melanoma), detected and treated early (colon and rectum, female breast, cervix, and oral), or because of the magnitude of their impact on incidence and mortality (prostate).

Additionally, the CRFP law requires Maryland jurisdictions to develop plans to: 1) eliminate the higher incidence and mortality rates of cancer in minority populations (as defined in the CRFP law as women or individuals of African, Hispanic, Native American, and Asian descent) and the higher rates in rural areas, and 2) increase availability of and access to health care services for medically underserved populations and uninsured individuals.

This revised 2010 CRFP Cancer Report includes information on cancer incidence, mortality, stage of disease at diagnosis, public health evidence for prevention and screening, recommended areas for public health intervention, and Maryland screening behaviors compared to the Healthy People 2010 targets for cancer prevention and screening

B. Major Highlights of the Report

1. Major findings for all cancer sites:

- In 2007, a total of 26,377 new cases of cancer were diagnosed in Maryland.
- The overall cancer incidence rate declined steadily in Maryland from 1998 to 2007, at a pace comparable to the decline in the U.S. rate.
- Incidence rates for all cancer sites have remained slightly higher among whites than blacks in Maryland from 2003 to 2007, although rates declined for both races over the period.
- Mortality rates for all cancer sites decreased from 1998 to 2007. Blacks have a higher mortality rates than whites, although the average yearly decline for blacks is greater than the decline for whites.
- Maryland ranks 20th among all states and the District of Columbia in total cancer mortality for the period 2003-2007, no change from the period 2002-2006.

2. Major findings for lung and bronchus cancer:

- Lung cancer is the leading cause of cancer deaths in both men and women in Maryland; it accounts for 27.6% of all cancer deaths in 2007.
- Lung cancer incidence and mortality rates decreased in Maryland from 2003 to 2007; the 2007 lung cancer incidence rate in Maryland continued to remain higher than the U.S. rate.
- From 2003-2007, lung cancer incidence rates in Maryland declined more rapidly among blacks than whites.
- Tobacco use is the primary cause of lung cancer; tobacco smoking causes an estimated 90% of lung cancer in males and 78% of lung cancer in females.
- The public health intervention for lung cancer is the prevention and cessation of tobacco use.
- Smoking rates among Maryland adults continue to decline. In 2008, 14.9% of adults age 18 years and older were current smokers; Maryland had not yet attained the Healthy People 2010 goal of reducing the percentage of adult smokers to 12%.

3. Major findings for colon and rectum cancer:

- In 2007, the Maryland incidence rate for colorectal cancer was lower than the U.S. rate.
- Incidence and mortality rates for colorectal cancer declined in Maryland from 2003 to 2007. Incidence and mortality rates decreased faster among Maryland blacks than whites over the period.
- The recommended public health intervention for colorectal cancer is early detection with screening colonoscopy or with a combination of fecal occult blood testing and flexible sigmoidoscopy.
- The percentage of Maryland adults age 50 years and older ever receiving colonoscopy or sigmoidoscopy screening increased from 69% in 2006 to 75% in 2008.

- Maryland continues to surpass the Healthy People 2010 target for colorectal cancer screening.
4. Major findings for **female breast** cancer:
- Breast cancer is the second leading cause of cancer deaths among women after lung cancer; Maryland ranks 6th in the nation for breast cancer mortality in the U.S.
 - Both incidence and mortality rates for female breast cancer declined from 2003 to 2007.
 - The recommended public health intervention for breast cancer is early detection using mammography and clinical breast examination by a health care professional.
 - Maryland women continue to surpass the Healthy People 2010 target for mammography screening.
5. Major findings for **prostate** cancer:
- Prostate cancer is the second leading cause of cancer death among men after lung cancer; Maryland ranks 11th in prostate cancer mortality in the U.S.
 - Prostate cancer incidence and mortality rates decreased from 2003 to 2007.
 - Racial disparities in prostate cancer incidence and mortality decreased from 2003 to 2007, largely due to declines among black men. Prostate cancer incidence and mortality rates for black men in Maryland decreased more than 3% per year during this period.
 - The recommended public health intervention for prostate cancer is that clinicians should discuss with their patients the potential benefits and uncertainties regarding prostate cancer screening and treatment, consider individual patient preferences, and individualize the decision to screen.
6. Major findings for **oral** cancer:
- Oral cancer incidence decreased an average of more than 7% per year among blacks and almost 4% per year among whites in Maryland from 2003 to 2007; whereas, mortality rates increased in this time period for blacks and whites.
 - There is extensive evidence that tobacco use causes oral cancer.
 - The recommended public health interventions for oral cancer are: avoidance and cessation of tobacco use; avoidance and reduction of alcohol consumption; avoidance of sun and use of lip balm that blocks ultraviolet (UV) light; and screening for oral cancer targeted to individuals 40 years of age and older.
 - Marylanders have consistently surpassed the Healthy People 2010 target for oral cancer screening. In 2008, 40% of Marylanders age 40 years and older reported having an oral cancer exam in the past year.
7. Major findings for **melanoma** skin cancer:
- Melanoma incidence rates in Maryland increased an average of 2.3% per year from 2003 to 2007. The rate of increase was twice as high among males as females.

- Mortality rates increased from 2003 to 2007 for both females and males.
- The recommended public health intervention for skin cancer is reduction of exposure to UV light by: 1) avoiding the sun, especially between 10 a.m. and 4 p.m., 2) wearing sun protective clothing, hat, and sunglasses when exposed to sunlight, 3) avoiding artificial sources of UV light (e.g., tanning booths), and 4) using sunscreens with a SPF of 15 or higher, if sun exposure cannot be avoided.

8. Major findings for **cervical** cancer:

- Cervical cancer incidence among Maryland women decreased steadily from 2003 to 2007; in 2007, the statewide cervical cancer incidence rate was lower than the U.S. rate.
- Disparities in cervical cancer incidence between white and black women decreased in Maryland from 2003 to 2007. Incidence rates for black women decreased an average of 10.8% per year, compared to a decrease of 7.2% per year among white women.
- Mortality rates for cervical cancer increased from 2003 to 2007, with blacks having an increase of 2.8% and whites having a decrease of 0.1% per year.
- The recommended public health interventions for cervical cancer are early detection using the Pap test for women beginning within 3 years of onset of sexual activity or by age 21 years, whichever comes first, and human papillomavirus (HPV) vaccination.
- In 2008, 84% of Maryland women age 18 years and older had a Pap test within the past 3 years, slightly below the Healthy People 2010 target of 90%.
- The Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP) recommends the HPV vaccine as a means for preventing cervical cancer. ACIP recommends the vaccine be given routinely to girls when they are age 11 or 12 years. The ACIP recommendation also allows for vaccination of girls beginning at age 9 years, and for vaccination of girls and women age 13-26 years who have not been previously vaccinated.

C. Major Changes to this Report from the 2009 Cancer Report

- This report presents incidence and mortality data for 2007 and 5-year aggregate data for 2003-2007.
- County-specific incidence and mortality tables included in previous CRF Cancer Reports have been removed.

Important note: The 2006 case counts presented in this report for Montgomery and Prince George's counties are underreported for all cancer sites combined due to delay in case reporting. Cancers reported to the MCR after the annual cutoff date are not included in the MCR official Maryland case counts and rates. The case undercounts resulted in lower than actual age-adjusted incidence rates for Montgomery and Prince George's counties, for the National Capital geographic region, and to a lesser degree, for Maryland, for 2006, thereby affecting the 5-year period 2003-2007.

II. All Cancer Sites

Incidence (New Cases)

A total of 26,377 new cases of cancer diagnosed in 2007 in Maryland residents were reported to the Maryland Cancer Registry. The total age-adjusted cancer incidence rate for Maryland in 2007 was 455.3 per 100,000 population (449.8-460.9, 95% Confidence Interval [C.I.]). The 2007 Maryland cancer incidence rate is similar to the 2007 U.S. SEER rate of 458.0 per 100,000 population (456.5-459.5, 95% C.I.).

Mortality (Deaths)

Cancer is the second leading cause of death in Maryland, accounting for 23.3% of all deaths in 2007. A total of 10,179 Maryland residents died from cancer in 2007. The Maryland mortality rate for all cancer sites was 180.4 per 100,000 population (176.9-183.9, 95% C.I.) for 2007. This rate is similar to the 2007 U.S. cancer mortality rate of 178.4 per 100,000 population (177.9-178.8, 95% C.I.). Maryland ranks 20th highest among all states and the District of Columbia in total cancer mortality for the period 2003-2007.

Table 1.
All Cancer Sites Incidence and Mortality Rates*
by Gender and Race, Maryland and the United States, 2007

<i>Incidence 2007</i>	<i>Total</i>	<i>Males</i>	<i>Females</i>	<i>Whites</i>	<i>Blacks</i>	<i>Other</i>
New Cases (count)	26,377	13,409	12,952	18,978	6,251	948
MD Incidence Rate	455.3	528.9	404.1	460.5	444.0	343.9
U.S. SEER Rate	458.0	533.0	405.3	464.6	474.8	307.2
<i>Mortality 2007</i>	<i>Total</i>	<i>Males</i>	<i>Females</i>	<i>Whites</i>	<i>Blacks</i>	<i>Other</i>
Deaths (count)	10,179	5,144	5,035	7,317	2,664	198
MD Mortality Rate	180.4	219.5	155.0	176.6	207.7	83.4
U.S. Mortality Rate	178.4	217.5	151.3	177.5	215.5	108.4


* Rates are per 100,000 and are age-adjusted to 2000 U.S. standard population

Total includes cases reported as transsexual, hermaphrodite, or unknown gender

Sources: MD incidence data from Maryland Cancer Registry

U.S. SEER rates from SEER*Stat software

MD mortality data from NCHS Compressed Mortality File in CDC WONDER




Sources: Maryland Cancer Registry (MD rates)
NCI SEER*Stat (U.S. SEER 13 rates)

Maryland vs. United States, All Cancer Sites Incidence Rates, All Age Groups

All cancer sites incidence rates in Maryland declined over the 10-year period from 1998 to 2007, at a pace comparable to the U.S. rate.


Maryland incidence rates decreased at a rate of 0.7% per year; U.S. incidence rates decreased at a rate of 0.9% per year.



Source: NCHS Compressed Mortality File in CDC WONDER

Maryland vs. United States, All Cancer Sites Mortality Rates, All Age Groups

Maryland cancer mortality rates have declined since 1998. From 1998 to 2007, all cancer sites mortality rates in Maryland decreased at a rate of 1.9% per year. The U.S. mortality rate for all cancer sites declined at a rate of 1.5% per year over the same period.



Rates are age-adjusted to 2000 U.S. standard population

Sources: Maryland Cancer Registry (incidence rates)


NCHS Compressed Mortality File in CDC WONDER (mortality rates)

Incidence and Mortality Trends

In Maryland, the incidence rate for all cancer sites decreased at a rate of 2.4% per year from 2003 to 2007.

Cancer mortality rates decreased at a rate of 1.8% per year from 2003 to 2007.

See Appendix I, Tables 1 and 2.




Rates are age-adjusted to 2000 U.S. standard population

Source: Maryland Cancer Registry

Incidence Trends by Race

Incidence rates for all cancer sites have remained higher among whites than blacks in Maryland, although rates have generally declined for both races. From 2003 to 2007, incidence rates for all cancer sites decreased at a rate of 2.0% per year among whites and 3.3% per year among blacks.

See Appendix I, Table 3.




Rates are age-adjusted to 2000 U.S. standard population
Source: NCHS Compressed Mortality File in CDC WONDER

Mortality Trends by Race

Blacks have higher mortality rates of all cancer sites than whites. Both blacks and whites showed declines in cancer mortality from 2003 to 2007, with declines of 2.2% per year for blacks and 1.5% per year for whites.

See Appendix I, Table 5.




Source: Maryland Cancer Registry

Stage at Diagnosis

Of all cancers diagnosed in Maryland in 2007, 45.9% were found at the localized (early) stage, 21.1% at the regional stage, and 20.9% at the distant (late) stage. The proportion of all cancers reported as unstaged has steadily decreased in recent years.

See Appendix J, Table 1.



Mortality Rates Compared to Healthy People 2010 Target

The overall cancer mortality rate in Maryland for 2007, is 180.4 per 100,000 population. The Healthy People 2010 goal is to reduce cancer mortality to 158.6 per 100,000 population.

Summary – Identification of Targeted Cancers

The cancers targeted under the Cigarette Restitution Fund in 2010 include: lung and bronchus, colon and rectum, prostate, breast, cervical, oral, and melanoma of the skin. These cancers were chosen due to the capacity to prevent, detect early, and effectively treat these cancers, and due to the magnitude of their impact on incidence and mortality. The remaining sections of this report address these targeted cancers. The public health interventions to reduce the impact of these and other cancers among Marylanders are listed in the chart below.

Public Health Interventions for Targeted and Other Cancers	
» Prevention, including:	
• stopping tobacco use or not starting it	• limiting alcohol use
• being physically active	• staying at a healthy weight
• eating a healthy diet	
» Early detection (screening) and treatment of:	
• colon and rectum cancer	• cervical cancer
• breast cancer	• oral cancer
» Human papillomavirus vaccine to prevent cervical cancer	
» Protection of the skin from excessive sun and other sources of ultraviolet light exposure	
» Men should be made aware of availability of prostate cancer screening tests and should discuss potential benefits and harms with their health care provider	

Table 2.
Number of Cancer Cases for All Cancer Sites
by Jurisdiction, Gender and Race, Maryland, 2007

Jurisdiction	Total	Gender		Race			
		Males	Females	Whites	Blacks	Other	Unknown
Maryland	26,377	13,409	12,952	18,978	6,251	948	200
Allegany	449	228	221	440	s	<6	0
Anne Arundel	2,488	1,241	1,244	2,145	275	55	13
Baltimore City	2,975	1,465	1,509	1,057	1,858	50	10
Baltimore County	4,155	2,079	2,073	3,364	673	102	16
Calvert	424	228	195	374	47	<6	<6
Caroline	168	89	79	145	s	0	<6
Carroll	825	417	407	789	16	s	<6
Cecil	512	250	262	486	23	<6	<6
Charles	554	305	247	366	169	s	<6
Dorchester	194	97	97	139	s	0	<6
Frederick	889	431	458	809	47	19	14
Garrett	149	86	63	149	0	0	0
Harford	1,244	677	566	1,102	118	17	7
Howard	1,128	564	564	871	160	85	12
Kent	140	74	66	118	s	<6	0
Montgomery	4,193	2,065	2,126	3,166	564	407	56
Prince George's	3,001	1,555	1,445	977	1,868	119	37
Queen Anne's	274	158	115	246	20	<6	<6
Saint Mary's	441	240	201	375	55	s	<6
Somerset	145	75	70	100	39	<6	<6
Talbot	281	148	133	241	s	<6	0
Washington	790	438	352	742	37	s	<6
Wicomico	490	250	240	394	91	<6	<6
Worcester	395	222	173	337	37	s	<6
Unknown	73	27	46	46	12	<6	s

Total includes cases reported as transsexual, hermaphrodite, or unknown gender

<6 = Case counts of 1-5 are suppressed per DHMH/MCR Data Use Policy and Procedures

s = Case counts are suppressed to prevent disclosure of data in other cell(s). (See Appendix C for methods.)

Source: Maryland Cancer Registry

Table 3.
All Cancer Sites Age-Adjusted Incidence Rates*
by Jurisdiction, Gender and Race, Maryland, 2007

Jurisdiction	Total	Gender		Race		
		Males	Females	Whites	Blacks	Other
Maryland	455.3	528.9	404.1	460.5	444.0	343.9
Allegany	486.8	558.4	436.1	495.3	**	**
Anne Arundel	486.0	533.4	452.3	492.5	447.2	376.3
Baltimore City	459.6	548.4	402.6	440.7	465.2	445.9
Baltimore County	458.5	526.2	410.3	459.9	465.9	346.3
Calvert	515.0	625.2	432.2	540.5	397.0	**
Caroline	488.6	584.1	410.7	497.0	464.7	0.0
Carroll	473.7	528.8	435.8	474.3	266.1	**
Cecil	523.5	546.3	509.5	529.4	503.6	**
Charles	468.9	594.5	381.0	453.0	499.4	398.1
Dorchester	463.0	527.2	415.5	435.3	552.6	0.0
Frederick	426.8	473.1	400.8	430.0	324.3	253.0
Garrett	409.6	503.9	333.0	413.2	0.0	0.0
Harford	515.6	630.5	434.1	515.2	529.2	287.5
Howard	445.1	499.7	409.4	455.2	435.6	337.6
Kent	522.3	597.0	469.4	519.5	513.0	**
Montgomery	411.6	468.7	374.9	415.7	439.7	315.4
Prince George's	409.8	506.1	345.4	385.6	424.1	335.9
Queen Anne's	524.8	643.2	418.8	529.0	435.7	**
Saint Mary's	492.1	580.0	425.2	507.4	426.8	**
Somerset	521.7	586.2	469.5	494.0	528.9	**
Talbot	519.2	595.0	459.5	512.3	577.7	**
Washington	506.7	629.2	422.8	505.2	614.5	**
Wicomico	493.7	575.9	432.8	511.6	454.2	**
Worcester	534.6	641.5	451.7	528.0	397.4	4,886.7

* Rates are per 100,000 and are age-adjusted to 2000 U.S. standard population

** Rates based on case counts of 1-15 are suppressed per DHMH/MCR Data Use Policy and Procedures

Source: Maryland Cancer Registry

Table 4.
All Cancer Sites Cases and Age-Adjusted Incidence Rates*
Among Hispanics[§] by Geographical Area in Maryland, 2007

Jurisdiction	Cases	Rate
Maryland	565	291.6
Allegany	<6	**
Anne Arundel	49	561.8
Baltimore City	36	368.9
Baltimore County	35	243.9
Calvert	<6	**
Caroline	<6	**
Carroll	11	**
Cecil	6	**
Charles	13	**
Dorchester	<6	**
Frederick	19	332.2
Garrett	0	0.0
Harford	18	443.2
Howard	18	314.6
Kent	<6	**
Montgomery	211	240.2
Prince George's	107	261.2
Queen Anne's	<6	**
St. Mary's	7	**
Somerset	0	0.0
Talbot	<6	**
Washington	11	**
Wicomico	<6	**
Worcester	0	0.0
Region	Cases	Rate
Baltimore Metropolitan Area ^	167	370.2
Eastern Shore Region	21	364.5
National Capital Area	318	245.2
Northwest Region	33	445.8
Southern Region	24	589.8

* Rates are per 100,000 and are age-adjusted to 2000 U.S. standard population

§ Case counts were prepared using MCR data and an algorithm to determine Hispanic ethnicity.

(See Appendix C, Section D.6.)

<6 = Case counts of 1-5 are suppressed per DHMH/MCR Data Use Policy

** Rates based on case counts of 1-15 are suppressed per DHMH/MCR Data Use Policy

^ Includes Baltimore City

Source: Maryland Cancer Registry

Table 5.
Number of Deaths for All Cancer Sites
by Jurisdiction, Gender and Race, Maryland, 2007

Jurisdiction	Total	Gender		Race		
		Males	Females	Whites	Blacks	Other
Maryland	10,179	5,144	5,035	7,317	2,664	198
Allegany	194	103	91	188	<6	<6
Anne Arundel	986	484	502	864	108	14
Baltimore City	1,427	728	699	465	956	6
Baltimore County	1,661	824	837	1,385	255	21
Calvert	150	85	65	126	s	<6
Caroline	78	49	29	69	s	<6
Carroll	293	145	148	284	s	<6
Cecil	207	115	92	191	s	<6
Charles	209	104	105	148	s	<6
Dorchester	91	40	51	73	s	<6
Frederick	387	209	178	350	s	<6
Garrett	68	32	36	67	<6	<6
Harford	430	230	200	392	s	<6
Howard	318	154	164	263	46	9
Kent	64	32	32	56	s	<6
Montgomery	1,257	592	665	971	190	96
Prince George's	1,218	623	595	441	746	31
Queen Anne's	122	74	48	107	s	<6
Saint Mary's	155	78	77	135	s	<6
Somerset	55	24	31	35	s	<6
Talbot	94	49	45	78	s	<6
Washington	309	156	153	286	s	<6
Wicomico	256	138	118	212	s	<6
Worcester	150	76	74	131	s	<6

<6 = Death counts of 0-5 are suppressed per DHMH/CCSC Mortality Data Suppression Policy

s = Death counts are suppressed to prevent disclosure of data in other cell(s). (See Appendix C for methods.)

Source: NCHS Compressed Mortality File in CDC WONDER

Table 6.
All Cancer Sites Age-Adjusted Mortality Rates*
by Jurisdiction, Gender and Race, Maryland, 2007

Jurisdiction	Total	Gender		Race		
		Males	Females	Whites	Blacks	Other
Maryland	180.4	219.5	155.0	176.6	207.7	83.4
Allegany	195.0	251.2	164.3	193.9	**	**
Anne Arundel	205.8	233.6	186.2	209.5	196.8	**
Baltimore City	221.5	285.8	181.8	186.2	245.4	**
Baltimore County	178.4	213.2	156.1	177.5	201.0	78.6
Calvert	198.5	265.6	152.9	198.4	218.5	**
Caroline	224.1	327.0	146.7	233.2	**	**
Carroll	173.9	201.1	155.7	175.5	**	**
Cecil	220.0	278.7	177.5	214.7	357.6	**
Charles	201.7	252.1	170.8	202.9	208.6	**
Dorchester	205.0	219.2	196.4	214.8	180.1	**
Frederick	197.4	257.4	155.7	196.0	264.8	**
Garrett	179.8	185.0	178.1	178.4	**	**
Harford	187.7	229.3	157.0	190.7	174.0	**
Howard	142.7	166.5	128.6	153.5	142.9	**
Kent	222.9	255.5	207.2	227.2	**	**
Montgomery	127.0	147.5	115.8	126.0	165.0	86.6
Prince George's	183.4	235.4	151.6	173.5	201.5	98.2
Queen Anne's	239.3	306.8	176.8	237.8	**	**
Saint Mary's	186.3	214.2	170.2	196.4	154.2	**
Somerset	201.9	200.6	195.9	177.1	264.7	**
Talbot	152.6	185.1	128.6	143.7	214.7	**
Washington	192.9	230.4	169.6	187.6	375.9	**
Wicomico	254.3	331.5	198.6	269.8	208.2	**
Worcester	197.7	219.9	183.8	200.4	193.2	**

* Rates are per 100,000 and age-adjusted to 2000 U.S. standard population

** Rates based on death counts of 0-15 are suppressed per DHMH/CCSC Mortality Data Suppression Policy

Source: NCHS Compressed Mortality File in CDC WONDER

Table 7.
Number of Cancer Cases for All Cancer Sites
by Jurisdiction, Gender and Race, Maryland, 2003-2007

Jurisdiction	Total	Gender		Race			
		Males	Females	Whites	Blacks	Other	Unknown
Maryland	128,322	64,392	63,804	93,515	29,201	4,387	1,219
Allegany	2,281	1,178	1,103	2,212	61	8	0
Anne Arundel	11,596	5,970	5,595	10,005	1,266	239	86
Baltimore City	14,927	7,533	7,385	5,986	8,620	220	101
Baltimore County	21,824	10,700	11,117	17,574	3,537	529	184
Calvert	1,875	949	922	1,613	224	10	28
Caroline	826	420	405	697	116	7	6
Carroll	4,130	2,080	2,048	3,934	120	52	24
Cecil	2,257	1,168	1,089	2,127	98	16	16
Charles	2,521	1,324	1,190	1,805	631	58	27
Dorchester	930	502	427	712	208	s	<6
Frederick	5,135	2,513	2,618	4,743	273	84	35
Garrett	741	391	349	732	s	0	<6
Harford	5,640	3,007	2,631	5,070	456	90	24
Howard	5,128	2,473	2,651	4,005	734	332	57
Kent	674	358	316	576	87	<6	s
Montgomery †	19,696	9,345	10,338	15,046	2,525	1,879	246
Prince George's †	14,508	7,203	7,290	5,139	8,536	639	194
Queen Anne's	1,170	672	495	1,036	114	11	9
Saint Mary's	1,936	1,050	883	1,626	248	32	30
Somerset	663	365	298	460	190	s	<6
Talbot	1,280	637	643	1,097	173	s	<6
Washington	3,693	1,936	1,756	3,506	138	37	12
Wicomico	2,222	1,124	1,098	1,754	423	35	10
Worcester	1,743	935	807	1,491	187	58	7
Unknown	926	559	350	569	s	s	104

Total includes cases reported as transsexual, hermaphrodite, or unknown gender

<6 = Case counts of 1-5 are suppressed per DHMH/MCR Data Use Policy and Procedures

s = Case counts are suppressed to prevent disclosure of data in other cell(s). (See Appendix C for methods.)

† 2006 case counts for Montgomery and Prince George's counties are underreported. (See Appendix C, Section I.A.1.)

Source: Maryland Cancer Registry

Table 8.
All Cancer Sites Age-Adjusted Incidence Rates*
by Jurisdiction, Gender and Race, Maryland, 2003-2007

Jurisdiction	Total	Gender		Race		
		Males	Females	Whites	Blacks	Other
Maryland	458.9	530.0	410.0	463.9	441.9	357.2
Allegany	485.9	570.5	431.0	486.4	669.4	**
Anne Arundel	469.0	538.6	418.3	472.0	449.1	348.2
Baltimore City	461.4	569.6	392.0	488.6	438.7	409.5
Baltimore County	489.3	553.3	446.3	480.4	545.8	406.9
Calvert	479.6	547.5	432.0	485.2	419.2	**
Caroline	490.4	550.4	443.1	485.7	495.8	**
Carroll	497.4	566.7	453.3	493.3	498.1	720.6
Cecil	488.3	551.6	441.0	486.7	475.7	556.2
Charles	449.3	552.0	377.7	454.1	430.8	375.5
Dorchester	454.6	559.3	380.5	454.6	443.5	**
Frederick	519.0	590.6	477.6	524.3	444.2	306.6
Garrett	406.8	463.0	361.5	404.7	**	0.0
Harford	488.7	582.5	418.6	489.7	474.7	404.5
Howard	431.3	474.2	405.5	438.5	439.9	302.9
Kent	507.6	582.1	454.1	512.9	439.9	**
Montgomery †	410.8	452.9	384.6	414.4	430.0	327.1
Prince George's †	408.7	480.9	359.5	399.8	407.7	372.1
Queen Anne's	466.5	564.1	379.2	460.8	494.5	**
Saint Mary's	459.2	544.1	394.7	463.4	415.7	392.7
Somerset	487.3	584.3	417.2	470.5	526.1	**
Talbot	486.7	535.5	447.3	479.2	529.7	**
Washington	483.8	571.7	426.4	483.7	546.3	540.8
Wicomico	467.8	545.8	416.3	473.0	443.5	543.5
Worcester	488.0	557.2	434.9	481.5	418.4	3,364.1

* Rates are per 100,000 and are age-adjusted to 2000 U.S. standard population

** Rates based on case counts of 1-15 are suppressed per DHMH/MCR Data Use Policy and Procedures

† 2003-2007 incidence rates for Montgomery and Prince George's counties are lower than actual due to case underreporting in 2006. (See Appendix C, Section I.A.1.)

Source: Maryland Cancer Registry

Table 9.
Number of Cancer Deaths for All Cancer Sites
by Jurisdiction, Gender and Race, Maryland, 2003-2007

Jurisdiction	Total	Gender		Race		
		Males	Females	Whites	Blacks	Other
Maryland	51,360	25,907	25,453	37,364	12,981	1,015
Allegany	972	511	461	952	s	<6
Anne Arundel	4,706	2,397	2,309	4,078	555	73
Baltimore City	7,552	3,831	3,721	2,824	4,691	37
Baltimore County	8,846	4,412	4,434	7,512	1,227	107
Calvert	769	403	366	639	s	<6
Caroline	382	211	171	318	s	<6
Carroll	1,505	767	738	1,451	43	11
Cecil	955	505	450	910	s	<6
Charles	1,093	558	535	801	272	20
Dorchester	426	233	193	323	s	<6
Frederick	1,768	922	846	1,642	118	8
Garrett	319	168	151	315	<6	<6
Harford	2,112	1,083	1,029	1,903	185	24
Howard	1,498	721	777	1,182	241	75
Kent	301	156	145	251	s	<6
Montgomery	6,415	2,998	3,417	5,105	864	446
Prince George's	6,228	3,091	3,137	2,395	3,654	179
Queen Anne's	503	284	219	439	s	<6
Saint Mary's	835	469	366	705	s	<6
Somerset	325	182	143	241	s	<6
Talbot	516	262	254	440	s	<6
Washington	1,517	778	739	1,447	s	<6
Wicomico	1,063	545	518	836	219	8
Worcester	754	420	334	655	s	<6

<6 = Death counts of 0-5 are suppressed per DHMH/CCSC Mortality Data Suppression Policy

s = Death counts are suppressed to prevent disclosure of data in other cell(s). (See Appendix C for methods.)

Source: NCHS Compressed Mortality File in CDC WONDER

Table 10.
All Cancer Sites Age-Adjusted Mortality Rates*
by Jurisdiction, Gender and Race, Maryland, 2003-2007


Jurisdiction	Total	Gender		Race		
		Males	Females	Whites	Blacks	Other
Maryland	188.5	229.6	161.8	184.6	215.0	94.6
Allegany	196.0	249.6	162.7	197.0	158.1	**
Anne Arundel	203.1	242.4	176.9	203.1	219.0	116.3
Baltimore City	233.2	301.0	191.7	218.5	244.9	73.9
Baltimore County	193.2	233.5	166.6	193.2	211.4	87.0
Calvert	215.0	264.6	182.0	211.9	248.6	**
Caroline	225.6	289.7	178.8	220.4	263.1	**
Carroll	188.5	229.4	162.0	188.5	201.7	**
Cecil	216.4	263.0	184.3	217.5	215.0	**
Charles	220.0	276.9	185.6	224.3	217.2	138.8
Dorchester	202.4	266.0	160.6	198.4	213.6	**
Frederick	188.5	237.9	156.8	189.7	211.3	**
Garrett	172.1	203.7	149.2	171.1	**	**
Harford	193.9	229.5	168.1	193.6	209.3	115.3
Howard	143.4	168.5	130.9	146.3	161.2	79.1
Kent	208.2	249.7	184.2	202.4	243.8	**
Montgomery	135.8	156.5	123.8	137.3	162.7	91.6
Prince George's	194.9	240.6	167.1	186.6	209.0	116.1
Queen Anne's	206.9	249.2	168.6	203.0	264.7	**
Saint Mary's	213.0	271.0	171.6	216.2	218.2	**
Somerset	238.7	304.0	191.6	240.9	235.3	**
Talbot	177.3	211.6	151.3	171.7	220.9	**
Washington	194.8	238.4	166.6	193.7	308.4	**
Wicomico	223.3	277.5	187.3	223.4	232.0	**
Worcester	200.6	248.8	163.8	200.2	208.0	**

* Rates are per 100,000 and are age-adjusted to 2000 U.S. standard population

** Rates based on death counts of 0-15 are suppressed per DHMH/CCSC Mortality Data Suppression Policy

Source: NCHS Compressed Mortality File in CDC WONDER

Maryland All Cancer Sites Incidence Rates by Geographical Area: Comparison to U.S. Rate, 2003-2007



Rates are age-adjusted to the 2000 U.S. standard population and are per 100,000 population.


Maryland area-specific rates with 95% confidence intervals are presented in Appendix H.

U.S. all cancer sites incidence rate, 2003-2007: 461.6/100,000

Maryland all cancer sites incidence rate, 2003-2007: 458.9/100,000

Source: MD incidence rates from Maryland Cancer Registry, 2003-2007
U.S. (SEER 17) rate from SEER*Stat Software

Maryland All Cancer Sites Mortality Rates by Geographical Area: Comparison to U.S. Rate, 2003-2007



Rates are age-adjusted to the 2000 U.S. standard population and are per 100,000 population.

Maryland area-specific rates with 95% confidence intervals are presented in Appendix H.

U.S. all cancer sites mortality rate, 2003-2007: 183.6/100,000

Maryland all cancer sites mortality rate, 2003-2007: 188.5/100,000

Source: MD and U.S. mortality rates from NCHS Compressed Mortality File in CDC WONDER

III. Targeted Cancers

A. Lung and Bronchus Cancer

Incidence (New Cases)

There were 3,522 new cases of lung and bronchus cancer (called lung cancer) reported among Maryland residents in 2007. The 2007 Maryland age-adjusted lung cancer incidence rate was 62.4 per 100,000 population (60.4-64.6, 95% C.I.), which is statistically significantly higher than the 2007 U.S. SEER lung cancer incidence rate of 59.9 per 100,000 population (59.4-60.5, 95% C.I.).

Mortality (Deaths)

There were 2,812 lung cancer deaths among Maryland residents in 2007. In 2007, lung cancer accounted for 27.6% of all cancer deaths in Maryland and was the leading cause of cancer deaths in both men and women. The 2007 age-adjusted lung cancer mortality rate was 50.1 per 100,000 population (48.2-51.9, 95% C.I.) in Maryland. This rate is similar to the 2007 U.S. mortality rate for lung and bronchus cancer of 50.6 per 100,000 population (50.4-50.9, 95% C.I.). Maryland had the 22nd highest lung cancer mortality rate among the states and the District of Columbia for the period 2003-2007.

Table 11.
Lung Cancer Incidence and Mortality Rates*
by Gender and Race, Maryland and the United States, 2007

<i>Incidence 2007</i>	<i>Total</i>	<i>Males</i>	<i>Females</i>	<i>Whites</i>	<i>Blacks</i>	<i>Other</i>
New Cases (count)	3,522	1,799	1,720	2,640	794	s
MD Incidence Rate	62.4	74.2	54.2	64.3	60.3	36.0
U.S. SEER Rate	59.9	71.8	51.2	61.6	68.1	36.7
<i>Mortality 2007</i>	<i>Total</i>	<i>Males</i>	<i>Females</i>	<i>Whites</i>	<i>Blacks</i>	<i>Other</i>
Deaths (count)	2,812	1,497	1,315	2,116	654	42
MD Mortality Rate	50.1	62.9	41.1	51.4	51.2	18.0
U.S. Mortality Rate	50.6	65.0	40.0	51.2	55.6	26.4

* Rates are per 100,000 and are age-adjusted to 2000 U.S. standard population


Total includes cases reported as transsexual, hermaphrodite, or unknown gender

s = Counts are suppressed to prevent disclosure of data in other cell(s) based on Table 12

Sources: MD incidence data from Maryland Cancer Registry

U.S. SEER rates from SEER*Stat software

MD mortality data from NCHS Compressed Mortality File in CDC WONDER




Incidence and Mortality Trends

Lung cancer incidence rates in Maryland decreased at a rate of 3.3% per year from 2003 to 2007.

Lung cancer mortality rates decreased at a rate of 2.7% per year from 2003 to 2007.

See Appendix I, Tables 1 and 2.

Rates are age-adjusted to 2000 U.S. standard population
Sources: Maryland Cancer Registry (incidence rates)
NCHS Compressed Mortality File in CDC WONDER (mortality rates)




Incidence Trends by Race

In recent years, lung cancer incidence rates in Maryland have been decreasing at a faster pace among blacks than whites, and by 2007, the incidence rates were lower among blacks. From 2003 to 2007, lung cancer incidence rates for blacks declined at a rate of 5.8% per year, compared to a decline of 2.6% per year among whites.

See Appendix I, Table 3.

Rates are age-adjusted to 2000 U.S. standard population
Source: Maryland Cancer Registry




Rates are age-adjusted to 2000 U.S. standard population
Source: NCHS Compressed Mortality File in CDC WONDER

Mortality Trends by Race

Lung cancer mortality rates are declining for both blacks and whites. From 2003 to 2007, rates decreased at a rate of 5.2% per year for blacks, and 1.8% per year for whites.

See Appendix I, Table 5.




Source: Maryland Cancer Registry

Stage at Diagnosis

A higher proportion of lung cancer cases are diagnosed at the distant stage than at the localized or regional stage of cancer. In 2007, 47.8% of lung cancer cases in Maryland were diagnosed at the distant stage, 23.7% were detected at the regional stage, and 18.7% were found at the localized stage. The proportion of lung cancers reported as unstaged has declined in recent years.

See Appendix J, Table 2.




* Current smoker is defined as a person who smokes cigarettes every day or some days

Sources: Maryland BRFSS
Healthy People 2010, U.S. Department of Health and Human Services (2000)

Smoking Prevalence Among Maryland Adults

One Healthy People 2010 target is to reduce the percentage of adults who are current smokers to 12%. Although Maryland has not yet attained this goal, the percentage of adult smokers has declined at a rate of 3.9% per year since 2000, with a consistent downward trend since 2003.



* Current use of cigarettes is defined as smoking cigarettes on 1 or more days in the previous 30 days.

Sources: MYTS
Healthy People 2010, U.S. Department of Health and Human Services (2000)

Cigarette Use by Maryland Youth

Healthy People 2010 has established a target of reducing the percentage of youth in grades 9-12 who have smoked cigarettes in the previous 30 days to 16%.

Based on results of the 2006 and 2008 Maryland Youth Tobacco Surveys, Maryland has met the Healthy People 2010 target for reducing current cigarette use among high school students.

Public Health Evidence (quoted from National Cancer Institute [NCI], Physician Data Query [PDQ], 8/6/2009 and 10/19/2009, and United States Preventive Services Task Force [USPSTF], 5/2004)

Primary Prevention

The most important risk factor for lung cancer (as well as many other cancers) is tobacco use. Cigarette smoking has been established as the predominant cause of lung cancer, and tobacco smoking is estimated to cause 90% of lung cancer in males and 78% of lung cancer in females. Cigar and pipe smoking have also been associated, independently, with increased lung cancer risk. Based on solid evidence, cigarette smoking causes lung cancer and therefore, smoking avoidance would result in decreased mortality from primary lung cancers. Additionally, long-term sustained smoking cessation results in decreased incidence of lung cancer and of second primary lung tumors. Compared with persistent smokers, a 30 to 50% reduction of lung cancer mortality has been noted after 10 years of smoking cessation.

Environmental, or secondhand, tobacco smoke contains the same components as inhaled mainstream smoke at 1% to 10% the concentration, depending on the component. Indoor exposure to radon increases lung cancer incidence and mortality. Considered in total, occupational exposures have been estimated to account for approximately 10% of lung cancers. These carcinogens include asbestos, radon, tar and soot (source of polycyclic aromatic hydrocarbons), arsenic, chromium, and nickel. For many of these workplace carcinogens, cigarette smoking interacts to synergistically increase the risk.

Screening

Based on fair evidence, screening with chest x-ray and/or sputum cytology does not reduce mortality from lung cancer. Evidence is inadequate to determine whether screening with low-dose helical computed tomography (LDCT) decreases mortality from lung cancer. Based on solid evidence, screening with chest x-ray (CXR) and/or sputum cytology or with LDCT would lead to false-positive tests with unnecessary invasive diagnostic procedures and treatments.

The United States Preventive Services Task Force (USPSTF) similarly concluded that the evidence is insufficient to recommend for or against screening asymptomatic persons for lung cancer with LDCT, CXR, sputum cytology, or a combination of these tests. Because of the high number of false-positive tests in certain populations and the invasive nature of diagnostic testing, there is potential for significant harms from screening and diagnostic procedures.

Chemoprevention

Chemoprevention studies of beta-carotene found that high-intensity smokers (one or more packs per day) who take pharmacological doses of beta-carotene supplementation (≥ 20 mg/day) have an *increased* lung cancer incidence and mortality that is associated with taking the supplement. In these studies, beta-carotene did not increase lung cancer risk among moderate smokers, former smokers, or non-smokers. Based on solid evidence, taking vitamin E supplements does not affect the risk of lung cancer.

Public Health Intervention for Lung Cancer (CDC Best Practices for Comprehensive Tobacco Control Programs-2007, 10/2007)

- Prevent tobacco use among youth and young adults.
- Promote cessation among adults and young people.
- Eliminate exposure to secondhand smoke.
- Identify and eliminate tobacco-related disparities.

The CDC Best Practice Guidelines address five components of Comprehensive Tobacco Control Programs including:

▪ **State and Community Interventions:**

- ✓ Support and implement programs and policies to influence organizations, systems, and networks.
- ✓ Include local and statewide policies and programs, chronic disease and tobacco-related disparity elimination initiatives, and interventions aimed at youth.

▪ **Health Communication Interventions:**

- ✓ Deliver strategic, culturally appropriate, and high-impact messages in sustained and adequately funded campaigns.
- ✓ Use traditional health communication interventions and counter-marketing strategies, as well as innovations including more focused targeting of specific audiences and fostering message development and distribution.

▪ **Cessation Interventions:**

- ✓ Use interventions that encompass a broad array of policy, system, and population-based measures.
- ✓ Ensure that all patients seen in the health care system are screened for tobacco use, receive brief interventions to help them quit, and are offered more intensive counseling services and FDA-approved cessation medications.
- ✓ Make quitline counseling available to all tobacco users willing to access the service.

▪ **Surveillance and Evaluation:**

- ✓ Monitor tobacco-related attitudes, behaviors, and health outcomes.
- ✓ Collect baseline data related to each objective and performance indicator to ensure program effects are adequately measured.

▪ **Administration and Management:**

- ✓ Have sufficient funding, internal capacity, and skilled staff for effective tobacco prevention and control programs.

Table 12.
Number of Lung and Bronchus Cancer Cases
by Jurisdiction, Gender and Race, Maryland, 2007

Jurisdiction	Total	Gender		Race			
		Males	Females	Whites	Blacks	Other	Unknown
Maryland	3,522	1,799	1,720	2,640	794	s	<6
Allegany	71	40	31	71	0	0	0
Anne Arundel	381	189	191	346	s	<6	0
Baltimore City	482	234	248	s	314	<6	0
Baltimore County	624	319	305	539	76	9	0
Calvert	59	29	29	51	8	0	0
Caroline	27	18	9	s	<6	0	0
Carroll	106	57	49	102	<6	<6	<6
Cecil	75	35	40	s	<6	0	0
Charles	56	34	22	41	s	<6	0
Dorchester	33	17	16	23	10	0	0
Frederick	131	74	57	122	s	<6	0
Garrett	s	s	<6	s	0	0	0
Harford	173	89	84	160	s	<6	0
Howard	127	56	71	107	13	7	0
Kent	25	12	13	18	7	0	0
Montgomery	393	194	198	287	69	s	<6
Prince George's	333	162	171	141	181	11	0
Queen Anne's	41	20	21	s	<6	0	0
Saint Mary's	53	26	27	46	7	0	0
Somerset	27	14	13	15	s	<6	0
Talbot	36	15	21	30	6	0	0
Washington	105	70	35	96	s	<6	0
Wicomico	90	51	39	76	14	0	0
Worcester	53	29	24	46	<6	<6	0
Unknown	<6	<6	<6	<6	<6	0	0

Total includes cases reported as transsexual, hermaphrodite, or unknown gender

<6 = Case counts of 1-5 are suppressed per DHMH/MCR Data Use Policy and Procedures

s = Case counts are suppressed to prevent disclosure of data in other cell(s). (See Appendix C for methods.)

Source: Maryland Cancer Registry

Table 13.
Lung and Bronchus Cancer Age-Adjusted Incidence Rates*
by Jurisdiction, Gender and Race, Maryland, 2007

Jurisdiction	Total	Gender		Race		
		Males	Females	Whites	Blacks	Other
Maryland	62.4	74.2	54.2	64.3	60.3	36.0
Allegany	72.9	97.5	53.3	75.0	0.0	0.0
Anne Arundel	76.8	85.3	70.2	81.1	51.8	**
Baltimore City	75.0	89.4	65.5	68.9	78.6	**
Baltimore County	68.7	83.1	58.9	71.5	62.3	**
Calvert	76.9	86.6	67.9	78.7	**	0.0
Caroline	79.8	116.6	**	91.2	**	0.0
Carroll	62.4	73.6	53.7	62.7	**	**
Cecil	78.0	80.2	77.6	81.7	**	0.0
Charles	50.4	68.3	36.7	53.2	**	**
Dorchester	76.2	89.6	69.2	67.9	**	0.0
Frederick	68.1	89.2	54.1	69.2	**	**
Garrett	50.5	**	**	50.8	0.0	0.0
Harford	75.1	87.8	66.3	77.7	**	**
Howard	55.7	58.4	55.2	61.1	**	**
Kent	88.1	**	**	72.4	**	0.0
Montgomery	40.2	46.3	36.1	38.5	63.5	31.1
Prince George's	50.1	58.2	45.3	56.7	46.9	**
Queen Anne's	80.6	85.2	76.4	88.5	**	0.0
Saint Mary's	61.8	68.4	58.4	66.1	**	0.0
Somerset	98.5	**	**	**	**	**
Talbot	58.1	**	63.7	56.0	**	0.0
Washington	67.1	102.7	40.9	64.2	**	**
Wicomico	89.5	117.2	69.3	96.6	**	0.0
Worcester	67.0	79.8	56.7	64.7	**	**

* Rates are per 100,000 and are age-adjusted to 2000 U.S. standard population

** Rates based on case counts of 1-15 are suppressed per DHMH/MCR Data Use Policy and Procedures

Source: Maryland Cancer Registry

Table 14.
Number of Lung and Bronchus Cancer Deaths
by Jurisdiction, Gender and Race, Maryland, 2007

Jurisdiction	Total	Gender		Race		
		Males	Females	Whites	Blacks	Other
Maryland	2,812	1,497	1,315	2,116	654	42
Allegany	65	37	28	s	<6	<6
Anne Arundel	296	144	152	280	s	<6
Baltimore City	401	214	187	s	269	<6
Baltimore County	478	249	229	411	s	<6
Calvert	39	25	14	32	s	<6
Caroline	19	12	7	17	<6	<6
Carroll	95	52	43	92	<6	<6
Cecil	61	31	30	56	<6	<6
Charles	52	27	25	40	s	<6
Dorchester	24	9	15	23	<6	<6
Frederick	113	71	42	104	s	<6
Garrett	22	15	7	s	<6	<6
Harford	137	73	64	127	s	<6
Howard	73	36	37	63	s	<6
Kent	17	10	7	11	s	<6
Montgomery	291	144	147	225	43	23
Prince George's	289	159	130	123	159	7
Queen Anne's	39	23	16	36	<6	<6
Saint Mary's	44	22	22	38	s	<6
Somerset	19	9	10	14	<6	<6
Talbot	30	16	14	25	<6	<6
Washington	80	48	32	73	s	<6
Wicomico	86	46	40	73	s	<6
Worcester	42	25	17	36	s	<6

<6 = Death counts of 0-5 are suppressed per DHMH/CCSC Mortality Data Suppression Policy

s = Death counts are suppressed to prevent disclosure of data in other cell(s). (See Appendix C for methods.)

Source: NCHS Compressed Mortality File in CDC WONDER

Table 15.
Lung and Bronchus Cancer Age-Adjusted Mortality Rates*
by Jurisdiction, Gender and Race, Maryland, 2007

Jurisdiction	Total	Gender		Race		
		Males	Females	Whites	Blacks	Other
Maryland	50.1	62.9	41.1	51.4	51.2	18.0
Allegany	66.2	90.1	51.1	68.1	**	**
Anne Arundel	60.6	67.9	55.6	66.3	**	**
Baltimore City	63.1	83.6	49.2	54.6	69.4	**
Baltimore County	51.7	64.2	43.3	53.2	51.7	**
Calvert	51.5	72.3	**	50.7	**	**
Caroline	54.8	**	**	58.3	**	**
Carroll	56.5	71.1	47.6	57.1	**	**
Cecil	65.2	73.5	60.2	63.6	**	**
Charles	50.7	61.2	41.6	53.8	**	**
Dorchester	54.8	**	**	69.0	**	**
Frederick	57.8	85.9	36.9	58.2	**	**
Garrett	57.0	**	**	57.4	**	**
Harford	59.1	69.4	50.4	60.7	**	**
Howard	34.2	39.7	31.1	38.5	**	**
Kent	58.6	**	**	**	**	**
Montgomery	29.7	35.2	26.2	29.6	39.0	20.3
Prince George's	43.9	58.7	33.7	49.2	41.9	**
Queen Anne's	76.6	94.4	59.5	79.8	**	**
Saint Mary's	54.6	63.0	50.2	57.9	**	**
Somerset	70.8	**	**	**	**	**
Talbot	50.7	58.9	**	47.9	**	**
Washington	51.3	70.2	37.0	49.2	**	**
Wicomico	84.7	109.7	69.0	91.5	**	**
Worcester	53.0	71.1	39.4	51.8	**	**

* Rates are per 100,000 and age-adjusted to 2000 U.S. standard population

** Rates based on death counts of 0-15 are suppressed per DHMH/CCSC Mortality Data Suppression Policy

Source: NCHS Compressed Mortality File in CDC WONDER

Table 16.
Number of Lung and Bronchus Cancer Cases
by Jurisdiction, Gender and Race, Maryland, 2003-2007

Jurisdiction	Total	Gender		Race			
		Males	Females	Whites	Blacks	Other	Unknown
Maryland	18,181	9,374	8,785	13,788	3,990	385	18
Allegany	401	237	164	391	s	<6	0
Anne Arundel	1,706	875	823	1,528	154	24	0
Baltimore City	2,651	1,406	1,245	1,104	1,539	8	0
Baltimore County	3,355	1,648	1,707	2,826	485	44	0
Calvert	279	140	138	242	s	<6	0
Caroline	154	85	69	136	s	<6	0
Carroll	581	326	255	559	15	s	<6
Cecil	387	196	191	375	12	0	0
Charles	330	181	149	260	s	<6	0
Dorchester	176	100	76	133	s	<6	0
Frederick	700	383	316	661	33	6	0
Garrett	97	60	37	97	0	0	0
Harford	849	466	382	770	68	11	0
Howard	542	265	277	448	70	24	0
Kent	110	57	53	89	21	0	0
Montgomery †	1,962	887	1,073	1,560	238	158	6
Prince George's †	1,761	905	854	764	928	s	<6
Queen Anne's	196	104	91	174	s	<6	0
Saint Mary's	294	155	139	257	37	0	0
Somerset	139	90	49	95	s	<6	0
Talbot	197	76	121	175	22	0	0
Washington	541	326	215	514	s	<6	0
Wicomico	414	223	191	340	68	6	0
Worcester	286	148	138	245	31	10	0
Unknown	73	35	32	45	16	<6	s

Total includes cases reported as transsexual, hermaphrodite, or unknown gender

<6 = Case counts of 1-5 are suppressed per DHMH/MCR Data Use Policy and Procedures

s = Case counts are suppressed to prevent disclosure of data in other cell(s). (See Appendix C for methods.)

† 2006 case counts for Montgomery and Prince George's counties are underreported. (See Appendix C, Section I.A.1.)

Source: Maryland Cancer Registry

Table 17.
Lung and Bronchus Cancer Age-Adjusted Incidence Rates*
by Jurisdiction, Gender and Race, Maryland, 2003-2007

Jurisdiction	Total	Gender		Race		
		Males	Females	Whites	Blacks	Other
Maryland	66.6	80.0	57.0	68.6	64.3	35.5
Allegany	82.1	113.8	58.5	81.9	**	**
Anne Arundel	72.0	82.9	63.3	74.5	58.2	43.6
Baltimore City	82.2	108.2	65.2	89.4	78.7	**
Baltimore County	74.5	85.8	66.8	74.7	82.9	34.2
Calvert	76.1	87.2	67.9	77.6	69.4	**
Caroline	92.0	115.3	76.0	95.2	72.5	**
Carroll	72.5	93.0	58.2	72.4	**	**
Cecil	86.5	97.8	78.8	88.5	**	0.0
Charles	64.5	85.4	51.0	70.6	51.1	**
Dorchester	84.1	112.2	65.6	82.6	89.8	**
Frederick	74.8	95.4	60.4	76.5	62.4	**
Garrett	52.0	68.9	36.8	52.3	0.0	0.0
Harford	75.7	94.4	61.8	76.0	76.7	**
Howard	51.8	57.9	48.1	55.0	47.4	27.9
Kent	80.9	90.6	77.1	77.3	104.8	0.0
Montgomery †	42.4	45.3	40.7	43.5	46.8	31.4
Prince George's †	53.9	66.6	45.4	59.4	49.6	43.6
Queen Anne's	79.1	89.4	70.0	78.7	87.6	**
Saint Mary's	73.1	82.2	65.5	77.0	62.6	0.0
Somerset	101.6	142.6	62.3	93.7	113.0	**
Talbot	70.0	60.7	77.9	70.7	66.3	0.0
Washington	70.8	97.8	51.4	70.1	102.7	**
Wicomico	86.9	109.1	71.0	90.6	74.0	**
Worcester	74.2	83.8	67.0	72.6	67.1	**

* Rates are per 100,000 and are age-adjusted to 2000 U.S. standard population

** Rates based on case counts of 1-15 are suppressed per DHMH/MCR Data Use Policy and Procedures

† 2003-2007 incidence rates for Montgomery and Prince George's counties are lower than actual due to case underreporting in 2006. (See Appendix C, Section I.A.1.)

Source: Maryland Cancer Registry

Table 18.
Number of Lung and Bronchus Cancer Deaths
by Jurisdiction, Gender and Race, Maryland, 2003-2007

Jurisdiction	Total	Gender		Race		
		Males	Females	Whites	Blacks	Other
Maryland	14,563	7,899	6,664	10,929	3,407	227
Allegany	305	186	119	300	<6	<6
Anne Arundel	1,439	771	668	1,289	134	16
Baltimore City	2,332	1,284	1,048	914	1,410	8
Baltimore County	2,565	1,339	1,226	2,234	315	16
Calvert	215	120	95	183	s	<6
Caroline	128	78	50	111	s	<6
Carroll	443	253	190	429	s	<6
Cecil	304	155	149	291	s	<6
Charles	330	177	153	253	s	<6
Dorchester	140	75	65	112	s	<6
Frederick	463	274	189	440	s	<6
Garrett	85	54	31	s	<6	<6
Harford	662	371	291	599	57	6
Howard	358	184	174	284	57	17
Kent	81	44	37	s	s	<6
Montgomery	1,424	672	752	1,153	167	104
Prince George's	1,569	888	681	694	832	43
Queen Anne's	162	93	69	142	s	<6
Saint Mary's	252	146	106	217	s	<6
Somerset	116	67	49	89	s	<6
Talbot	150	71	79	129	s	<6
Washington	461	272	189	441	s	<6
Wicomico	358	199	159	292	s	<6
Worcester	221	126	95	188	s	<6

<6 = Death counts of 0-5 are suppressed per DHMH/CCSC Mortality Data Suppression Policy

s = Death counts are suppressed to prevent disclosure of data in other cell(s). (See Appendix C for methods.)

Source: NCHS Compressed Mortality File in CDC WONDER

Table 19.
Lung and Bronchus Cancer Age-Adjusted Mortality Rates*
by Jurisdiction, Gender and Race, Maryland, 2003-2007


Jurisdiction	Total	Gender		Race		
		Males	Females	Whites	Blacks	Other
Maryland	53.5	68.7	42.8	54.1	56.2	21.6
Allegany	61.6	89.3	41.7	62.0	**	**
Anne Arundel	61.7	75.5	51.4	63.7	53.0	29.4
Baltimore City	72.4	99.8	54.4	72.5	73.1	**
Baltimore County	56.3	70.1	46.6	57.9	54.9	11.7
Calvert	60.6	79.3	47.4	61.2	62.7	**
Caroline	75.9	106.0	53.8	77.5	70.5	**
Carroll	55.4	73.0	43.2	55.6	**	**
Cecil	69.1	79.6	62.2	69.7	**	**
Charles	67.0	89.1	54.2	71.0	58.5	**
Dorchester	66.0	85.1	54.1	68.9	56.8	**
Frederick	49.9	70.6	35.5	51.2	42.1	**
Garrett	45.2	63.4	30.0	45.5	**	**
Harford	59.8	76.6	47.3	59.8	65.4	**
Howard	34.9	41.1	30.6	35.8	37.3	21.0
Kent	57.7	70.8	50.1	49.8	104.2	**
Montgomery	30.6	34.9	27.7	31.4	32.8	22.0
Prince George's	49.0	66.9	36.7	53.8	46.2	26.1
Queen Anne's	65.1	78.0	52.7	63.6	83.8	**
Saint Mary's	64.7	84.0	50.5	67.4	58.9	**
Somerset	84.4	105.8	64.0	88.5	77.2	**
Talbot	52.6	57.1	48.8	51.0	60.8	**
Washington	59.9	81.9	44.0	59.7	94.1	**
Wicomico	75.1	99.8	58.2	77.8	66.0	**
Worcester	57.3	73.5	44.8	55.6	68.9	**

* Rates are per 100,000 and are age-adjusted to 2000 U.S. standard population

** Rates based on death counts of 0-15 are suppressed per DHMH/CCSC Mortality Data Suppression Policy

Source: NCHS Compressed Mortality File in CDC WONDER

Maryland Lung Cancer Incidence Rates by Geographical Area: Comparison to U.S. Rate, 2003-2007



Rates are age-adjusted to the 2000 U.S. standard population and are per 100,000 population.


Maryland area-specific rates with 95% confidence intervals are presented in Appendix H.

U.S. lung cancer incidence rate, 2003-2007: 62.5/100,000

Maryland lung cancer incidence rate, 2003-2007: 66.6/100,000

Source: MD incidence rates from Maryland Cancer Registry, 2003-2007
U.S. (SEER 17) rate from SEER*Stat Software

Maryland Lung Cancer Mortality Rates by Geographical Area: Comparison to U.S. Rate, 2003-2007



Rates are age-adjusted to the 2000 U.S. standard population and are per 100,000 population.

Maryland area-specific rates with 95% confidence intervals are presented in Appendix H.

U.S. lung cancer mortality rate, 2003-2007: 52.4/100,000

Maryland lung cancer mortality rate, 2003-2007: 53.5/100,000

Source: MD and U.S. mortality rates from NCHS Compressed Mortality File in CDC WONDER

B. Colon and Rectum Cancer

Incidence (New Cases)

In 2007, there were 2,382 new cases of cancer of the colon or rectum (called colorectal cancer) reported among Maryland residents. The age-adjusted colorectal cancer incidence rate in Maryland for 2007 was 41.6 per 100,000 population (40.0-43.4, 95% C.I.), which is statistically significantly lower than the 2007 U.S. SEER age-adjusted colorectal cancer incidence rate of 45.5 per 100,000 population (45.0-46.0, 95% C.I.).

Mortality (Deaths)

A total of 989 persons died of colorectal cancer in 2007 in Maryland. In 2007, colorectal cancer accounted for 9.7% of all cancer deaths and was the second leading cause of cancer deaths in Maryland. The age-adjusted colorectal cancer mortality rate in Maryland was 17.5 per 100,000 population (16.4-18.6, 95% C.I.). This rate is similar to the 2007 U.S. colorectal cancer mortality rate of 16.8 per 100,000 population (16.6-16.9, 95% C.I.). Maryland had the 16th highest colorectal cancer mortality rate among the states and the District of Columbia for the period 2003-2007.

Table 20.
Colorectal Cancer Incidence and Mortality Rates*
by Gender and Race, Maryland and the United States, 2007

<i>Incidence 2007</i>	<i>Total</i>	<i>Males</i>	<i>Females</i>	<i>Whites</i>	<i>Blacks</i>	<i>Other</i>
New Cases (count)	2,382	1,206	1,175	1,688	597	84
MD Incidence Rate	41.6	48.8	35.8	40.6	44.8	32.1
U.S. SEER Rate	45.5	52.8	39.7	44.7	55.8	37.8
<i>Mortality 2007</i>	<i>Total</i>	<i>Males</i>	<i>Females</i>	<i>Whites</i>	<i>Blacks</i>	<i>Other</i>
Deaths (count)	989	520	469	658	305	26
MD Mortality Rate	17.5	22.2	14.1	15.7	24.1	11.0
U.S. Mortality Rate	16.8	20.0	14.2	16.3	23.4	11.0


* Rates are per 100,000 and are age-adjusted to 2000 U.S. standard population

Total includes cases reported as transsexual, hermaphrodite, or unknown gender

Sources: MD incidence data from Maryland Cancer Registry

U.S. SEER rates from SEER*Stat software

MD mortality data from NCHS Compressed Mortality File in CDC WONDER




Rates are age-adjusted to 2000 U.S. standard population
 Sources: Maryland Cancer Registry (incidence rates)
 NCHS Compressed Mortality File in CDC WONDER (mortality rates)

Incidence and Mortality Trends

Incidence rates for colorectal cancer have been declining in Maryland. From 2003 to 2007, incidence rates declined at a rate of 6.8% per year.

Colorectal cancer mortality rates declined at a rate of 2.5% per year from 2003 to 2007.

See Appendix I, Tables 1 and 2.




Rates are age-adjusted to 2000 U.S. standard population
 Source: Maryland Cancer Registry

Incidence Trends by Race

From 2003 to 2007, colorectal cancer incidence rates declined at a rate of 9.0% per year for blacks and 5.9% per year among whites. In 2007, the incidence rate for colorectal cancer was 40.6 for whites and 44.8 for blacks in Maryland.

See Appendix I, Table 3.




Rates are age-adjusted to 2000 U.S. standard population
Source: NCHS Compressed Mortality File in CDC WONDER

Mortality Trends by Race

From 2003 to 2007, colorectal cancer mortality rates declined for blacks and whites. Mortality rates in blacks decreased at a rate of 3.0% per year; whereas, among whites, the decline was 2.8% per year.

See Appendix I, Table 5.




Source: Maryland Cancer Registry

Stage at Diagnosis

In 2007, 39.3% of colorectal cancers diagnosed in Maryland were detected at the localized stage, 32.8% were detected at the regional stage, and 18.1% were found at the distant stage. The proportion of colorectal cancers reported as unstaged has decreased in recent years.

See Appendix J, Table 3.




Note: Graphic includes results from both the Maryland BRFSS and Maryland Cancer Survey. See Appendix C for a cautionary note on comparing these data.

Sources: † Maryland BRFSS 1999 and 2001
 § Maryland Cancer Survey 2002, 2004, 2006, and 2008
 Healthy People 2010 Midcourse Review, U.S. Department of Health and Human Services (2006)

Screening with Fecal Occult Blood Test

One Healthy People 2010 target for colorectal cancer is to increase to 33% the proportion of adults age 50 years and older who received a fecal occult blood test (FOBT) in the preceding 2 years. FOBT testing in Maryland increased steadily from 1999 to 2002, surpassing the Healthy People 2010 target, but declined to 28% by 2008. The declining rate of FOBT screening has occurred in parallel with the increased use of endoscopy (see below).



Note: Graphic includes results from both the Maryland BRFSS and Maryland Cancer Survey. See Appendix C for a cautionary note on comparing these data.

Sources: † Maryland BRFSS 1999 and 2001
 § Maryland Cancer Survey 2002, 2004, 2006, and 2008
 Healthy People 2010, U.S. Department of Health and Human Services (2000)

Screening with Sigmoidoscopy or Colonoscopy

The second Healthy People 2010 target for colorectal cancer is to increase to 50% the proportion of adults age 50 years and older who ever received a sigmoidoscopy. In 2008, 75% of Maryland adults age 50 years and older reported ever having a sigmoidoscopy or colonoscopy, surpassing the Healthy People target. (Note: The Maryland BRFSS and MCS ask respondents whether they have ever had either a sigmoidoscopy or colonoscopy.)

Public Health Evidence (quoted from NCI PDQ, 4/1/2010 and 6/30/2009, and USPSTF, 11/2008)

Prevention

Based on fair evidence, removal of adenomatous polyps reduces the risk of colorectal cancer (CRC). Harms of polyp removal include infrequent perforation of the colon during the procedure, as well as bleeding and infection following the procedure. There is inadequate evidence to suggest that a diet low in fat and high in fiber, fruits, and vegetables decreases the risk of CRC; however, there are no known harms from dietary modification, including reduction of fatty acids and increase in the intake of fiber, fruits, and vegetables. Obesity is associated with a two-fold risk increase in CRC in premenopausal women. Cigarette smoking is associated with an increased tendency to form adenomas and to develop CRC.

Screening

Screening for CRC reduces CRC mortality but there is little evidence that it reduces all-cause mortality, possibly because of an observed increase in other causes of death. The United States Preventive Services Task Force (USPSTF) recommends screening men and women for CRC using fecal occult blood testing, sigmoidoscopy, or colonoscopy beginning at age 50 years and continuing until age 75 years. The USPSTF recommends against routine screening for CRC in adults age 76 to 85 years, but considerations may support CRC screening in an individual patient. The USPSTF recommends against CRC screening for adults older than age 85 years because there is moderate certainty that the benefits of screening do not outweigh the harms. Barium enema studies are no longer recommended due to lower sensitivity compared with other studies, lack of screening trials, and declining use. The USPSTF concluded that the benefits from screening substantially outweigh potential harms for persons age 50 to 75 years, but the risks and benefits vary with each method. They recommend that efforts to reduce CRC mortality should focus on maximizing the number of individuals who get screening and that test selection should be based on patient preference, local test availability, and quality. The USPSTF found insufficient evidence to assess the benefits and harms of computer tomographic (CT) colonography (“virtual colonoscopy”) and fecal DNA testing as screening modalities for CRC.

Chemoprevention

There is inadequate evidence that the use of nonsteroidal anti-inflammatory drugs (NSAIDs) reduces the risk of CRC. Based on solid evidence, NSAIDs reduce the risk of adenomas, but the extent to which this translates into a reduction of CRC is uncertain. However, harms of NSAID use include upper gastrointestinal bleeding and serious cardiovascular events such as heart attack, heart failure, and hemorrhagic stroke. Based on solid evidence, postmenopausal estrogen plus progesterone hormone use decreases the incidence of CRC, but this benefit is not applicable to estrogen alone use. However, harms of postmenopausal combined estrogen plus progestin hormone use include increased risk of breast cancer, coronary heart disease, stroke, and other thromboembolic events.

Public Health Intervention for CRC (USPSTF 2008; DHMH CRC Medical Advisory Committee, 2009)

- | |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <ul style="list-style-type: none">➤ For those age 50 to 75 years at average risk, screen with colonoscopy or with FOBT and flexible sigmoidoscopy. Persons older than age 75 years may also be screened if there are considerations to support screening after taking into account comorbidities, longevity, and past CRC screening results. The harms likely outweigh the benefits of CRC screening for persons age 85 years or older.➤ For those unable or unwilling to undergo colonoscopy or sigmoidoscopy, FOBT is an alternative initial screening method.➤ Reserve other CRC screening tests as alternatives for situations where the patient and the provider discuss and determine that such tests are indicated for the individual. |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

Table 21.
Number of Colorectal Cancer Cases
by Jurisdiction, Gender and Race, Maryland, 2007

Jurisdiction	Total	Gender		Race			
		Males	Females	Whites	Blacks	Other	Unknown
Maryland	2,382	1,206	1,175	1,688	597	84	13
Allegany	53	28	25	50	<6	<6	0
Anne Arundel	188	91	97	158	27	<6	<6
Baltimore City	288	136	152	s	184	<6	0
Baltimore County	390	186	203	319	65	6	0
Calvert	38	21	17	32	6	0	0
Caroline	19	9	10	s	<6	0	0
Carroll	65	36	29	65	0	0	0
Cecil	46	24	22	s	<6	0	0
Charles	52	31	21	32	s	<6	0
Dorchester	24	10	14	14	10	0	0
Frederick	82	49	33	76	<6	<6	<6
Garrett	16	9	7	16	0	0	0
Harford	108	59	49	93	s	<6	0
Howard	97	54	43	76	14	s	<6
Kent	s	<6	<6	<6	<6	0	0
Montgomery	343	169	174	258	44	s	<6
Prince George's	289	139	150	103	167	s	<6
Queen Anne's	32	17	15	s	<6	0	0
Saint Mary's	40	21	19	33	<6	<6	0
Somerset	17	s	<6	11	6	0	0
Talbot	22	12	10	14	8	0	0
Washington	74	43	31	71	<6	<6	0
Wicomico	50	26	24	42	8	0	0
Worcester	39	19	20	30	<6	s	0
Unknown	<6	0	<6	<6	<6	0	<6

Total includes cases reported as transsexual, hermaphrodite, or unknown gender

<6 = Case counts of 1-5 are suppressed per DHMH/MCR Data Use Policy and Procedures

s = Case counts are suppressed to prevent disclosure of data in other cell(s). (See Appendix C for methods.)

Source: Maryland Cancer Registry

Table 22.
Colorectal Cancer Age-Adjusted Incidence Rates*
by Jurisdiction, Gender and Race, Maryland, 2007

Jurisdiction	Total	Gender		Race		
		Males	Females	Whites	Blacks	Other
Maryland	41.6	48.8	35.8	40.6	44.8	32.1
Allegany	55.5	67.6	45.4	53.4	**	**
Anne Arundel	38.6	41.1	36.1	38.1	48.2	**
Baltimore City	44.6	52.5	39.4	40.7	47.2	**
Baltimore County	41.9	47.2	37.1	41.0	46.1	**
Calvert	47.8	57.5	39.2	49.2	**	0.0
Caroline	55.3	**	**	54.4	**	0.0
Carroll	38.1	45.8	30.9	39.6	0.0	0.0
Cecil	47.8	53.3	41.6	47.5	**	0.0
Charles	48.7	72.9	33.9	41.3	69.3	**
Dorchester	57.0	**	**	**	**	0.0
Frederick	39.5	52.8	27.1	40.3	**	**
Garrett	41.9	**	**	42.3	0.0	0.0
Harford	47.2	58.9	38.3	46.1	**	**
Howard	41.0	46.2	34.3	42.7	**	**
Kent	**	**	**	**	**	0.0
Montgomery	33.3	38.5	29.2	32.8	34.3	28.3
Prince George's	41.7	47.7	37.7	40.9	40.1	**
Queen Anne's	65.0	74.5	**	67.3	**	0.0
Saint Mary's	44.8	47.7	41.1	44.9	**	**
Somerset	63.7	**	**	**	**	0.0
Talbot	39.8	**	**	**	**	0.0
Washington	46.2	63.7	33.9	46.6	**	**
Wicomico	51.0	61.1	40.5	53.7	**	0.0
Worcester	48.6	53.3	42.8	43.5	**	**

* Rates are per 100,000 and are age-adjusted to 2000 U.S. standard population

** Rates based on case counts of 1-15 are suppressed per DHMH/MCR Data Use Policy and Procedures

Source: Maryland Cancer Registry

Table 23.
Number of Colorectal Cancer Deaths
by Jurisdiction, Gender and Race, Maryland, 2007

Jurisdiction	Total	Gender		Race		
		Males	Females	Whites	Blacks	Other
Maryland	989	520	469	658	305	26
Allegany	19	9	10	18	<6	<6
Anne Arundel	95	41	54	79	s	<6
Baltimore City	152	85	67	s	103	<6
Baltimore County	158	76	82	131	s	<6
Calvert	18	10	8	14	<6	<6
Caroline	6	<6	<6	s	<6	<6
Carroll	31	13	18	29	<6	<6
Cecil	17	11	6	15	<6	<6
Charles	30	17	13	21	s	<6
Dorchester	11	<6	s	6	<6	<6
Frederick	36	14	22	31	<6	<6
Garrett	6	<6	<6	<6	<6	<6
Harford	26	16	10	24	<6	<6
Howard	25	18	7	21	<6	<6
Kent	<6	<6	<6	<6	<6	<6
Montgomery	115	66	49	78	21	16
Prince George's	133	69	64	s	84	<6
Queen Anne's	12	s	<6	9	<6	<6
Saint Mary's	13	6	7	11	<6	<6
Somerset	<6	<6	<6	<6	<6	<6
Talbot	11	<6	s	8	<6	<6
Washington	30	19	11	27	<6	<6
Wicomico	24	16	8	16	s	<6
Worcester	13	s	<6	12	<6	<6

<6 = Death counts of 0-5 are suppressed per DHMH/CCSC Mortality Data Suppression Policy

s = Death counts are suppressed to prevent disclosure of data in other cell(s). (See Appendix C for methods.)

Source: NCHS Compressed Mortality File in CDC WONDER

Table 24.
Colorectal Cancer Age-Adjusted Mortality Rates*
by Jurisdiction, Gender and Race, Maryland, 2007

Jurisdiction	Total	Gender		Race		
		Males	Females	Whites	Blacks	Others
Maryland	17.5	22.2	14.1	15.7	24.1	11.0
Allegany	18.5	**	**	17.8	**	**
Anne Arundel	20.7	19.4	20.7	19.9	31.5	**
Baltimore City	23.1	34.4	16.5	17.9	26.5	**
Baltimore County	16.7	19.6	14.4	16.2	19.9	**
Calvert	23.3	**	**	**	**	**
Caroline	**	**	**	**	**	**
Carroll	18.0	**	18.3	17.5	**	**
Cecil	19.2	**	**	**	**	**
Charles	31.9	55.7	**	32.4	**	**
Dorchester	**	**	**	**	**	**
Frederick	18.5	**	18.5	18.0	**	**
Garrett	**	**	**	**	**	**
Harford	11.9	16.1	**	12.3	**	**
Howard	10.5	17.5	**	12.2	**	**
Kent	**	**	**	**	**	**
Montgomery	11.7	16.6	8.5	9.9	17.5	14.9
Prince George's	20.0	24.6	16.5	17.2	23.4	**
Queen Anne's	**	**	**	**	**	**
Saint Mary's	**	**	**	**	**	**
Somerset	**	**	**	**	**	**
Talbot	**	**	**	**	**	**
Washington	18.2	27.3	**	17.2	**	**
Wicomico	23.3	35.5	**	19.8	**	**
Worcester	**	**	**	**	**	**

* Rates are per 100,000 and age-adjusted to 2000 U.S. standard population

** Rates based on death counts of 0-15 are suppressed per DHMH/CCSC Mortality Data Suppression Policy

Source: NCHS Compressed Mortality File in CDC WONDER

Table 25.
Number of Colorectal Cancer Cases
by Jurisdiction, Gender and Race, Maryland, 2003-2007

Jurisdiction	Total	Gender		Race			
		Males	Females	Whites	Blacks	Other	Unknown
Maryland	12,811	6,362	6,438	9,073	3,205	441	92
Allegany	286	153	133	275	s	<6	0
Anne Arundel	1,048	567	480	866	148	26	8
Baltimore City	1,593	743	848	609	961	17	6
Baltimore County	2,183	1,041	1,141	1,757	373	40	13
Calvert	203	94	108	167	s	<6	<6
Caroline	87	53	34	75	12	0	0
Carroll	410	208	202	394	12	<6	<6
Cecil	237	126	111	221	s	<6	<6
Charles	301	162	139	210	82	<6	<6
Dorchester	121	70	51	92	29	0	0
Frederick	505	261	243	464	32	s	<6
Garrett	86	42	44	s	<6	0	0
Harford	503	250	253	449	44	s	<6
Howard	481	255	226	362	79	s	<6
Kent	62	30	32	52	10	0	0
Montgomery †	1,810	863	945	1,354	242	192	22
Prince George's †	1,527	718	808	519	919	75	14
Queen Anne's	123	68	55	107	s	<6	<6
Saint Mary's	208	121	87	166	34	s	<6
Somerset	70	42	28	47	s	<6	0
Talbot	132	71	61	109	23	0	0
Washington	362	182	180	341	17	<6	<6
Wicomico	234	124	110	180	47	s	<6
Worcester	170	92	78	141	20	9	0
Unknown	69	26	41	s	26	<6	9

Total includes cases reported as transsexual, hermaphrodite, or unknown gender

<6 = Case counts of 1-5 are suppressed per DHMH/MCR Data Use Policy and Procedures

s = Case counts are suppressed to prevent disclosure of data in other cell(s). (See Appendix C for methods.)

† 2006 case counts for Montgomery and Prince George's counties are underreported. (See Appendix C, Section I.A.1.)

Source: Maryland Cancer Registry

Table 26.
Colorectal Cancer Age-Adjusted Incidence Rates*
by Jurisdiction, Gender and Race, Maryland, 2003-2007

Jurisdiction	Total	Gender		Race		
		Males	Females	Whites	Blacks	Other
Maryland	46.4	53.7	40.9	44.7	50.8	37.5
Allegany	58.3	75.0	46.6	57.6	**	**
Anne Arundel	44.2	53.6	36.9	42.2	57.7	44.4
Baltimore City	49.0	56.9	43.8	47.8	49.4	35.7
Baltimore County	47.9	54.1	43.3	45.8	60.7	32.8
Calvert	54.3	54.1	53.3	53.5	63.1	**
Caroline	51.1	71.2	36.1	51.6	**	0.0
Carroll	50.8	59.2	44.4	50.6	**	**
Cecil	53.1	61.1	46.0	52.3	**	**
Charles	60.3	77.7	48.3	58.2	64.3	**
Dorchester	58.2	80.4	42.9	56.3	62.5	0.0
Frederick	53.1	65.2	44.8	53.0	56.1	**
Garrett	46.4	50.4	43.3	46.1	**	0.0
Harford	45.6	50.5	41.2	45.5	46.2	**
Howard	42.8	50.9	36.9	42.0	50.9	31.0
Kent	43.9	48.9	39.2	42.8	**	0.0
Montgomery †	37.9	42.6	34.4	36.6	42.8	34.8
Prince George's †	45.1	48.8	42.1	40.6	47.7	43.1
Queen Anne's	50.2	59.7	42.1	48.7	**	**
Saint Mary's	50.0	64.5	39.0	47.7	57.8	**
Somerset	51.3	66.9	37.9	46.4	61.6	**
Talbot	48.6	59.5	38.8	45.8	70.1	0.0
Washington	46.6	54.3	40.5	45.9	73.2	**
Wicomico	49.2	62.0	40.1	47.8	49.5	**
Worcester	45.8	53.5	39.1	44.0	44.8	**

* Rates are per 100,000 and are age-adjusted to 2000 U.S. standard population

** Rates based on case counts of 1-15 are suppressed per DHMH/MCR Data Use Policy and Procedures

† 2003-2007 incidence rates for Montgomery and Prince George's counties are lower than actual due to case underreporting in 2006. (See Appendix C, Section I.A.1.)

Source: Maryland Cancer Registry

Table 27.
Number of Colorectal Cancer Deaths
by Jurisdiction, Gender and Race, Maryland, 2003-2007

Jurisdiction	Total	Gender		Race		
		Males	Females	Whites	Blacks	Other
Maryland	5,049	2,553	2,496	3,513	1,438	98
Allegany	94	44	50	92	<6	<6
Anne Arundel	443	236	207	368	67	8
Baltimore City	743	345	398	s	466	<6
Baltimore County	878	439	439	720	148	10
Calvert	91	45	46	72	s	<6
Caroline	32	19	13	29	<6	<6
Carroll	176	80	96	164	s	<6
Cecil	94	49	45	89	<6	<6
Charles	144	82	62	101	s	<6
Dorchester	52	27	25	36	s	<6
Frederick	185	86	99	166	s	<6
Garrett	26	12	14	25	<6	<6
Harford	170	87	83	149	s	<6
Howard	154	92	62	109	36	9
Kent	30	16	14	23	s	<6
Montgomery	581	297	284	448	88	45
Prince George's	650	312	338	229	405	16
Queen Anne's	53	30	23	44	s	<6
Saint Mary's	76	45	31	63	s	<6
Somerset	19	13	6	s	<6	<6
Talbot	47	25	22	35	s	<6
Washington	135	74	61	128	s	<6
Wicomico	114	57	57	79	s	<6
Worcester	62	41	21	55	s	<6

<6 = Death counts of 0-5 are suppressed per DHMH/CCSC Mortality Data Suppression Policy

s = Death counts are suppressed to prevent disclosure of data in other cell(s). (See Appendix C for methods.)

Source: NCHS Compressed Mortality File in CDC WONDER

Table 28.
Colorectal Cancer Age-Adjusted Mortality Rates*
by Jurisdiction, Gender and Race, Maryland, 2003-2007


Jurisdiction	Total	Gender		Race		
		Males	Females	Whites	Blacks	Other
Maryland	18.6	22.7	15.7	17.3	24.6	9.1
Allegany	18.8	21.6	18.0	19.0	**	**
Anne Arundel	19.6	23.8	16.2	18.7	27.6	**
Baltimore City	22.8	27.5	19.9	20.6	24.7	**
Baltimore County	19.0	23.2	15.9	18.2	26.3	**
Calvert	25.7	28.5	23.4	24.5	35.6	**
Caroline	19.2	26.1	**	20.5	**	**
Carroll	22.3	24.1	20.5	21.6	**	**
Cecil	21.8	25.9	18.5	21.8	**	**
Charles	31.0	44.8	22.5	29.4	38.8	**
Dorchester	25.1	32.4	20.3	22.4	34.1	**
Frederick	20.0	21.1	18.4	19.5	29.7	**
Garrett	13.8	**	**	13.4	**	**
Harford	16.1	17.9	14.1	15.7	21.8	**
Howard	15.2	21.5	10.8	14.0	24.9	**
Kent	22.1	27.5	**	18.7	**	**
Montgomery	12.3	15.5	10.1	11.9	16.9	9.1
Prince George's	20.9	23.6	18.7	17.8	24.6	11.5
Queen Anne's	22.2	27.7	17.5	20.7	**	**
Saint Mary's	19.8	25.6	15.0	19.5	**	**
Somerset	13.9	**	**	**	**	**
Talbot	15.9	19.8	13.1	13.4	**	**
Washington	17.1	23.0	13.1	16.8	**	**
Wicomico	23.8	28.9	20.0	20.9	35.2	**
Worcester	16.1	23.0	10.1	16.4	**	**

* Rates are per 100,000 and are age-adjusted to 2000 U.S. standard population

** Rates based on death counts of 0-15 are suppressed per DHMH/CCSC Mortality Data Suppression Policy

Source: NCHS Compressed Mortality File in CDC WONDER

Maryland Colorectal Cancer Incidence Rates by Geographical Area: Comparison to U.S. Rate, 2003-2007



Rates are age-adjusted to the 2000 U.S. standard population and are per 100,000 population.


Maryland area-specific rates with 95% confidence intervals are presented in Appendix H.

U.S. colorectal cancer incidence rate, 2003-2007: 47.9/100,000

Maryland colorectal cancer incidence rate, 2003-2007: 46.4/100,000

Source: MD incidence rates from Maryland Cancer Registry, 2003-2007
U.S. (SEER 17) rate from SEER*Stat Software

Maryland Colorectal Cancer Mortality Rates by Geographical Area: Comparison to U.S. Rate, 2003-2007



Rates are age-adjusted to the 2000 U.S. standard population and are per 100,000 population.

Maryland area-specific rates with 95% confidence intervals are presented in Appendix H.

U.S. colorectal cancer mortality rate, 2003-2007: 17.6/100,000

Maryland colorectal cancer mortality rate, 2003-2007: 18.6/100,000

Source: MD and U.S. mortality rates from NCHS Compressed Mortality File in CDC WONDER

C. Female Breast Cancer

Incidence (New Cases)

In 2007, a total of 3,976 cases of breast cancer were reported among Maryland women. The 2007 age-adjusted incidence rate in Maryland was 123.2 per 100,000 women (119.4-127.2, 95% C.I.); this rate is similar to the 2007 U.S. SEER age-adjusted incidence rate for breast cancer of 123.4 per 100,000 women (122.3-124.4, 95% C.I.).

Mortality (Deaths)

In 2007, a total of 814 women died of breast cancer in Maryland. Female breast cancer accounted for 8.0% of all cancer deaths in Maryland in 2007. Breast cancer is the second leading cause of cancer death among women in Maryland after lung cancer. The 2007 age-adjusted mortality rate for breast cancer in Maryland was 24.8 per 100,000 women (23.1-26.6, 95% C.I.). This rate is similar to the 2007 U.S. breast cancer mortality rate of 22.9 per 100,000 population of women (22.7-23.2, 95% C.I.). Maryland ranked 6th highest for female breast cancer mortality among the states and the District of Columbia for the period 2003-2007.

Table 29.
Female Breast Incidence and Mortality Rates*
by Race, Maryland and the United States, 2007

<i>Incidence 2007</i>	<i>Total</i>	<i>Whites</i>	<i>Blacks</i>	<i>Other</i>
New Cases (count)	3,976	2,781	1,012	170
MD Incidence Rate	123.2	125.4	117.2	102.3
U.S. SEER Rate	123.4	126.3	120.7	90.8
<i>Mortality 2007</i>	<i>Total</i>	<i>Whites</i>	<i>Blacks</i>	<i>Other</i>
Deaths (count)	814	535	266	13
MD Mortality Rate	24.8	22.8	32.4	**
U.S. Mortality Rate	22.9	22.4	31.4	11.3


* Rates are per 100,000 and are age-adjusted to 2000 U.S. standard population

** MD mortality rates based on death counts of 0-15 are suppressed per DHMH/CCSC Mortality Data Suppression Policy

Sources: MD incidence data from Maryland Cancer Registry

U.S. SEER rates from SEER*Stat software

MD mortality data from NCHS Compressed Mortality File in CDC WONDER




Rates are age-adjusted to 2000 U.S. standard population
 Sources: Maryland Cancer Registry (incidence rates)
 NCHS Compressed Mortality File in CDC WONDER (mortality rates)

Incidence and Mortality Trends

From 2003 to 2007, incidence rates for female breast cancer declined in Maryland. Breast cancer incidence rates decreased at a rate of 2.5% annually.

Breast cancer mortality rates for females decreased at a rate of 2.3% per year.

See Appendix I, Tables 1 and 2.




Rates are age-adjusted to 2000 U.S. standard population
 Source: Maryland Cancer Registry

Incidence Trends by Race

Breast cancer incidence rates decreased in Maryland from 2003 to 2007, narrowing the gap between white and black women. Incidence rates decreased at a rate of 2.7% per year among white women and 0.6% among black women. In 2007, the breast cancer incidence rate for white women in Maryland was 125.4 compared to 117.2 for black women.

See Appendix I, Table 3.




Rates are age-adjusted to 2000 U.S. standard population
Source: NCHS Compressed Mortality File in CDC WONDER

Mortality Trends by Race

Female breast cancer mortality rates declined from 2003 to 2007. Mortality rates in blacks decreased at a rate of 2.3% per year compared to whites who had a decrease of 2.1% per year.

See Appendix I, Table 5.




Source: Maryland Cancer Registry

Stage of Disease at Diagnosis

In 2007, 58.4% of all female breast cancer cases in Maryland were diagnosed at the local stage, 31.6% were found at the regional stage, and 5.8% were diagnosed at the distant stage.

See Appendix J, Table 4.



Breast Cancer Screening

The Healthy People 2010 target for breast cancer is to increase to 70% the proportion of women age 40 years and older who received a mammogram within the preceding 2 years. Maryland women have consistently surpassed this target. In 2008, 77% of Maryland women age 40 years and older reported receiving a mammogram within the preceding 2 years.

Sources: Maryland BRFSS
Healthy People 2010, U.S. Department of Health and Human Services (2000)

Public Health Evidence (quoted from NCI PDQ, 4/29/2010 and 4/9/2010; USPSTF Chemoprevention 7/2002, Screening 11/2009)

Primary Prevention

Factors associated with increased female breast cancer risk are: combination hormone therapy (HT) with estrogen-progestin (evidence for increased risk with estrogen only therapy is mixed); ionizing radiation; obesity in postmenopausal women who have not used HT; alcohol (dose-dependent association); inherited gene mutations associated with breast cancer. Solid evidence shows that exercising vigorously more than 4 hours per week and breast-feeding are associated with reduced breast cancer risk. It is uncertain whether reducing weight or decreasing alcohol exposure would decrease the risk of breast cancer.

Screening

Based on fair evidence, screening mammography in women aged 40-70 years decreases breast cancer mortality. The benefit is higher for older women, in part because their breast cancer risk is higher. Relative breast cancer-specific mortality is decreased by 15%-20%. Absolute mortality benefit for women screened annually starting at age 40 years is 4 per 10,000 at 10.7 years. The comparable mortality benefit for women screened annually starting at age 50 years is approximately 5 per 1,000. The United States Preventive Services Task Force (USPSTF) recommends that the decision to start regular, biennial screening mammography before the age of 50 years should be an individual one and take patient context into account, including the patient's values regarding specific benefits and harms. Based on solid evidence, screening mammography may lead to the following harms: treatment of insignificant cancers; additional testing; false sense of security and delay in cancer diagnosis; radiation-induced cell mutations that can cause breast cancer, especially if exposed before age 30 years. Based on fair evidence, screening by clinical breast examination reduces breast cancer mortality, but leads to additional testing and a false reassurance that may delay cancer diagnosis. Based on fair evidence, teaching breast self-examination (BSE) does not reduce breast cancer mortality; BSE leads to more breast biopsies and to the diagnosis of more benign breast lesions.

Chemoprevention

The USPSTF recommends against the routine use of tamoxifen or raloxifene (selective estrogen receptor modulators) for the primary prevention of breast cancer in women at low or average risk for breast cancer. The USPSTF recommends that clinicians discuss chemoprevention with women at high risk for breast cancer and at low risk for adverse effects of chemoprevention. Clinicians should inform patients of the potential benefits and harms of chemoprevention. Based on solid evidence for tamoxifen and fair evidence for raloxifene, treatment reduces the incidence of breast cancer in postmenopausal women. Tamoxifen also reduced the risk of breast cancer in high-risk premenopausal women. Treatment with tamoxifen reduced breast cancer by about 50%. Treatment with raloxifene has a similar effect on reduction of invasive breast cancer but appears to be less effective for prevention of noninvasive tumors. Based on solid evidence, tamoxifen treatment increases the risk of endometrial cancer, thrombotic vascular events (pulmonary embolism, stroke, deep venous thrombosis), and cataracts. Based on fair evidence, raloxifene also increases venous pulmonary embolism and deep venous thrombosis but not endometrial cancer. Aromatase inhibitors or inactivators reduce the incidence of new breast cancers in postmenopausal women who have a history of breast cancer but may cause decreased bone mineral density, increased falls, and decreased cognitive function.

Public Health Intervention for Breast Cancer (DHMH Breast Cancer Medical Advisory Committee, 2009)
Early detection of breast cancer: <ul style="list-style-type: none">➤ Screen using mammography and a clinical breast examination by a health professional, every 1-2 years for women age 40 years and older.

Table 30.
Number of Female Breast Cancer Cases
by Jurisdiction and Race, Maryland, 2007

Jurisdiction	Total	Race			
		Whites	Blacks	Other	Unknown
Maryland	3,976	2,781	1,012	170	13
Allegany	52	s	0	<6	0
Anne Arundel	357	289	47	21	0
Baltimore City	395	122	266	<6	<6
Baltimore County	603	478	103	s	<6
Calvert	67	56	s	0	<6
Caroline	24	s	<6	0	0
Carroll	137	134	<6	<6	0
Cecil	82	s	<6	0	0
Charles	76	47	s	<6	0
Dorchester	27	19	8	0	0
Frederick	146	133	7	6	0
Garrett	21	21	0	0	0
Harford	168	139	s	<6	<6
Howard	178	139	27	12	0
Kent	25	s	<6	0	0
Montgomery	742	571	95	s	<6
Prince George's	473	123	337	s	<6
Queen Anne's	34	30	<6	<6	0
Saint Mary's	67	56	s	<6	0
Somerset	19	13	6	0	0
Talbot	48	42	<6	<6	0
Washington	93	89	<6	<6	0
Wicomico	68	52	s	<6	0
Worcester	54	43	s	<6	0
Unknown	20	12	s	0	<6

<6 = Case counts of 1-5 are suppressed per DHMH/MCR Data Use Policy and Procedures

s = Case counts are suppressed to prevent disclosure of data in other cell(s). (See Appendix C for methods.)

Source: Maryland Cancer Registry

Table 31.
Female Breast Cancer Age-Adjusted Incidence Rates*
by Jurisdiction and Race, Maryland, 2007

Jurisdiction	Total	Race		
		Whites	Blacks	Other
Maryland	123.2	125.4	117.2	102.3
Allegany	106.7	107.3	0.0	**
Anne Arundel	125.2	120.1	129.6	208.0
Baltimore City	108.1	96.6	113.4	**
Baltimore County	122.0	122.0	111.5	109.3
Calvert	142.4	143.0	**	0.0
Caroline	125.2	124.8	**	0.0
Carroll	144.2	146.7	**	**
Cecil	161.7	166.9	**	0.0
Charles	109.7	105.0	120.4	**
Dorchester	123.2	116.6	**	0.0
Frederick	126.3	127.7	**	**
Garrett	106.3	107.0	0.0	0.0
Harford	126.0	118.9	205.8	**
Howard	124.6	133.5	111.3	**
Kent	182.6	198.7	**	0.0
Montgomery	128.2	136.3	114.1	97.1
Prince George's	106.8	94.4	117.7	**
Queen Anne's	120.4	120.0	**	**
Saint Mary's	138.0	140.9	**	**
Somerset	122.3	**	**	0.0
Talbot	170.5	179.1	**	**
Washington	110.4	110.6	**	**
Wicomico	125.3	125.5	**	**
Worcester	153.8	144.1	**	**

* Rates are per 100,000 and are age-adjusted to 2000 U.S. standard population

** Rates based on case counts of 1-15 are suppressed per DHMH/MCR Data Use Policy and Procedures

Source: Maryland Cancer Registry

Table 32.
Number of Female Breast Cancer Deaths
by Jurisdiction and Race, Maryland, 2007

Jurisdiction	Total	Race		
		Whites	Blacks	Other
Maryland	814	535	266	13
Allegany	12	11	<6	<6
Anne Arundel	78	64	s	<6
Baltimore City	103	s	82	<6
Baltimore County	120	95	s	<6
Calvert	12	8	<6	<6
Caroline	<6	<6	<6	<6
Carroll	22	21	<6	<6
Cecil	13	s	<6	<6
Charles	18	12	s	<6
Dorchester	<6	<6	<6	<6
Frederick	31	28	<6	<6
Garrett	9	s	<6	<6
Harford	29	22	s	<6
Howard	26	23	<6	<6
Kent	<6	<6	<6	<6
Montgomery	114	89	s	<6
Prince George's	131	s	92	<6
Queen Anne's	12	11	<6	<6
Saint Mary's	16	s	<6	<6
Somerset	<6	<6	<6	<6
Talbot	7	6	<6	<6
Washington	23	21	<6	<6
Wicomico	13	12	<6	<6
Worcester	13	10	<6	<6

<6 = Death counts of 0-5 are suppressed per DHMH/CCSC Mortality Data Suppression Policy

s = Death counts are suppressed to prevent disclosure of data in other cell(s). (See Appendix C for methods.)

Source: NCHS Compressed Mortality File in CDC WONDER

Table 33.
Female Breast Cancer Age-Adjusted Mortality Rates*
by Jurisdiction and Race, Maryland, 2007

Jurisdiction	Total	Race		
		Whites	Blacks	Other
Maryland	24.8	22.8	32.4	**
Allegany	**	**	**	**
Anne Arundel	28.3	27.4	**	**
Baltimore City	27.6	15.7	35.2	**
Baltimore County	23.3	22.5	26.1	**
Calvert	**	**	**	**
Caroline	**	**	**	**
Carroll	21.6	21.6	**	**
Cecil	**	**	**	**
Charles	26.4	**	**	**
Dorchester	**	**	**	**
Frederick	26.5	26.6	**	**
Garrett	**	**	**	**
Harford	22.5	19.4	**	**
Howard	19.3	22.6	**	**
Kent	**	**	**	**
Montgomery	19.5	19.9	28.8	**
Prince George's	30.5	25.3	33.6	**
Queen Anne's	**	**	**	**
Saint Mary's	33.7	40.9	**	**
Somerset	**	**	**	**
Talbot	**	**	**	**
Washington	24.9	23.5	**	**
Wicomico	**	**	**	**
Worcester	**	**	**	**

* Rates are per 100,000 and age-adjusted to 2000 U.S. standard population

** Rates based on death counts of 0-15 are suppressed per DHMH/CCSC Mortality Data Suppression Policy

Source: NCHS Compressed Mortality File in CDC WONDER

Table 34.
Number of Female Breast Cancer Cases
by Jurisdiction and Race, Maryland, 2003-2007

Jurisdiction	Total	Race			
		Whites	Blacks	Other	Unknown
Maryland	19,176	13,613	4,676	727	160
Allegany	280	274	<6	<6	0
Anne Arundel	1,653	1,385	208	54	6
Baltimore City	1,902	733	1,121	30	18
Baltimore County	3,179	2,453	621	72	33
Calvert	266	229	s	<6	<6
Caroline	129	112	s	<6	0
Carroll	616	586	19	s	<6
Cecil	297	285	s	<6	0
Charles	368	239	118	s	<6
Dorchester	117	92	s	<6	0
Frederick	779	708	47	s	<6
Garrett	120	117	<6	0	<6
Harford	730	650	71	s	<6
Howard	905	716	123	59	7
Kent	106	97	9	0	0
Montgomery †	3,488	2,671	437	341	39
Prince George's †	2,444	748	1,591	78	27
Queen Anne's	135	122	s	<6	0
Saint Mary's	242	209	26	7	0
Somerset	74	52	22	0	0
Talbot	191	162	s	<6	0
Washington	467	453	8	6	0
Wicomico	327	252	66	<6	<6
Worcester	247	205	30	12	0
Unknown	114	63	37	<6	s

<6 = Case counts of 1-5 are suppressed per DHMH/MCR Data Use Policy and Procedures

s = Case counts are suppressed to prevent disclosure of data in other cell(s). (See Appendix C for methods.)

† 2006 case counts for Montgomery and Prince George's counties are underreported.

(See Appendix C, Section I.A.1.)

Source: Maryland Cancer Registry

Table 35.
Female Breast Cancer Age-Adjusted Incidence Rates*
by Jurisdiction and Race, Maryland, 2003-2007

Jurisdiction	Total	Race		
		Whites	Blacks	Other
Maryland	122.4	125.0	113.6	95.7
Allegany	115.7	115.9	**	**
Anne Arundel	120.2	118.7	123.3	117.4
Baltimore City	102.8	113.8	95.4	96.2
Baltimore County	130.4	125.6	150.0	91.8
Calvert	119.8	122.2	111.2	**
Caroline	143.5	147.1	**	**
Carroll	133.9	132.6	154.0	**
Cecil	118.9	121.0	**	**
Charles	109.3	104.8	118.1	**
Dorchester	108.1	112.5	82.3	**
Frederick	139.5	139.1	126.0	145.1
Garrett	125.2	122.8	**	0.0
Harford	113.2	113.3	122.5	**
Howard	129.6	136.5	113.6	85.5
Kent	159.0	173.0	**	0.0
Montgomery †	128.1	133.8	113.0	97.6
Prince George's †	114.0	111.4	115.1	74.5
Queen Anne's	101.9	103.8	**	**
Saint Mary's	105.9	110.9	77.3	**
Somerset	106.9	103.7	119.1	0.0
Talbot	141.3	139.5	150.1	**
Washington	114.9	116.6	**	**
Wicomico	127.3	127.1	122.1	**
Worcester	139.1	134.7	121.6	**

* Rates are per 100,000 and are age-adjusted to 2000 U.S. standard population

** Rates based on case counts of 1-15 are suppressed per DHMH/MCR Data Use Policy and Procedures

† 2003-2007 incidence rates for Montgomery and Prince George's counties are lower than actual due to case underreporting in 2006. (See Appendix C, Section I.A.1.)

Source: Maryland Cancer Registry

Table 36.
Number of Female Breast Cancer Deaths
by Jurisdiction and Race, Maryland, 2003-2007

Jurisdiction	Total	Race		
		Whites	Blacks	Other
Maryland	4,110	2,784	1,259	67
Allegany	75	72	<6	<6
Anne Arundel	352	294	52	6
Baltimore City	591	s	389	<6
Baltimore County	659	531	121	7
Calvert	71	58	s	<6
Caroline	23	20	<6	<6
Carroll	118	114	<6	<6
Cecil	62	60	<6	<6
Charles	92	63	s	<6
Dorchester	18	15	<6	<6
Frederick	138	126	s	<6
Garrett	35	s	<6	<6
Harford	157	134	s	<6
Howard	120	98	s	<6
Kent	21	17	<6	<6
Montgomery	567	428	114	25
Prince George's	622	182	425	15
Queen Anne's	41	36	<6	<6
Saint Mary's	55	49	s	<6
Somerset	24	17	s	<6
Talbot	31	25	s	<6
Washington	110	107	<6	<6
Wicomico	77	61	s	<6
Worcester	51	42	s	<6

<6 = Death counts of 0-5 are suppressed per DHMH/CCSC Mortality Data Suppression Policy

s = Death counts are suppressed to prevent disclosure of data in other cell(s). (See Appendix C for methods.)

Source: NCHS Compressed Mortality File in CDC WONDER

Table 37.
Female Breast Cancer Age-Adjusted Mortality Rates*
by Jurisdiction and Race, Maryland, 2003-2007


Jurisdiction	Total	Race		
		Whites	Blacks	Other
Maryland	25.9	24.3	31.8	9.7
Allegany	25.6	24.9	**	**
Anne Arundel	26.1	25.6	31.2	**
Baltimore City	31.0	27.2	33.2	**
Baltimore County	25.4	24.6	30.6	**
Calvert	34.0	33.6	**	**
Caroline	24.1	24.6	**	**
Carroll	25.5	25.5	**	**
Cecil	25.1	25.6	**	**
Charles	29.4	29.5	27.8	**
Dorchester	15.4	**	**	**
Frederick	25.0	24.8	**	**
Garrett	36.7	36.9	**	**
Harford	24.9	23.7	39.8	**
Howard	18.8	20.3	19.0	**
Kent	24.7	24.2	**	**
Montgomery	20.3	20.0	30.2	7.7
Prince George's	30.4	25.2	33.4	**
Queen Anne's	31.2	31.5	**	**
Saint Mary's	24.8	26.7	**	**
Somerset	34.1	31.6	**	**
Talbot	20.7	19.4	**	**
Washington	25.0	25.2	**	**
Wicomico	28.8	29.5	28.4	**
Worcester	26.7	25.9	**	**

* Rates are per 100,000 and are age-adjusted to 2000 U.S. standard population

** Rates based on death counts of 0-15 are suppressed per DHMH/CCSC Mortality Data
Suppression Policy

Source: NCHS Compressed Mortality File in CDC WONDER

Maryland Female Breast Cancer Incidence Rates by Geographical Area: Comparison to U.S. Rate, 2003-2007



Rates are age-adjusted to the 2000 U.S. standard population and are per 100,000 population.


Maryland area-specific rates with 95% confidence intervals are presented in Appendix H.

U.S. female breast cancer incidence rate, 2003-2007: 122.9/100,000

Maryland female breast cancer incidence rate, 2003-2007: 122.4/100,000

Source: MD incidence rates from Maryland Cancer Registry, 2003-2007
U.S. (SEER 17) rate from SEER*Stat Software

Maryland Female Breast Cancer Mortality Rates by Geographical Area: Comparison to U.S. Rate, 2003-2007



Rates are age-adjusted to the 2000 U.S. standard population and are per 100,000 population.

Maryland area-specific rates with 95% confidence intervals are presented in Appendix H.

U.S. female breast cancer mortality rate, 2003-2007: 24.0 /100,000

Maryland female breast cancer mortality rate, 2003-2007: 25.9/100,000

Source: MD and U.S. mortality rates from NCHS Compressed Mortality File in CDC WONDER

D. Prostate Cancer

Incidence (New Cases)

In 2007, a total of 4,274 cases of prostate cancer were reported among men in Maryland. The age-adjusted prostate cancer incidence rate in Maryland for 2007 was 162.5 per 100,000 men (157.5-167.5, 95% C.I.); this is similar to the 2007 U.S. SEER age-adjusted incidence rate for prostate cancer of 159.8 per 100,000 men (158.5-161.2, 95% C.I.).

Mortality (Deaths)

Prostate cancer is the second leading cause of cancer deaths among men in Maryland, after lung cancer. In 2007, 550 men died of prostate cancer in Maryland, accounting for 5.4% of all cancer deaths in Maryland. The 2007 age-adjusted mortality rate for prostate cancer in Maryland was 26.6 per 100,000 men (24.4-28.9, 95% C.I.). This rate is statistically significantly higher than the 2007 U.S. mortality rate for prostate cancer of 23.5 per 100,000 men (23.2-23.8, 95% C.I.). Maryland had the 11th highest mortality rate for prostate cancer among the states and the District of Columbia for the period 2003-2007.

Table 38.
Prostate Cancer Incidence and Mortality Rates*
by Race, Maryland and the United States, 2007

<i>Incidence 2007</i>	<i>Total</i>	<i>Whites</i>	<i>Blacks</i>	<i>Other</i>
New Cases (count)	4,274	2,813	1,230	175
MD Incidence Rate	162.5	146.5	209.0	143.3
U.S. SEER Rate	159.8	151.9	227.8	88.0
<i>Mortality 2007</i>	<i>Total</i>	<i>Whites</i>	<i>Blacks</i>	<i>Other</i>
Deaths (count)	550	367	s	<6
MD Mortality Rate	26.6	23.0	45.3	**
U.S. Mortality Rate	23.5	21.6	51.5	11.0

* Rates are per 100,000 and are age-adjusted to 2000 U.S. standard population

s = Counts are suppressed to prevent disclosure of data in other cell(s) based on Table 41

<6 = MD death counts of 0-5 are suppressed per DHMH/CCSC Mortality Data Suppression Policy


** MD mortality rates based on death counts of 0-15 are suppressed per DHMH/CCSC

Mortality Data Suppression Policy

Sources: MD incidence data from Maryland Cancer Registry

U.S. SEER rates from SEER*Stat software

MD mortality data from NCHS Compressed Mortality File in CDC WONDER



Rates are age-adjusted to 2000 U.S. standard population

Sources: Maryland Cancer Registry (incidence rates)


NCHS Compressed Mortality File in CDC WONDER (mortality rates)

Incidence and Mortality Trends

The prostate cancer incidence rate in Maryland decreased at a rate of 1.3% per year from 2003 to 2007.

Prostate cancer mortality rates declined from 2003 to 2007, with a yearly decline of 2.7%.

See Appendix I, Tables 1 and 2.



Rates are age-adjusted to 2000 U.S. standard population


Source: Maryland Cancer Registry

Incidence Trends by Race

From 2003 to 2007, black men had consistently higher prostate cancer incidence rates than white men, although this disparity has been reduced over time.

Incidence rates for black men decreased at a rate of 3.6% per year during this 5-year period, while rates for white men held relatively steady (decrease of 0.1% per year).

See Appendix I, Table 3.




Rates are age-adjusted to 2000 U.S. standard population
Source: NCHS Compressed Mortality File in CDC WONDER

Mortality Trends by Race

Prostate cancer mortality rates declined from 2003 to 2007. Mortality rates in blacks declined at a rate of 3.6% per year compared to whites with a decline of 2.4% per year. While a gap exists, the difference is smaller in 2007 as compared to 2003.

See Appendix I, Table 5.




Source: Maryland Cancer Registry

Stage at Diagnosis

Of prostate cancers diagnosed in Maryland in 2007, 69.1% were detected at the localized stage, 10% were found at the regional stage, and 2.7% were diagnosed at the distant stage.

See Appendix J, Table 5.



Prostate-Specific Antigen Test

There is no Healthy People 2010 objective for prostate cancer detection.

In 2008, 76% of Maryland men age 50 years and older reported that they have ever had a prostate-specific antigen (PSA) test, and 59% of men age 50 years and older had a PSA in the last year. Screening rates have been relatively stable from 1999 to 2008.

Note: Graphic includes results from both the Maryland BRFSS and Maryland Cancer Survey.

See Appendix C for a cautionary note on comparing these data.

Sources: † Maryland BRFSS 1999 and 2001

§ Maryland Cancer Survey 2002, 2004, 2006, and 2008

Public Health Evidence (quoted from NCI PDQ, 7/27/2009 and 9/3/2010, and USPSTF, 8/2008)

Primary Prevention

The Selenium and Vitamin E Cancer Prevention Trial failed to demonstrate that these drugs reduce the period prevalence of prostate cancer.

Screening

The prostate specific antigen (PSA) blood test and the digital rectal examination (DRE) are two commonly used screening tests to detect prostate cancer. The evidence is insufficient to determine whether screening for prostate cancer with DRE or PSA reduces mortality from prostate cancer. The USPSTF concluded that current evidence is insufficient to assess the balance of benefits and harms of screening for prostate cancer in men younger than age 75 years, and recommended against screening for prostate cancer in men age 75 years or older. Screening tests are able to detect prostate cancer at an early stage, but it is not clear whether this earlier detection and consequent earlier treatment leads to any change in the disease natural history and outcome of the disease. Observational evidence shows a trend toward lower mortality for prostate cancer in some countries, but the relationship between these trends and intensity of screening is not clear, and associations with screening patterns are inconsistent. The observed trends may be due to screening or factors such as improved treatment. Solid evidence indicates that screening with PSA and/or DRE detects some prostate cancers that would never have caused clinical problems. Thus, screening leads to some degree of overtreatment. Current prostate cancer treatments, including radical prostatectomy and radiation therapy, result in permanent side effects in many men, including erectile dysfunction, and urinary incontinence. The screening process itself can lead to adverse psychological effects in men who have a prostate biopsy but not prostate cancer; prostate biopsies are associated with complications.

Chemoprevention

Based on solid evidence, chemoprevention with finasteride or dutasteride reduces the incidence of prostate cancer, but the evidence is inadequate to determine whether chemoprevention with finasteride or dutasteride reduces mortality from prostate cancer. There are significant complications associated with finasteride and dutasteride including erectile dysfunction, loss of libido and male breast enlargement (finasteride).

Public Health Intervention for Prostate Cancer (DHMH Prostate Cancer Medical Advisory Committee, 2010)

- On the basis of available data, men should be made aware of the availability of the PSA and DRE prostate cancer screening tests in order to make an informed choice about screening. Men ages 50-69 years with at least a 10-year life expectancy are most likely to benefit from screening.
- Clinicians should discuss with their patients the uncertainties and potential benefits and harms associated with prostate cancer screening and subsequent diagnosis and treatment, consider individual patient preferences, and individualize the decision to screen.
- Men may benefit from having a baseline PSA test *offered*, beginning at age 40 years of age. PSA screening thereafter would be guided by the results of baseline and subsequent screening tests, age, and risk factors of race, and family history.

Table 39.
Number of Prostate Cancer Cases
by Jurisdiction and Race, Maryland, 2007

Jurisdiction	Total	Race			
		Whites	Blacks	Other	Unknown
Maryland	4,274	2,813	1,230	175	56
Allegany	56	s	<6	0	0
Anne Arundel	348	299	44	<6	<6
Baltimore City	432	133	276	s	<6
Baltimore County	572	401	134	30	7
Calvert	55	46	9	0	0
Caroline	24	s	<6	0	0
Carroll	127	114	6	s	<6
Cecil	68	61	<6	<6	0
Charles	109	70	s	<6	0
Dorchester	25	s	<6	0	0
Frederick	119	108	6	<6	<6
Garrett	27	27	0	0	0
Harford	186	159	22	<6	<6
Howard	170	120	32	12	6
Kent	33	s	<6	0	0
Montgomery	812	582	144	66	20
Prince George's	622	157	434	21	10
Queen Anne's	51	43	<6	<6	<6
Saint Mary's	80	69	11	0	0
Somerset	13	s	<6	0	0
Talbot	60	54	6	0	0
Washington	144	136	<6	<6	0
Wicomico	60	37	23	0	0
Worcester	73	61	12	0	0
Unknown	8	<6	<6	<6	0

<6 = Case counts of 1-5 are suppressed per DHMH/MCR Data Use Policy and Procedures

s = Case counts are suppressed to prevent disclosure of data in other cell(s). (See Appendix C for methods.)

Source: Maryland Cancer Registry

Table 40.
Prostate Cancer Age-Adjusted Incidence Rates*
by Jurisdiction and Race, Maryland, 2007

Jurisdiction	Total	Race		
		Whites	Blacks	Other
Maryland	162.5	146.5	209.0	143.3
Allegany	132.3	131.0	**	0.0
Anne Arundel	139.7	138.7	160.3	**
Baltimore City	162.3	124.4	175.8	423.7
Baltimore County	140.4	121.0	219.0	283.5
Calvert	147.2	145.9	**	0.0
Caroline	160.3	158.0	**	0.0
Carroll	154.2	146.1	**	**
Cecil	138.9	130.6	**	**
Charles	205.4	185.3	249.1	**
Dorchester	127.3	129.7	**	0.0
Frederick	129.5	130.2	**	**
Garrett	144.7	145.7	0.0	0.0
Harford	164.5	156.2	262.5	**
Howard	139.5	126.9	184.2	**
Kent	252.1	250.4	**	0.0
Montgomery	176.5	167.9	260.8	111.8
Prince George's	189.9	133.1	233.3	133.1
Queen Anne's	204.5	194.4	**	**
Saint Mary's	190.8	194.6	**	0.0
Somerset	**	**	**	0.0
Talbot	240.3	242.4	**	0.0
Washington	206.2	203.7	**	**
Wicomico	133.6	104.1	275.6	0.0
Worcester	211.7	198.4	**	0.0

* Rates are per 100,000 and are age-adjusted to 2000 U.S. standard population

** Rates based on case counts of 1-15 are suppressed per DHMH/MCR Data Use Policy and Procedures

Source: Maryland Cancer Registry

Table 41.
Number of Prostate Cancer Deaths
by Jurisdiction and Race, Maryland, 2007

Jurisdiction	Total	Race		
		Whites	Blacks	Other
Maryland	550	367	s	<6
Allegany	9	8	<6	<6
Anne Arundel	38	30	s	<6
Baltimore City	87	s	61	<6
Baltimore County	90	75	s	<6
Calvert	8	6	<6	<6
Caroline	7	6	<6	<6
Carroll	15	s	<6	<6
Cecil	10	6	<6	<6
Charles	10	7	<6	<6
Dorchester	<6	<6	<6	<6
Frederick	16	12	<6	<6
Garrett	<6	<6	<6	<6
Harford	26	24	<6	<6
Howard	18	13	<6	<6
Kent	6	s	<6	<6
Montgomery	67	55	s	<6
Prince George's	78	s	54	<6
Queen Anne's	<6	<6	<6	<6
Saint Mary's	11	8	<6	<6
Somerset	<6	<6	<6	<6
Talbot	6	<6	<6	<6
Washington	16	15	<6	<6
Wicomico	13	10	<6	<6
Worcester	8	7	<6	<6

<6 = Death counts of 0-5 are suppressed per DHMH/CCSC Mortality Data Suppression Policy

s = Death counts are suppressed to prevent disclosure of data in other cell(s). (See Appendix C for methods.)

Source: NCHS Compressed Mortality File in CDC WONDER

Table 42.
Prostate Cancer Age-Adjusted Mortality Rates*
by Jurisdiction and Race, Maryland, 2007

Jurisdiction	Total	Race		
		Whites	Blacks	Other
Maryland	26.6	23.0	45.3	**
Allegany	**	**	**	**
Anne Arundel	23.1	21.2	**	**
Baltimore City	37.6	26.5	46.9	**
Baltimore County	24.1	22.7	**	**
Calvert	**	**	**	**
Caroline	**	**	**	**
Carroll	**	**	**	**
Cecil	**	**	**	**
Charles	**	**	**	**
Dorchester	**	**	**	**
Frederick	25.3	**	**	**
Garrett	**	**	**	**
Harford	34.0	35.1	**	**
Howard	28.5	**	**	**
Kent	**	**	**	**
Montgomery	17.8	18.2	**	**
Prince George's	37.4	23.7	54.9	**
Queen Anne's	**	**	**	**
Saint Mary's	**	**	**	**
Somerset	**	**	**	**
Talbot	**	**	**	**
Washington	25.4	**	**	**
Wicomico	**	**	**	**
Worcester	**	**	**	**

* Rates are per 100,000 and age-adjusted to 2000 U.S. standard population

** Rates based on death counts of 0-15 are suppressed per DHMH/CCSC Mortality Data Suppression Policy

Source: NCHS Compressed Mortality File in CDC WONDER

Table 43.
Number of Prostate Cancer Cases
by Jurisdiction and Race, Maryland, 2003-2007

Jurisdiction	Total	Race			
		Whites	Blacks	Other	Unknown
Maryland	19,600	12,843	5,572	751	434
Allegany	284	267	s	<6	0
Anne Arundel	1,727	1,433	238	27	29
Baltimore City	2,165	691	1,360	74	40
Baltimore County	2,958	2,109	623	169	57
Calvert	216	166	38	<6	s
Caroline	100	79	s	0	<6
Carroll	534	491	24	s	<6
Cecil	311	277	17	9	8
Charles	417	268	130	11	8
Dorchester	120	82	34	<6	<6
Frederick	700	641	42	11	6
Garrett	112	s	<6	0	0
Harford	873	738	97	27	11
Howard	743	521	155	42	25
Kent	117	96	16	<6	<6
Montgomery †	3,320	2,435	565	247	73
Prince George's †	2,702	716	1,807	88	91
Queen Anne's	194	165	23	<6	<6
Saint Mary's	294	225	50	<6	s
Somerset	73	44	29	0	0
Talbot	211	165	s	0	<6
Washington	561	530	22	s	<6
Wicomico	280	196	81	<6	<6
Worcester	262	213	43	<6	<6
Unknown	326	s	98	<6	37

<6 = Case counts of 1-5 are suppressed per DHMH/MCR Data Use Policy and Procedures

s = Case counts are suppressed to prevent disclosure of data in other cell(s). (See Appendix C for methods.)

† 2006 case counts for Montgomery and Prince George's counties are underreported.

(See Appendix C, Section I.A.1.)

Source: Maryland Cancer Registry

Table 44.
Prostate Cancer Age-Adjusted Incidence Rates*
by Jurisdiction and Race, Maryland, 2003-2007

Jurisdiction	Total	Race		
		Whites	Blacks	Other
Maryland	157.6	139.6	206.0	145.3
Allegany	133.5	129.3	**	**
Anne Arundel	148.2	140.7	197.5	92.9
Baltimore City	164.7	131.5	177.3	332.7
Baltimore County	150.8	129.1	236.9	304.9
Calvert	124.1	111.5	162.2	**
Caroline	128.4	118.6	178.5	0.0
Carroll	139.5	133.4	211.8	**
Cecil	139.7	129.9	201.9	**
Charles	168.5	146.9	219.3	**
Dorchester	126.4	110.3	167.8	**
Frederick	166.1	166.2	157.8	**
Garrett	127.0	124.6	**	0.0
Harford	166.3	154.8	249.4	309.5
Howard	131.4	116.4	206.1	98.0
Kent	185.1	177.6	180.0	**
Montgomery †	157.0	149.9	242.6	97.9
Prince George's †	173.0	121.5	204.4	128.3
Queen Anne's	155.0	144.4	245.8	**
Saint Mary's	151.2	137.0	192.0	**
Somerset	117.8	97.7	184.6	0.0
Talbot	171.5	151.9	297.8	0.0
Washington	165.7	163.2	185.4	**
Wicomico	132.4	117.1	203.1	**
Worcester	150.1	137.8	230.4	**

* Rates are per 100,000 and are age-adjusted to 2000 U.S. standard population

** Rates based on case counts of 1-15 are suppressed per DHMH/MCR Data Use Policy and Procedures

† 2003-2007 incidence rates for Montgomery and Prince George's counties are lower than actual due to case underreporting in 2006. (See Appendix C, Section I.A.1.)

Source: Maryland Cancer Registry

Table 45.
Number of Prostate Cancer Deaths
by Jurisdiction and Race, Maryland, 2003-2007

Jurisdiction	Total	Race		
		Whites	Blacks	Other
Maryland	2,697	1,765	898	34
Allegany	52	50	<6	<6
Anne Arundel	200	163	s	<6
Baltimore City	433	s	309	<6
Baltimore County	451	356	s	<6
Calvert	50	41	s	<6
Caroline	23	18	<6	<6
Carroll	70	67	<6	<6
Cecil	44	37	s	<6
Charles	52	33	s	<6
Dorchester	15	s	<6	<6
Frederick	83	70	s	<6
Garrett	19	18	<6	<6
Harford	92	83	s	<6
Howard	78	60	s	<6
Kent	22	18	<6	<6
Montgomery	346	273	61	12
Prince George's	370	117	242	11
Queen Anne's	19	18	<6	<6
Saint Mary's	54	38	s	<6
Somerset	22	14	s	<6
Talbot	35	27	s	<6
Washington	73	66	s	<6
Wicomico	47	28	s	<6
Worcester	47	39	s	<6

<6 = Death counts of 0-5 are suppressed per DHMH/CCSC Mortality Data Suppression Policy

s = Death counts are suppressed to prevent disclosure of data in other cell(s). (See Appendix C for methods.)

Source: NCHS Compressed Mortality File in CDC WONDER

Table 46.
Prostate Cancer Age-Adjusted Mortality Rates*
by Jurisdiction and Race, Maryland, 2003-2007


Jurisdiction	Total	Race		
		Whites	Blacks	Other
Maryland	27.3	22.9	50.2	9.9
Allegany	26.0	25.7	**	**
Anne Arundel	25.5	23.6	46.6	**
Baltimore City	37.3	23.3	50.0	**
Baltimore County	25.0	22.2	59.8	**
Calvert	40.1	38.2	**	**
Caroline	33.7	30.8	**	**
Carroll	24.9	24.6	**	**
Cecil	29.1	26.2	**	**
Charles	32.4	26.9	52.1	**
Dorchester	**	**	**	**
Frederick	25.7	23.4	**	**
Garrett	24.5	23.1	**	**
Harford	24.8	24.7	**	**
Howard	24.0	23.3	44.4	**
Kent	34.1	31.3	**	**
Montgomery	19.8	18.9	41.2	**
Prince George's	37.0	24.4	54.1	**
Queen Anne's	18.5	19.8	**	**
Saint Mary's	38.9	34.4	69.3	**
Somerset	43.6	**	**	**
Talbot	26.4	23.1	**	**
Washington	24.1	22.6	**	**
Wicomico	25.7	19.7	52.7	**
Worcester	27.9	26.3	**	**

* Rates are per 100,000 and are age-adjusted to 2000 U.S. standard population

** Rates based on death counts of 0-15 are suppressed per DHMH/CCSC Mortality Data
Suppression Policy

Source: NCHS Compressed Mortality File in CDC WONDER

Maryland Prostate Cancer Incidence Rates by Geographical Area: Comparison to U.S. Rate, 2003-2007



Rates are age-adjusted to the 2000 U.S. standard population and are per 100,000 population.


Maryland area-specific rates with 95% confidence intervals are presented in Appendix H.

U.S. prostate cancer incidence rate, 2003-2007: 156.9/100,000

Maryland prostate cancer incidence rate, 2003-2007: 157.6/100,000

Source: MD incidence rates from Maryland Cancer Registry, 2003-2007
U.S. (SEER 17) rate from SEER*Stat Software

Maryland Prostate Cancer Mortality Rates by Geographical Area: Comparison to U.S. Rate, 2003-2007



Rates are age-adjusted to the 2000 U.S. standard population and are per 100,000 population.

Maryland area-specific rates with 95% confidence intervals are presented in Appendix H.

U.S. prostate cancer mortality rate, 2003-2007: 24.6/100,000

Maryland prostate cancer mortality rate, 2003-2007: 27.3/100,000

Source: MD and U.S. mortality rates from NCHS Compressed Mortality File in CDC WONDER

E. Oral Cancer

Incidence (New Cases)

In 2007, a total of 572 cases of oral cavity and pharynx cancer (called oral cancer) were reported in Maryland. The age-adjusted incidence rate for oral cancer in Maryland in 2007 was 9.6 per 100,000 population (8.8-10.4, 95% C.I.), which is similar to the 2007 U.S. SEER age-adjusted oral cancer incidence rate of 10.3 per 100,000 population (10.1-10.6, 95% C.I.).

Mortality (Deaths)

In 2007, 148 persons in Maryland died of oral cancer. The 2007 age-adjusted mortality rate of 2.5 per 100,000 population (2.1-2.9, 95% C.I.) in Maryland is similar to the 2007 U.S. oral cancer mortality rate of 2.5 per 100,000 (2.5-2.6, 95% C.I.). Maryland ranked 23rd highest for oral cancer mortality among the states and the District of Columbia for the period 2003-2007.

Table 47.
Oral Cancer Incidence and Mortality Rates*
by Gender and Race, Maryland and the United States, 2007

<i>Incidence 2007</i>	<i>Total</i>	<i>Males</i>	<i>Females</i>	<i>Whites</i>	<i>Blacks</i>	<i>Other</i>
New Cases (count)	572	398	174	425	116	s
MD Incidence Rate	9.6	14.5	5.4	10.0	8.1	9.4
U.S. SEER Rate	10.3	15.5	5.9	10.6	9.6	7.0
<i>Mortality 2007</i>	<i>Total</i>	<i>Males</i>	<i>Females</i>	<i>Whites</i>	<i>Blacks</i>	<i>Other</i>
Deaths (count)	148	101	47	105	s	<6
MD Mortality Rate	2.5	3.9	1.5	2.5	2.8	**
U.S. Mortality Rate	2.5	3.9	1.4	2.4	3.3	1.9

* Rates are per 100,000 and are age-adjusted to 2000 U.S. standard population

s = Counts are suppressed to prevent disclosure of data in other cell(s) based on Tables 48 and 50

<6 = MD death counts of 0-5 are suppressed per DHMH/CCSC Mortality Data Suppression Policy


** MD mortality rates based on death counts of 0-15 are suppressed per DHMH/CCSC

Mortality Data Suppression Policy

Sources: MD incidence data from Maryland Cancer Registry

U.S. SEER rates from SEER*Stat software

MD mortality data from NCHS Compressed Mortality File in CDC WONDER



Rates are age-adjusted to 2000 U.S. standard population

Sources: Maryland Cancer Registry (incidence rates)


NCHS Compressed Mortality File in CDC WONDER (mortality rates)

Incidence and Mortality Trends

The incidence of oral cancer in Maryland decreased at a rate of 4.4% per year from 2003 to 2007.

Oral cancer mortality rates have increased from 2003 to 2007, with a rate increase of 2.0% annually.

See Appendix I, Tables 1 and 2.




Rates are age-adjusted to 2000 U.S. standard population

Source: Maryland Cancer Registry

Incidence Trends by Race

Over the 5-year period from 2003 to 2007, oral cancer incidence rates in Maryland declined at a rate of 7.4% per year for blacks and 3.6% per year for whites.

See Appendix I, Table 3.




Rates are age-adjusted to 2000 U.S. standard population
Source: NCHS Compressed Mortality File in CDC WONDER

Mortality Trends by Race

Oral cancer mortality rates are increasing for both blacks and whites. From 2003 to 2007, rates increased at a rate of 1.4% per year for blacks, and 2.1% per year for whites.

See Appendix I, Table 5.




Source: Maryland Cancer Registry

Stage at Diagnosis

In 2007, 17.0% of oral cancers in Maryland were diagnosed at the distant stage, 47.4% were diagnosed at the regional stage, and 27.3% were diagnosed at the localized stage. The proportion of oral cancers reported as unstaged had decreased in recent years.

See Appendix J, Table 6.



* Adults age 40 years and older

Sources: Maryland Cancer Survey

Healthy People 2010, U.S. Department of Health and Human Services (2000)

Oral Cancer Screening

The Healthy People 2010 target for oral cancer is to increase to 20% the proportion of adults age 40 years and older who report having had an oral cancer screening examination in the past 12 months to detect oral and pharynx cancer.

In the 2008 Maryland Cancer Survey, 40% of persons 40 years of age and older reported they had an oral cancer exam in the past year, again surpassing the Healthy People 2010 target.

Public Health Evidence (quoted from NCI PDQ, 6/30/2009 and 6/30/2009, and USPSTF, 2/2004)

Primary Prevention

Tobacco use (including use of cigarettes, cigars, pipes, and smokeless or spit tobacco) causes oral cancer. Tobacco use is responsible for more than 90% of oral cancer among men and 60% among women, and is responsible for more than 90% of oral cancer-related deaths in males. Alcohol use is a second independent major risk factor for oral cancer. It is suggested that beer and hard liquor confer greater risk of oral cancer than wine. The combined use of tobacco and alcohol increases the risks for oral cancer more than either risk behavior alone. There appears to be an association between human papillomavirus (HPV) and oral cancer; however, the role of HPV remains unclear. Sun exposure represents an important risk factor for lip cancer along with chronic direct exposure to tobacco.

Avoidance or cessation of tobacco use (e.g., cigarettes, pipes, cigars, and smokeless tobacco) would lead to a decrease in oral cancer. A 50% reduction of oral cancer risk has been noted after 3 to 5 years of smoking cessation and a return to normal risk noted within 10 years of cessation. Although alcohol use is a risk factor for oral cancer, there is inadequate evidence that cessation of alcohol use decreases the risk of oral cancer. A diet high in fruits and fiber is associated with a decreased risk of oral and pharyngeal cancer, particularly among smokers; however, there is inadequate evidence to determine whether a *change* in diet decreases the risk of oral cancer. There is inadequate evidence to determine whether reducing sun exposure would prevent lip cancer. Sunscreen use has been associated with a lower incidence of skin cancers and thus may lower the incidence of lip cancer.

Screening

The routine examination of asymptomatic and symptomatic patients can lead to detection of earlier stage cancers and premalignant lesions; however, there is no definitive evidence to show this screening can reduce mortality. The United States Preventive Services Task Force (USPSTF) concluded that the evidence is insufficient to recommend for or against routinely screening adults for oral cancer. The USPSTF found no new good-quality evidence that screening for oral cancer leads to improved health outcomes for either high-risk adults (i.e., those over age 50 years who use tobacco) or for average-risk adults in the general population. It is unlikely that controlled trials of screening for oral cancer will ever be conducted in the general population because of the very low incidence of oral cancer in the U.S. There is also no new evidence for the harms of screening. As a result, the USPSTF could not determine the balance between benefits and harms of screening.

Public Health Intervention for Oral Cancer (DHMH Oral Cancer Medical Advisory Committee, 2005)
<ul style="list-style-type: none">➤ Avoidance or cessation of smoking and other tobacco use➤ Avoidance or reduction of alcohol consumption➤ Avoidance of sun exposure; use of ultraviolet light-blocking lip balm➤ Screening for oral cancer targeted to individuals age 40 years and older

Table 48.
Number of Oral Cancer Cases
by Jurisdiction, Gender and Race, Maryland, 2007

Jurisdiction	Total	Gender		Race			
		Males	Females	Whites	Blacks	Other	Unknown
Maryland	572	398	174	425	116	s	<6
Allegany	10	s	<6	10	0	0	0
Anne Arundel	72	54	18	64	<6	<6	<6
Baltimore City	74	51	23	s	48	<6	0
Baltimore County	83	50	33	69	s	<6	0
Calvert	8	s	<6	8	0	0	0
Caroline	<6	<6	0	<6	0	0	0
Carroll	16	s	<6	s	0	0	<6
Cecil	10	s	<6	10	0	0	0
Charles	11	s	<6	s	<6	0	0
Dorchester	<6	<6	<6	<6	0	0	0
Frederick	17	s	<6	s	<6	0	0
Garrett	<6	<6	<6	<6	0	0	0
Harford	29	20	9	26	<6	<6	0
Howard	28	15	13	19	<6	s	<6
Kent	0	0	0	0	0	0	0
Montgomery	89	66	23	70	11	8	0
Prince George's	60	41	19	23	33	<6	<6
Queen Anne's	<6	<6	<6	<6	0	0	0
Saint Mary's	11	s	<6	11	0	0	0
Somerset	<6	<6	<6	<6	<6	0	0
Talbot	7	<6	<6	7	0	0	0
Washington	12	s	<6	s	0	<6	0
Wicomico	<6	<6	0	<6	0	0	0
Worcester	9	s	<6	s	<6	0	0
Unknown	<6	<6	<6	<6	0	0	0

<6 = Case counts of 1-5 are suppressed per DHMH/MCR Data Use Policy and Procedures

s = Case counts are suppressed to prevent disclosure of data in other cell(s). (See Appendix C for methods.)

Source: Maryland Cancer Registry

Table 49.
Oral Cancer Age-Adjusted Incidence Rates*
by Jurisdiction, Gender and Race, Maryland, 2007

Jurisdiction	Total	Gender		Race		
		Males	Females	Whites	Blacks	Other
Maryland	9.6	14.5	5.4	10.0	8.1	9.4
Allegany	**	**	**	**	0.0	0.0
Anne Arundel	12.9	20.1	6.5	13.3	**	**
Baltimore City	11.1	17.8	5.9	8.9	11.6	**
Baltimore County	9.0	12.2	6.3	9.4	**	**
Calvert	**	**	**	**	0.0	0.0
Caroline	**	**	0.0	**	0.0	0.0
Carroll	9.0	**	**	**	0.0	0.0
Cecil	**	**	**	**	0.0	0.0
Charles	**	**	**	**	**	0.0
Dorchester	**	**	**	**	0.0	0.0
Frederick	6.9	**	**	7.2	**	0.0
Garrett	**	**	**	**	0.0	0.0
Harford	11.8	16.2	**	11.6	**	**
Howard	10.5	**	**	10.1	**	**
Kent	0.0	0.0	0.0	0.0	0.0	0.0
Montgomery	8.7	14.6	4.1	8.8	**	**
Prince George's	7.6	12.5	4.3	8.9	6.8	**
Queen Anne's	**	**	**	**	0.0	0.0
Saint Mary's	**	**	**	**	0.0	0.0
Somerset	**	**	**	**	**	0.0
Talbot	**	**	**	**	0.0	0.0
Washington	**	**	**	**	0.0	**
Wicomico	**	**	0.0	**	0.0	0.0
Worcester	**	**	**	**	**	0.0

* Rates are per 100,000 and are age-adjusted to 2000 U.S. standard population

** Rates based on case counts of 1-15 are suppressed per DHMH/MCR Data Use Policy and Procedures

Source: Maryland Cancer Registry

Table 50.
Number of Oral Cancer Deaths
by Jurisdiction, Gender and Race, Maryland, 2007

Jurisdiction	Total	Gender		Race		
		Males	Females	Whites	Blacks	Other
Maryland	148	101	47	105	s	<6
Allegany	<6	<6	<6	<6	<6	<6
Anne Arundel	17	s	<6	s	<6	<6
Baltimore City	27	19	8	s	21	<6
Baltimore County	27	14	13	25	<6	<6
Calvert	<6	<6	<6	<6	<6	<6
Caroline	<6	<6	<6	<6	<6	<6
Carroll	<6	<6	<6	<6	<6	<6
Cecil	<6	<6	<6	<6	<6	<6
Charles	<6	<6	<6	<6	<6	<6
Dorchester	<6	<6	<6	<6	<6	<6
Frederick	<6	<6	<6	<6	<6	<6
Garrett	<6	<6	<6	<6	<6	<6
Harford	10	s	<6	s	<6	<6
Howard	<6	<6	<6	<6	<6	<6
Kent	<6	<6	<6	<6	<6	<6
Montgomery	16	s	<6	11	<6	<6
Prince George's	12	s	<6	<6	8	<6
Queen Anne's	<6	<6	<6	<6	<6	<6
Saint Mary's	<6	<6	<6	<6	<6	<6
Somerset	<6	<6	<6	<6	<6	<6
Talbot	<6	<6	<6	<6	<6	<6
Washington	<6	<6	<6	<6	<6	<6
Wicomico	<6	<6	<6	<6	<6	<6
Worcester	<6	<6	<6	<6	<6	<6

<6 = Death counts of 0-5 are suppressed per DHMH/CCSC Mortality Data Suppression Policy

s = Death counts are suppressed to prevent disclosure of data in other cell(s). (See Appendix C for methods.)

Source: NCHS Compressed Mortality File in CDC WONDER

Table 51.
Oral Cancer Age-Adjusted Mortality Rates*
by Jurisdiction, Gender and Race, Maryland, 2007

Jurisdiction	Total	Gender		Race		
		Males	Females	Whites	Blacks	Other
Maryland	2.5	3.9	1.5	2.5	2.8	**
Allegany	**	**	**	**	**	**
Anne Arundel	3.5	**	**	4.0	**	**
Baltimore City	3.9	6.8	**	**	4.8	**
Baltimore County	3.0	**	**	3.5	**	**
Calvert	**	**	**	**	**	**
Caroline	**	**	**	**	**	**
Carroll	**	**	**	**	**	**
Cecil	**	**	**	**	**	**
Charles	**	**	**	**	**	**
Dorchester	**	**	**	**	**	**
Frederick	**	**	**	**	**	**
Garrett	**	**	**	**	**	**
Harford	**	**	**	**	**	**
Howard	**	**	**	**	**	**
Kent	**	**	**	**	**	**
Montgomery	1.6	**	**	**	**	**
Prince George's	**	**	**	**	**	**
Queen Anne's	**	**	**	**	**	**
Saint Mary's	**	**	**	**	**	**
Somerset	**	**	**	**	**	**
Talbot	**	**	**	**	**	**
Washington	**	**	**	**	**	**
Wicomico	**	**	**	**	**	**
Worcester	**	**	**	**	**	**

* Rates are per 100,000 and age-adjusted to 2000 U.S. standard population

** Rates based on death counts of 0-15 are suppressed per DHMH/CCSC Mortality Data Suppression Policy

Source: NCHS Compressed Mortality File in CDC WONDER

Table 52.
Number of Oral Cancer Cases
by Jurisdiction, Gender and Race, Maryland, 2003-2007

Jurisdiction	Total	Gender		Race			
		Males	Females	Whites	Blacks	Other	Unknown
Maryland	2,784	1,906	877	2,054	609	100	21
Allegany	48	33	15	s	<6	0	0
Anne Arundel	290	216	74	259	21	s	<6
Baltimore City	359	258	100	s	226	<6	0
Baltimore County	432	283	149	351	68	s	<6
Calvert	51	32	19	s	<6	0	0
Caroline	13	s	<6	13	0	0	0
Carroll	81	58	23	77	<6	<6	<6
Cecil	56	42	14	s	<6	0	0
Charles	64	43	21	48	s	0	<6
Dorchester	14	s	<6	s	<6	0	0
Frederick	97	66	31	88	<6	<6	<6
Garrett	14	s	<6	s	<6	0	0
Harford	132	89	43	119	s	<6	0
Howard	103	66	37	81	s	14	<6
Kent	20	12	8	s	<6	0	0
Montgomery †	398	251	147	314	s	41	<6
Prince George's †	310	209	101	128	170	s	<6
Queen Anne's	27	16	11	s	<6	0	0
Saint Mary's	59	40	19	48	7	<6	<6
Somerset	15	s	<6	9	<6	<6	0
Talbot	27	14	13	s	<6	<6	0
Washington	72	57	15	69	<6	<6	0
Wicomico	44	36	8	34	10	0	0
Worcester	35	27	8	30	<6	<6	0
Unknown	23	15	8	17	<6	<6	<6

Total includes cases reported as transsexual, hermaphrodite, or unknown gender

<6 = Case counts of 1-5 are suppressed per DHMH/MCR Data Use Policy and Procedures

s = Case counts are suppressed to prevent disclosure of data in other cell(s). (See Appendix C for methods.)

† 2006 case counts for Montgomery and Prince George's counties are underreported. (See Appendix C, Section I.A.1.)

Source: Maryland Cancer Registry

Table 53.
Oral Cancer Age-Adjusted Incidence Rates*
by Jurisdiction, Gender and Race, Maryland, 2003-2007

Jurisdiction	Total	Gender		Race		
		Males	Females	Whites	Blacks	Other
Maryland	9.6	14.5	5.6	10.0	8.7	7.6
Allegany	10.6	15.9	**	10.6	**	0.0
Anne Arundel	11.0	17.5	5.4	11.4	7.5	**
Baltimore City	10.9	18.4	5.1	10.4	11.1	**
Baltimore County	9.7	14.2	6.1	9.7	10.4	**
Calvert	11.9	16.1	8.5	13.7	**	0.0
Caroline	**	**	**	**	0.0	0.0
Carroll	9.6	14.5	5.0	9.5	**	**
Cecil	11.5	17.6	**	11.3	**	0.0
Charles	10.5	13.8	7.2	10.8	**	0.0
Dorchester	**	**	**	**	**	0.0
Frederick	8.9	13.1	5.3	8.9	**	**
Garrett	**	**	**	**	**	0.0
Harford	10.8	15.3	6.9	10.9	**	**
Howard	8.1	11.1	5.9	8.4	**	**
Kent	13.8	**	**	12.7	**	0.0
Montgomery †	8.2	11.6	5.5	8.5	6.9	7.1
Prince George's †	8.3	12.5	5.0	10.0	7.4	**
Queen Anne's	10.7	13.2	**	11.5	**	0.0
Saint Mary's	13.1	19.1	7.6	13.2	**	**
Somerset	**	**	**	**	**	**
Talbot	10.9	**	**	11.7	**	**
Washington	9.6	16.0	**	9.7	**	**
Wicomico	9.3	16.6	**	9.4	**	0.0
Worcester	10.2	17.4	**	10.0	**	**

* Rates are per 100,000 and are age-adjusted to 2000 U.S. standard population

** Rates based on case counts of 1-15 are suppressed per DHMH/MCR Data Use Policy and Procedures

† 2003-2007 incidence rates for Montgomery and Prince George's counties are lower than actual due to case underreporting in 2006. (See Appendix C, Section I.A.1.)

Source: Maryland Cancer Registry

Table 54.
Number of Oral Cancer Deaths
by Jurisdiction, Gender and Race, Maryland, 2003-2007

Jurisdiction	Total	Gender		Race		
		Males	Females	Whites	Blacks	Other
Maryland	726	518	208	502	212	12
Allegany	9	<6	<6	s	<6	<6
Anne Arundel	71	54	17	65	s	<6
Baltimore City	146	112	34	s	102	<6
Baltimore County	119	74	45	104	s	<6
Calvert	10	s	<6	9	<6	<6
Caroline	<6	<6	<6	<6	<6	<6
Carroll	14	s	<6	s	<6	<6
Cecil	18	s	<6	s	<6	<6
Charles	17	s	<6	10	s	<6
Dorchester	<6	<6	<6	<6	<6	<6
Frederick	15	9	6	14	<6	<6
Garrett	<6	<6	<6	<6	<6	<6
Harford	32	21	11	31	<6	<6
Howard	20	10	10	13	<6	<6
Kent	<6	<6	<6	<6	<6	<6
Montgomery	76	53	23	58	s	<6
Prince George's	83	62	21	s	49	<6
Queen Anne's	10	s	<6	8	<6	<6
Saint Mary's	9	s	<6	7	<6	<6
Somerset	<6	<6	<6	<6	<6	<6
Talbot	<6	<6	<6	<6	<6	<6
Washington	24	17	7	23	<6	<6
Wicomico	14	s	<6	9	<6	<6
Worcester	11	s	<6	s	<6	<6

<6 = Death counts of 0-5 are suppressed per DHMH/CCSC Mortality Data Suppression Policy

s = Death counts are suppressed to prevent disclosure of data in other cell(s). (See Appendix C for methods.)

Source: NCHS Compressed Mortality File in CDC WONDER

Table 55.
Oral Cancer Age-Adjusted Mortality Rates*
by Jurisdiction, Gender and Race, Maryland, 2003-2007


Jurisdiction	Total	Gender		Race		
		Males	Females	Whites	Blacks	Other
Maryland	2.6	4.2	1.3	2.5	3.2	**
Allegany	**	**	**	**	**	**
Anne Arundel	3.0	5.3	1.3	3.1	**	**
Baltimore City	4.4	8.0	1.7	3.4	5.1	**
Baltimore County	2.7	3.7	1.8	2.8	**	**
Calvert	**	**	**	**	**	**
Caroline	**	**	**	**	**	**
Carroll	**	**	**	**	**	**
Cecil	4.0	7.8	**	4.2	**	**
Charles	3.5	**	**	**	**	**
Dorchester	**	**	**	**	**	**
Frederick	**	**	**	**	**	**
Garrett	**	**	**	**	**	**
Harford	2.8	3.7	**	3.0	**	**
Howard	1.9	**	**	**	**	**
Kent	**	**	**	**	**	**
Montgomery	1.6	2.7	0.8	1.5	**	**
Prince George's	2.4	4.3	1.0	2.5	2.6	**
Queen Anne's	**	**	**	**	**	**
Saint Mary's	**	**	**	**	**	**
Somerset	**	**	**	**	**	**
Talbot	**	**	**	**	**	**
Washington	3.2	4.8	**	3.2	**	**
Wicomico	**	**	**	**	**	**
Worcester	**	**	**	**	**	**

* Rates are per 100,000 and are age-adjusted to 2000 U.S. standard population


** Rates based on death counts of 0-15 are suppressed per DHMH/CCSC Mortality Data Suppression Policy

Source: NCHS Compressed Mortality File in CDC WONDER

Maryland Oral Cancer Incidence Rates by Geographical Area: Comparison to U.S. Rate, 2003-2007



Maryland Oral Cancer Mortality Rates by Geographical Area: Comparison to U.S. Rate, 2003-2007



F. Melanoma of the Skin

There are three major types of skin cancer: basal cell carcinoma, squamous cell carcinoma, and melanoma. Basal cell and squamous cell carcinoma are the most common forms of skin cancer and are not reportable to the Maryland Cancer Registry (MCR). Melanoma is the less frequent but the most serious type of skin cancer (NCI PDQ) and is reportable to the MCR.

Incidence (New Cases)

In 2007, a total of 1,232 cases of melanoma of the skin were reported in Maryland. The age-adjusted incidence rate for melanoma for 2007 was 21.2 per 100,000 population (20.0-22.5, 95% C.I.). This Maryland incidence rate is similar to the 2007 U.S. SEER age-adjusted incidence rate for melanoma of 20.4 per 100,000 population (20.1-20.8, 95% C.I.).

Mortality (Deaths)

In 2007, a total of 140 persons died of melanoma in Maryland. The 2007 age-adjusted mortality rate for melanoma in Maryland was 2.4 per 100,000 population (2.0-2.9, 95% C.I.). This rate is similar to the 2007 U.S. melanoma mortality rate of 2.7 per 100,000 population (2.6-2.7, 95% C.I.). Maryland ranked 32nd in the nation for melanoma mortality for the period 2003-2007.

Table 56.
Melanoma Incidence and Mortality Rates*
by Gender and Race, Maryland and the United States, 2007

<i>Incidence 2007</i>	<i>Total</i>	<i>Males</i>	<i>Females</i>	<i>Whites</i>	<i>Blacks</i>	<i>Other</i>
New Cases (count)	1,232	697	534	1,182	17	12
MD Incidence Rate	21.2	27.2	17.1	29.5	1.2	**
U.S. SEER Rate	20.4	26.1	16.5	23.6	1.1	1.7
<i>Mortality 2007</i>	<i>Total</i>	<i>Males</i>	<i>Females</i>	<i>Whites</i>	<i>Blacks</i>	<i>Other</i>
Deaths (count)	140	83	57	136	<6	<6
MD Mortality Rate	2.4	3.5	1.8	3.3	**	**
U.S. Mortality Rate	2.7	4.0	1.7	3.0	0.5	0.5

* Rates are per 100,000 and are age-adjusted to 2000 U.S. standard population

Total includes cases reported as transsexual, hermaphrodite, or unknown gender


<6 = MD death counts of 0-5 are suppressed per DHMH/CCSC Mortality Data Suppression Policy

** MD incidence rates based on case counts of 1-15 are suppressed per DHMH/MCR Data Use Policy and Procedures; MD mortality rates based on death counts of 0-15 are suppressed per DHMH/CCSC Mortality Data Suppression Policy

Sources: MD incidence data from Maryland Cancer Registry

U.S. SEER rates from SEER*Stat software

MD mortality data from NCHS Compressed Mortality File in CDC WONDER



Rates are age-adjusted to 2000 U.S. standard population

Sources: Maryland Cancer Registry (incidence rates)


NCHS Compressed Mortality File in CDC WONDER (mortality rates)

Incidence and Mortality Trends

Melanoma incidence rates in Maryland increased at a rate of 2.3% yearly from 2003 to 2007.

Melanoma mortality rates increased at a rate of 0.2% per year from 2003 to 2007.

See Appendix I, Tables 1 and 2.




Rates are age-adjusted to 2000 U.S. standard population

Source: Maryland Cancer Registry

Incidence Trends by Gender

Melanoma incidence rates are increasing for both males and females in Maryland. Over the period 2003 to 2007, incidence rates for males increased at a rate of 3.2% per year, and rates among females increased at a rate of 1.6% per year. In 2007, melanoma incidence rates were almost 60% higher among males than females in Maryland.

See Appendix I, Table 4.




Rates are age-adjusted to 2000 U.S. standard population
Source: NCHS Compressed Mortality File in CDC WONDER

Mortality Trends by Gender

Melanoma mortality rates in males increased at a rate of 1.0% per year from 2003 to 2007. Female melanoma mortality rates increased at a rate of 2.4% per year.

See Appendix I, Table 6.



Source: Maryland Cancer Registry

Stage at Diagnosis


In 2007, 68.4% of all melanoma was diagnosed at the localized stage, 9.2% was found at the regional stage, and 3.6% was found at the distant stage. The proportion of melanoma reported as unstaged decreased in recent years, and the proportion found at the local stage increased.

See Appendix J, Table 7.

Sun Exposure Protection

The Healthy People 2010 target is to increase to 85% the percentage of persons age 18 years and older who use at least one of the following measures that may reduce the risk of skin cancer: avoid sun between 10 a.m. and 4 p.m.; wear sun-protective clothing when exposed to sunlight; use sunscreen with a sun protective factor of 15 or higher; and avoid artificial sources of ultraviolet light (e.g., tanning booths).

In 2006, the Maryland BRFSS found that 67% of adults age 18 years and older and 70% of those age 40 years and older used at least one method of protection against sun exposure.



Note: Graphic includes results from both the Maryland BRFSS and Maryland Cancer Survey. See Appendix C for a cautionary note on comparing these data.

* Sun exposure protection means percentage of adults who report “always” or “nearly always” using one or more of the following measures: a) avoid sun between 10 a.m. and 4 p.m., b) wear sun-protective clothing when exposed to sunlight, c) use sunscreen with a sun protective factor of 15 or higher, and d) wear a hat when outdoors. The BRFSS and MCS do not include questions regarding frequency of exposure to ultraviolet light.

Sources: † Maryland BRFSS 1998 and 2006

§ Maryland Cancer Survey 2002 and 2004

Healthy People 2010 Midcourse Review, U.S. Department of Health and Human Services (2006)

Public Health Evidence (quoted from NCI PDQ, 6/30/2009 and 6/30/2009, and USPSTF, 2/2009)

Primary Prevention

Melanoma is less common but more aggressive than the other two types of skin cancer, basal cell carcinoma and squamous cell carcinoma. Epidemiologic evidence suggests that exposure to ultraviolet (UV) radiation from the sun or artificial sources, and the sensitivity of an individual's skin to UV radiation are risk factors for skin cancer, though the type of exposure (high-intensity and short-duration vs. chronic exposure) and pattern of exposure (continuous vs. intermittent) may differ among the three main types of skin cancer.

Intermittent acute sun exposure leading to sunburn, particularly in childhood or adolescence, appears to be an important risk factor for melanoma. Non-modifiable factors, such as the likelihood of getting a burn, a large number of benign melanocytic nevi (moles), and atypical nevi may also increase the risk of melanoma. Individuals with certain types of pigmented lesions (dysplastic or atypical nevi), with several large nondysplastic nevi, with many small nevi, or with moderate freckling, have a twofold to threefold increased risk of developing melanoma of the skin. Individuals with familial dysplastic nevus syndrome or with several dysplastic or atypical nevi are at high risk (greater than fivefold risk) of developing melanoma. There is inadequate evidence to determine whether the avoidance of sunburns alters the incidence of melanoma.

Increased cumulative sun exposure is an important risk factor for basal and squamous cell skin cancers. Individuals whose skin tans poorly or burns easily after sun exposure are particularly susceptible. There is inadequate evidence to determine whether the use of sunscreen reduces the incidence of basal and squamous cell skin cancer.

The best defense against skin cancer is protection from the sun and UV light. As of October 2008, an owner, employee, or operator of a tanning facility in Maryland may not allow a minor under the age of 18 years to use a tanning device unless the minor's parent or legal guardian provides written consent on the premises and in the presence of an owner, employee, or operator of the facility.

Screening

The United States Preventive Services Task Force (USPSTF) concludes that the current evidence is insufficient to assess the balance of benefits and harms of using a whole-body skin examination by a primary care clinician or a patient skin self-examination for the early detection of melanoma of the skin, basal cell cancer, or squamous cell skin cancer in the adult general population.

Public Health Intervention for Skin Cancer
Reduction of exposure to the sun and other UV light by: <ul style="list-style-type: none">➤ Avoiding sun exposure, especially between 10 a.m. and 4 p.m.➤ Wearing sun-protective clothing, hat, and sunglasses when exposed to sunlight➤ Avoiding artificial sources of UV light (e.g., tanning booths)➤ If sun cannot be avoided, using sunscreen with a SPF of 15 or higher

Table 57.
Number of Melanoma Cases
by Jurisdiction, Gender and Race, Maryland, 2007

Jurisdiction	Total	Gender		Race			
		Males	Females	Whites	Blacks	Other	Unknown
Maryland	1,232	697	534	1,182	17	12	21
Allegany	13	6	7	13	0	0	0
Anne Arundel	176	113	62	166	<6	<6	<6
Baltimore City	50	22	28	47	<6	<6	0
Baltimore County	218	130	88	211	<6	<6	<6
Calvert	40	30	10	40	0	0	0
Caroline	8	<6	<6	8	0	0	0
Carroll	50	22	28	s	0	0	<6
Cecil	26	8	18	26	0	0	0
Charles	17	9	8	s	0	0	<6
Dorchester	7	<6	<6	7	0	0	0
Frederick	49	24	25	46	<6	0	<6
Garrett	8	<6	<6	8	0	0	0
Harford	84	49	35	s	0	0	<6
Howard	86	49	37	83	0	<6	<6
Kent	<6	0	<6	<6	0	0	0
Montgomery	177	95	82	171	<6	<6	<6
Prince George's	58	28	30	51	<6	<6	<6
Queen Anne's	20	14	6	s	0	0	<6
Saint Mary's	23	14	9	23	0	0	0
Somerset	s	<6	<6	s	0	0	<6
Talbot	16	10	6	16	0	0	0
Washington	35	20	15	35	0	0	0
Wicomico	24	16	8	24	0	0	0
Worcester	27	18	9	s	0	<6	0
Unknown	8	<6	s	<6	0	0	<6

Total includes cases reported as transsexual, hermaphrodite, or unknown gender

<6 = Case counts of 1-5 are suppressed per DHMH/MCR Data Use Policy and Procedures

s = Case counts are suppressed to prevent disclosure of data in other cell(s). (See Appendix C for methods.)

Source: Maryland Cancer Registry

Table 58.
Melanoma Age-Adjusted Incidence Rates*
by Jurisdiction, Gender and Race, Maryland, 2007

Jurisdiction	Total	Gender		Race		
		Males	Females	Whites	Blacks	Other
Maryland	21.2	27.2	17.1	29.5	1.2	**
Allegany	**	**	**	**	0.0	0.0
Anne Arundel	33.7	47.1	22.6	38.1	**	**
Baltimore City	7.8	8.2	7.7	20.0	**	**
Baltimore County	25.2	33.6	19.3	32.0	**	**
Calvert	47.3	76.3	**	56.3	0.0	0.0
Caroline	**	**	**	**	0.0	0.0
Carroll	28.5	27.4	31.7	28.9	0.0	0.0
Cecil	25.8	**	34.1	27.5	0.0	0.0
Charles	12.4	**	**	18.0	0.0	0.0
Dorchester	**	**	**	**	0.0	0.0
Frederick	22.4	24.5	21.2	23.6	**	0.0
Garrett	**	**	**	**	0.0	0.0
Harford	34.9	47.1	27.8	39.0	0.0	0.0
Howard	31.1	41.9	23.9	40.8	0.0	**
Kent	**	0.0	**	**	0.0	0.0
Montgomery	17.1	21.0	14.2	22.6	**	**
Prince George's	7.9	10.6	6.6	20.4	**	**
Queen Anne's	40.1	**	**	41.9	0.0	0.0
Saint Mary's	24.9	**	**	30.1	0.0	0.0
Somerset	**	**	**	**	0.0	0.0
Talbot	35.8	**	**	42.2	0.0	0.0
Washington	23.0	28.4	**	24.7	0.0	0.0
Wicomico	24.5	36.1	**	32.0	0.0	0.0
Worcester	37.3	51.9	**	39.6	0.0	**

* Rates are per 100,000 and are age-adjusted to 2000 U.S. standard population

** Rates based on case counts of 1-15 are suppressed per DHMH/MCR Data Use Policy and Procedures

Source: Maryland Cancer Registry

Table 59.
Number of Melanoma Cancer Deaths
by Jurisdiction, Gender and Race, Maryland, 2007

Jurisdiction	Total	Gender		Race		
		Males	Females	Whites	Blacks	Other
Maryland	140	83	57	136	<6	<6
Allegany	7	<6	<6	s	<6	<6
Anne Arundel	11	<6	s	s	<6	<6
Baltimore City	13	7	6	12	<6	<6
Baltimore County	19	13	6	s	<6	<6
Calvert	<6	<6	<6	<6	<6	<6
Caroline	<6	<6	<6	<6	<6	<6
Carroll	<6	<6	<6	<6	<6	<6
Cecil	<6	<6	<6	<6	<6	<6
Charles	<6	<6	<6	<6	<6	<6
Dorchester	<6	<6	<6	<6	<6	<6
Frederick	7	<6	<6	s	<6	<6
Garrett	<6	<6	<6	<6	<6	<6
Harford	6	<6	<6	s	<6	<6
Howard	<6	<6	<6	<6	<6	<6
Kent	<6	<6	<6	<6	<6	<6
Montgomery	22	14	8	21	<6	<6
Prince George's	14	s	<6	12	<6	<6
Queen Anne's	<6	<6	<6	<6	<6	<6
Saint Mary's	<6	<6	<6	<6	<6	<6
Somerset	<6	<6	<6	<6	<6	<6
Talbot	<6	<6	<6	<6	<6	<6
Washington	<6	<6	<6	<6	<6	<6
Wicomico	<6	<6	<6	<6	<6	<6
Worcester	<6	<6	<6	<6	<6	<6

<6 = Death counts of 0-5 are suppressed per DHMH/CCSC Mortality Data Suppression Policy

s = Death counts are suppressed to prevent disclosure of data in other cell(s). (See Appendix C for methods.)

Source: NCHS Compressed Mortality File in CDC WONDER

Table 60.
Melanoma Age-Adjusted Mortality Rates*
by Jurisdiction, Gender and Race, Maryland, 2007

Jurisdiction	Total	Gender		Race		
		Males	Females	Whites	Blacks	Other
Maryland	2.4	3.5	1.8	3.3	**	**
Allegany	**	**	**	**	**	**
Anne Arundel	**	**	**	**	**	**
Baltimore City	**	**	**	**	**	**
Baltimore County	2.1	**	**	2.6	**	**
Calvert	**	**	**	**	**	**
Caroline	**	**	**	**	**	**
Carroll	**	**	**	**	**	**
Cecil	**	**	**	**	**	**
Charles	**	**	**	**	**	**
Dorchester	**	**	**	**	**	**
Frederick	**	**	**	**	**	**
Garrett	**	**	**	**	**	**
Harford	**	**	**	**	**	**
Howard	**	**	**	**	**	**
Kent	**	**	**	**	**	**
Montgomery	2.2	**	**	2.7	**	**
Prince George's	**	**	**	**	**	**
Queen Anne's	**	**	**	**	**	**
Saint Mary's	**	**	**	**	**	**
Somerset	**	**	**	**	**	**
Talbot	**	**	**	**	**	**
Washington	**	**	**	**	**	**
Wicomico	**	**	**	**	**	**
Worcester	**	**	**	**	**	**

* Rates are per 100,000 and age-adjusted to 2000 U.S. standard population

** Rates based on death counts of 0-15 are suppressed per DHMH/CCSC Mortality Data Suppression Policy

Source: NCHS Compressed Mortality File in CDC WONDER

Table 61.
Number of Melanoma Cases
by Jurisdiction, Gender and Race, Maryland, 2003-2007

Jurisdiction	Total	Gender		Race			
		Males	Females	Whites	Blacks	Other	Unknown
Maryland	5,688	3,236	2,447	5,416	63	51	158
Allegany	61	30	31	s	<6	0	0
Anne Arundel	741	435	304	715	8	<6	s
Baltimore City	272	148	124	255	9	<6	<6
Baltimore County	969	573	396	933	10	<6	s
Calvert	166	111	55	155	<6	0	s
Caroline	37	23	14	s	0	0	<6
Carroll	252	130	122	245	0	0	7
Cecil	110	61	49	s	0	0	<6
Charles	83	48	35	s	0	0	<6
Dorchester	29	18	11	29	0	0	0
Frederick	259	141	118	248	<6	0	s
Garrett	22	15	7	22	0	0	0
Harford	347	200	147	340	<6	0	s
Howard	349	187	160	332	<6	7	s
Kent	42	28	14	39	<6	0	<6
Montgomery †	849	461	388	787	11	19	32
Prince George's †	283	169	114	253	16	7	7
Queen Anne's	90	57	33	s	0	0	<6
Saint Mary's	114	61	53	s	0	0	<6
Somerset	34	17	17	s	0	<6	<6
Talbot	84	46	38	81	<6	0	<6
Washington	188	93	95	183	0	<6	<6
Wicomico	114	69	45	s	0	<6	0
Worcester	132	83	49	127	0	<6	<6
Unknown	61	32	28	49	<6	<6	s

Total includes cases reported as transsexual, hermaphrodite, or unknown gender

<6 = Case counts of 1-5 are suppressed per DHMH/MCR Data Use Policy and Procedures

s = Case counts are suppressed to prevent disclosure of data in other cell(s). (See Appendix C for methods.)

† 2006 case counts for Montgomery and Prince George's counties are underreported. (See Appendix C, Section I.A.1.)

Source: Maryland Cancer Registry

Table 62.
Melanoma Age-Adjusted Incidence Rates*
by Jurisdiction, Gender and Race, Maryland, 2003-2007

Jurisdiction	Total	Gender		Race		
		Males	Females	Whites	Blacks	Other
Maryland	20.1	25.9	16.0	27.4	1.0	3.9
Allegany	13.8	14.6	14.2	14.2	**	0.0
Anne Arundel	29.3	38.4	22.6	33.3	**	**
Baltimore City	8.3	10.9	6.8	21.1	**	**
Baltimore County	22.6	29.7	17.6	28.2	**	**
Calvert	41.5	61.5	25.7	45.5	**	0.0
Caroline	22.7	29.3	**	25.1	0.0	0.0
Carroll	28.9	32.6	27.3	29.5	0.0	0.0
Cecil	23.5	29.8	18.9	23.9	0.0	0.0
Charles	12.7	16.0	10.2	18.1	0.0	0.0
Dorchester	15.4	20.9	**	20.8	0.0	0.0
Frederick	24.1	29.6	20.4	25.5	**	0.0
Garrett	13.4	**	**	13.5	0.0	0.0
Harford	29.4	37.5	23.7	32.5	**	0.0
Howard	26.6	32.4	22.2	33.6	**	**
Kent	31.2	46.2	**	33.6	**	0.0
Montgomery †	17.6	21.5	14.7	22.1	**	3.3
Prince George's †	8.0	12.1	5.4	19.7	0.7	**
Queen Anne's	37.4	49.9	26.6	40.7	0.0	0.0
Saint Mary's	25.4	29.7	22.3	29.5	0.0	0.0
Somerset	25.6	25.8	28.1	36.3	0.0	**
Talbot	34.9	41.0	30.0	38.8	**	0.0
Washington	25.1	26.7	25.6	26.5	0.0	**
Wicomico	24.3	33.2	18.5	31.2	0.0	**
Worcester	39.9	53.2	28.1	44.6	0.0	**

* Rates are per 100,000 and are age-adjusted to 2000 U.S. standard population

** Rates based on case counts of 1-15 are suppressed per DHMH/MCR Data Use Policy and Procedures

† 2003-2007 incidence rates for Montgomery and Prince George's counties are lower than actual due to case underreporting in 2006. (See Appendix C, Section I.A.1.)

Source: Maryland Cancer Registry

Table 63.
Number of Melanoma Deaths
by Jurisdiction, Gender and Race, Maryland, 2003-2007

Jurisdiction	Total	Gender		Race		
		Males	Females	Whites	Blacks	Other
Maryland	747	468	279	725	s	<6
Allegany	18	8	10	s	<6	<6
Anne Arundel	90	55	35	s	<6	<6
Baltimore City	59	35	24	52	s	<6
Baltimore County	137	87	50	136	<6	<6
Calvert	9	s	<6	8	<6	<6
Caroline	6	<6	<6	s	<6	<6
Carroll	25	16	9	s	<6	<6
Cecil	11	s	<6	s	<6	<6
Charles	14	s	<6	s	<6	<6
Dorchester	<6	<6	<6	<6	<6	<6
Frederick	36	24	12	s	<6	<6
Garrett	<6	<6	<6	<6	<6	<6
Harford	38	26	12	s	<6	<6
Howard	27	18	9	26	<6	<6
Kent	10	<6	<6	s	<6	<6
Montgomery	104	63	41	101	<6	<6
Prince George's	52	29	23	45	<6	<6
Queen Anne's	8	<6	<6	s	<6	<6
Saint Mary's	15	s	<6	s	<6	<6
Somerset	<6	<6	<6	<6	<6	<6
Talbot	14	s	<6	13	<6	<6
Washington	24	13	11	s	<6	<6
Wicomico	19	13	6	s	<6	<6
Worcester	18	s	<6	s	<6	<6

<6 = Death counts of 0-5 are suppressed per DHMH/CCSC Mortality Data Suppression Policy

s = Death counts are suppressed to prevent disclosure of data in other cell(s). (See Appendix C for methods.)

Source: NCHS Compressed Mortality File in CDC WONDER

Table 64.
Melanoma Age-Adjusted Mortality Rates*
by Jurisdiction, Gender and Race, Maryland, 2003-2007


Jurisdiction	Total	Gender		Race		
		Males	Females	Whites	Blacks	Other
Maryland	2.7	4.0	1.8	3.6	0.3	**
Allegany	3.9	**	**	4.1	**	**
Anne Arundel	3.9	5.6	2.7	4.5	**	**
Baltimore City	1.8	2.9	1.2	4.0	**	**
Baltimore County	3.0	4.5	1.9	3.6	**	**
Calvert	**	**	**	**	**	**
Caroline	**	**	**	**	**	**
Carroll	2.9	4.2	**	3.0	**	**
Cecil	**	**	**	**	**	**
Charles	**	**	**	**	**	**
Dorchester	**	**	**	**	**	**
Frederick	3.7	5.6	**	4.0	**	**
Garrett	**	**	**	**	**	**
Harford	3.2	4.6	**	3.6	**	**
Howard	2.2	3.6	**	2.7	**	**
Kent	**	**	**	**	**	**
Montgomery	2.2	3.0	1.5	2.7	**	**
Prince George's	1.7	2.2	1.3	3.5	**	**
Queen Anne's	**	**	**	**	**	**
Saint Mary's	**	**	**	**	**	**
Somerset	**	**	**	**	**	**
Talbot	**	**	**	**	**	**
Washington	3.1	**	**	3.3	**	**
Wicomico	4.0	**	**	5.1	**	**
Worcester	5.2	**	**	6.0	**	**

* Rates are per 100,000 and are age-adjusted to 2000 U.S. standard population

** Rates based on death counts of 0-15 are suppressed per DHMH/CCSC Mortality Data Suppression Policy

Source: NCHS Compressed Mortality File in CDC WONDER

Maryland Melanoma Incidence Rates by Geographical Area: Comparison to U.S. Rate, 2003-2007



Rates are age-adjusted to the 2000 U.S. standard population and are per 100,000 population.


Maryland area-specific rates with 95% confidence intervals are presented in Appendix H.

U.S. melanoma incidence rate, 2003-2007: 20.1/100,000

Maryland melanoma incidence rate, 2003-2007: 20.1/100,000

Source: MD incidence rates from Maryland Cancer Registry, 2003-2007
U.S. (SEER 17) rate from SEER*Stat Software

Maryland Melanoma Cancer Mortality Rates by Geographical Area: Comparison to U.S. Rate, 2003-2007



G. Cervical Cancer

Incidence (New Cases)

A total of 194 cases of cervical cancer among women in Maryland were reported in 2007. The age-adjusted incidence rate for cervical cancer in Maryland in 2007 was 6.4 per 100,000 population of women (5.5-7.3, 95% C.I.). This rate is statistically significantly lower than the 2007 U.S. SEER age-adjusted cervical cancer incidence rate of 7.8 per 100,000 population of women (7.6-8.1, 95% C.I.).

Mortality (Deaths)

In 2007, a total of 75 women died of cervical cancer in Maryland. The age-adjusted cervical cancer mortality rate in Maryland in 2007 was 2.4 per 100,000 women (1.9-3.0, 95% C.I.). This rate is similar to the 2007 U.S. cervical cancer mortality rate of 2.4 per 100,000 population of women (2.3-2.5, 95% C.I.). Maryland ranked 30th highest for cervical cancer mortality rate among the states and the District of Columbia for the period 2003-2007.

Table 65.
Cervical Cancer Incidence and Mortality Rates*
by Race, Maryland and the United States, 2007

<i>Incidence 2007</i>	<i>Total</i>	<i>Whites</i>	<i>Blacks</i>	<i>Other</i>
New Cases (count)	194	120	61	s
MD Incidence Rate	6.4	6.2	7.2	**
U.S. SEER Rate	7.8	7.7	9.3	7.2
<i>Mortality 2007</i>	<i>Total</i>	<i>Whites</i>	<i>Blacks</i>	<i>Other</i>
Deaths (count)	75	38	s	<6
MD Mortality Rate	2.4	1.7	4.3	**
U.S. Mortality Rate	2.4	2.2	4.3	2.1

* Rates are per 100,000 and are age-adjusted to 2000 U.S. standard population

s = Counts are suppressed to prevent disclosure of data in other cell(s) based on Tables 66 and 68


<6 = MD death counts of 0-5 are suppressed per DHMH/CCSC Mortality Data Suppression Policy

** MD incidence rates based on case counts of 1-15 are suppressed per DHMH/MCR Data Use Policy and Procedures; MD mortality rates based on death counts of 0-15 are suppressed per DHMH/CCSC Mortality Data Suppression Policy

Sources: MD incidence data from Maryland Cancer Registry

U.S. SEER rates from SEER*Stat software

MD mortality data from NCHS Compressed Mortality File in CDC WONDER



Rates are age-adjusted to 2000 U.S. standard population

Sources: Maryland Cancer Registry (incidence rates)


NCHS Compressed Mortality File in CDC WONDER (mortality rates)

Incidence and Mortality Trends

Cervical cancer incidence rates among Maryland women decreased at a rate of 8.2% per year from 2003 to 2007.

Cervical cancer mortality rates increased at a rate of 1.4% per year from 2003 to 2007.

See Appendix I, Tables 1 and 2.




Rates are age-adjusted to 2000 U.S. standard population

Source: Maryland Cancer Registry

Incidence Trends by Race

Disparities in cervical cancer incidence rates between white and black women decreased in Maryland from 2003 to 2007. Cervical cancer incidence rates among black women decreased at a rate of 10.8% per year, compared to a decrease of 7.2% per year among white women.

See Appendix I, Table 3.




Rates are age-adjusted to 2000 U.S. standard population
Source: NCHS Compressed Mortality File in CDC WONDER

Mortality Trends by Race

Cervical cancer mortality rates increased from 2003 to 2007 for blacks and decreased for whites. Rates for blacks increased at a rate of 2.8% per year. Rates for whites decreased at a rate of 0.1% per year.

See Appendix I, Table 5.




Source: Maryland Cancer Registry

Stage at Diagnosis

In 2007, 38.1% of all cervical cancer cases in Maryland were diagnosed at the localized stage, 34.5% were diagnosed at the regional stage, and 16.0% were found at the distant stage. The proportion of cervical cancer cases reported as unstaged has decreased in recent years.

See Appendix J, Table 8.



Sources: Maryland BRFSS
Healthy People 2010, U.S. Department of Health and Human Services (2000)

Cervical Cancer Screening

One Healthy People 2010 target for cervical cancer is to increase to 90% the percentage of women age 18 years and older who have had a Pap test within the preceding 3 years. In 2008, 84% of Maryland women age 18 years and older reported they had a Pap test within the preceding 3 years. This is below the Healthy People 2010 target, and represents a decrease in prevalence of up-to-date cervical cancer screening compared to previous years.

Public Health Evidence (quoted from NCI PDQ, 7/30/2010 and 5/28/2010; Advisory Committee on Immunization Practices [ACIP] 3/23/2007, 5/28/2010; and USPSTF, 1/2003)

Primary Prevention

Human papillomavirus (HPV) is an oncogenic virus and the etiologic agent of cervical cancer and related premalignant disease. HPV is transmitted by sexual contact. Approximately 15 cancer-associated (high-risk or carcinogenic) HPV genotypes cause virtually all cases of cervical cancer and precursor lesions.

Based on solid evidence, the following measures are effective to minimize the risk of HPV infection and thus cervical cancer: abstinence from sexual activity; barrier protection and/or spermicidal gel during sexual intercourse; (based on fair evidence) vaccination against HPV-16/HPV-18; and screening via gynecologic exam and Papanicolaou (Pap) testing with treatment of precancerous abnormalities. Based on solid evidence, the following factors are associated with increased risk of cervical cancer: cigarette smoking (both active and passive); and high parity. The Advisory Committee on Immunization Practices (ACIP) recommends routine HPV vaccination (with three doses of bivalent or quadrivalent vaccine) of females age 11 or 12 years (vaccine can be administered as young as age 9 years). HPV vaccination is recommended for females age 13 through 26 years who previously have not been vaccinated. (The 3-dose series of quadrivalent HPV vaccine may be given to males age 9 through 26 years to reduce their likelihood of acquiring genital warts.)

Screening

Benefits: Based on solid evidence, screening of appropriate women via regular gynecologic examinations and cytology test (Pap test, either conventional or liquid-based cytology), with treatment of precancerous abnormalities, reduces the mortality from cervical cancer. Screening is effective when started within 3 years after first vaginal intercourse. The United States Preventive Services Task Force (USPSTF) concludes that the potential harms of screening are likely to exceed benefits among older women who have had normal results previously and who are not otherwise at high risk for cervical cancer. **Harms:** Based on solid evidence, regular screening with the Pap test leads to additional diagnostic procedures and treatment for low-grade squamous intraepithelial lesions with uncertain long-term consequences on fertility and pregnancy. Screening is not helpful in women who do not have a cervix as a result of a hysterectomy for a benign condition.

Public Health Intervention for Cervical Cancer (USPSTF and ACIP)

- | |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <ul style="list-style-type: none">➤ Screen using the Pap test for all women who have a cervix, within 3 years after onset of sexual activity or by age 21 years if not sexually active (whichever comes first).➤ Vaccinate girls and women according to ACIP recommendations. |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

Table 66.
Number of Cervical Cancer Cases
by Jurisdiction and Race, Maryland, 2007

Jurisdiction	Total	Race			
		Whites	Blacks	Other	Unknown
Maryland	194	120	61	s	<6
Allegany	<6	<6	0	0	0
Anne Arundel	20	17	<6	<6	0
Baltimore City	27	10	17	0	0
Baltimore County	32	21	s	<6	0
Calvert	<6	<6	<6	0	0
Caroline	0	0	0	0	0
Carroll	<6	<6	0	<6	0
Cecil	<6	<6	<6	0	0
Charles	7	<6	s	0	0
Dorchester	<6	<6	0	0	0
Frederick	7	7	0	0	0
Garrett	0	0	0	0	0
Harford	7	s	<6	0	0
Howard	7	s	0	<6	0
Kent	0	0	0	0	0
Montgomery	32	22	<6	<6	<6
Prince George's	26	s	17	<6	0
Queen Anne's	<6	<6	0	0	0
Saint Mary's	<6	0	<6	0	0
Somerset	0	0	0	0	0
Talbot	<6	<6	0	0	0
Washington	<6	<6	0	0	0
Wicomico	<6	<6	0	<6	0
Worcester	0	0	0	0	0
Unknown	<6	0	0	0	<6

<6 = Case counts of 1-5 are suppressed per DHMH/MCR Data Use Policy and Procedures

s = Case counts are suppressed to prevent disclosure of data in other cell(s). (See Appendix C for methods.)

Source: Maryland Cancer Registry

Table 67.
Cervical Cancer Age-Adjusted Incidence Rates*
by Jurisdiction and Race, Maryland, 2007

Jurisdiction	Total	Race		
		Whites	Blacks	Other
Maryland	6.4	6.2	7.2	**
Allegany	**	**	0.0	0.0
Anne Arundel	7.1	7.5	**	**
Baltimore City	7.9	**	7.9	0.0
Baltimore County	7.6	7.4	**	**
Calvert	**	**	**	0.0
Caroline	0.0	0.0	0.0	0.0
Carroll	**	**	0.0	**
Cecil	**	**	**	0.0
Charles	**	**	**	0.0
Dorchester	**	**	0.0	0.0
Frederick	**	**	0.0	0.0
Garrett	0.0	0.0	0.0	0.0
Harford	**	**	**	0.0
Howard	**	**	0.0	**
Kent	0.0	0.0	0.0	0.0
Montgomery	5.9	5.8	**	**
Prince George's	6.3	**	7.2	**
Queen Anne's	**	**	0.0	0.0
Saint Mary's	**	0.0	**	0.0
Somerset	0.0	0.0	0.0	0.0
Talbot	**	**	0.0	0.0
Washington	**	**	0.0	0.0
Wicomico	**	**	0.0	**
Worcester	0.0	0.0	0.0	0.0

* Rates are per 100,000 and are age-adjusted to 2000 U.S. standard population

** Rates based on case counts of 1-15 are suppressed per DHMH/MCR Data Use Policy and Procedures

Source: Maryland Cancer Registry

Table 68.
Number of Cervical Cancer Deaths
by Jurisdiction and Race, Maryland, 2007

Jurisdiction	Total	Race		
		Whites	Blacks	Other
Maryland	75	38	s	<6
Allegany	<6	<6	<6	<6
Anne Arundel	<6	<6	<6	<6
Baltimore City	21	<6	16	<6
Baltimore County	10	<6	<6	<6
Calvert	<6	<6	<6	<6
Caroline	<6	<6	<6	<6
Carroll	<6	<6	<6	<6
Cecil	<6	<6	<6	<6
Charles	<6	<6	<6	<6
Dorchester	<6	<6	<6	<6
Frederick	<6	<6	<6	<6
Garrett	<6	<6	<6	<6
Harford	<6	<6	<6	<6
Howard	<6	<6	<6	<6
Kent	<6	<6	<6	<6
Montgomery	9	6	<6	<6
Prince George's	13	<6	10	<6
Queen Anne's	<6	<6	<6	<6
Saint Mary's	<6	<6	<6	<6
Somerset	<6	<6	<6	<6
Talbot	<6	<6	<6	<6
Washington	<6	<6	<6	<6
Wicomico	<6	<6	<6	<6
Worcester	<6	<6	<6	<6

<6 = Death counts of 0-5 are suppressed per DHMH/CCSC Mortality Data Suppression Policy

s = Death counts are suppressed to prevent disclosure of data in other cell(s). (See Appendix C for methods.)

Source: NCHS Compressed Mortality File in CDC WONDER

Table 69.
Cervical Cancer Age-Adjusted Mortality Rates*
by Jurisdiction and Race, Maryland, 2007

Jurisdiction	Total	Race		
		Whites	Blacks	Other
Maryland	2.4	1.7	4.3	**
Allegany	**	**	**	**
Anne Arundel	**	**	**	**
Baltimore City	6.0	**	7.2	**
Baltimore County	**	**	**	**
Calvert	**	**	**	**
Caroline	**	**	**	**
Carroll	**	**	**	**
Cecil	**	**	**	**
Charles	**	**	**	**
Dorchester	**	**	**	**
Frederick	**	**	**	**
Garrett	**	**	**	**
Harford	**	**	**	**
Howard	**	**	**	**
Kent	**	**	**	**
Montgomery	**	**	**	**
Prince George's	**	**	**	**
Queen Anne's	**	**	**	**
Saint Mary's	**	**	**	**
Somerset	**	**	**	**
Talbot	**	**	**	**
Washington	**	**	**	**
Wicomico	**	**	**	**
Worcester	**	**	**	**

* Rates are per 100,000 and age-adjusted to 2000 U.S. standard population

** Rates based on death counts of 0-15 are suppressed per DHMH/CCSC Mortality Data Suppression Policy

Source: NCHS Compressed Mortality File in CDC WONDER

Table 70.
Number of Cervical Cancer Cases
by Jurisdiction and Race, Maryland, 2003-2007

Jurisdiction	Total	Race			
		Whites	Blacks	Other	Unknown
Maryland	1,148	684	365	67	32
Allegany	22	s	<6	0	0
Anne Arundel	89	70	11	8	0
Baltimore City	180	s	120	0	<6
Baltimore County	172	120	48	<6	<6
Calvert	18	s	<6	0	0
Caroline	7	7	0	0	0
Carroll	24	s	0	<6	<6
Cecil	24	s	<6	0	0
Charles	22	10	s	<6	<6
Dorchester	<6	<6	<6	0	0
Frederick	50	42	s	<6	<6
Garrett	<6	<6	0	0	0
Harford	36	s	<6	0	0
Howard	41	26	9	6	0
Kent	<6	<6	0	0	0
Montgomery †	207	119	38	38	12
Prince George's †	147	48	86	6	7
Queen Anne's	9	s	<6	0	0
Saint Mary's	20	14	6	0	0
Somerset	8	<6	<6	0	0
Talbot	<6	<6	0	0	0
Washington	23	19	<6	<6	<6
Wicomico	16	9	<6	<6	0
Worcester	9	s	<6	0	0
Unknown	8	<6	<6	0	<6

<6 = Case counts of 1-5 are suppressed per DHMH/MCR Data Use Policy and Procedures

s = Case counts are suppressed to prevent disclosure of data in other cell(s). (See Appendix C for methods.)

† 2006 case counts for Montgomery and Prince George's counties are underreported.

(See Appendix C, Section I.A.1.)

Source: Maryland Cancer Registry

Table 71.
Cervical Cancer Age-Adjusted Incidence Rates*
by Jurisdiction and Race, Maryland, 2003-2007

Jurisdiction	Total	Race		
		Whites	Blacks	Other
Maryland	7.6	7.0	8.8	8.4
Allegany	11.1	11.0	**	0.0
Anne Arundel	6.7	6.5	**	**
Baltimore City	10.3	10.2	10.7	0.0
Baltimore County	8.0	8.2	10.5	**
Calvert	8.6	**	**	0.0
Caroline	**	**	0.0	0.0
Carroll	5.4	5.1	0.0	**
Cecil	9.7	8.2	**	0.0
Charles	6.8	**	**	**
Dorchester	**	**	**	0.0
Frederick	9.0	8.5	**	**
Garrett	**	**	0.0	0.0
Harford	5.7	5.7	**	0.0
Howard	5.8	4.9	**	**
Kent	**	**	0.0	0.0
Montgomery †	8.1	6.5	9.4	10.1
Prince George's †	6.9	8.0	6.7	**
Queen Anne's	**	**	**	0.0
Saint Mary's	8.3	**	**	0.0
Somerset	**	**	**	0.0
Talbot	**	**	0.0	0.0
Washington	6.0	5.2	**	**
Wicomico	6.7	**	**	**
Worcester	**	**	**	0.0

* Rates are per 100,000 and are age-adjusted to 2000 U.S. standard population

** Rates based on case counts of 1-15 are suppressed per DHMH/MCR Data Use Policy and Procedures

† 2003-2007 incidence rates for Montgomery and Prince George's counties are lower than actual due to case underreporting in 2006. (See Appendix C, Section I.A.1.)

Source: Maryland Cancer Registry

Table 72.
Number of Cervical Cancer Deaths
by Jurisdiction and Race, Maryland, 2003-2007

Jurisdiction	Total	Race		
		Whites	Blacks	Other
Maryland	346	187	149	10
Allegany	6	s	<6	<6
Anne Arundel	29	19	s	<6
Baltimore City	81	s	59	<6
Baltimore County	47	27	s	<6
Calvert	<6	<6	<6	<6
Caroline	<6	<6	<6	<6
Carroll	8	s	<6	<6
Cecil	<6	<6	<6	<6
Charles	7	<6	<6	<6
Dorchester	<6	<6	<6	<6
Frederick	11	9	<6	<6
Garrett	<6	<6	<6	<6
Harford	16	s	<6	<6
Howard	<6	<6	<6	<6
Kent	<6	<6	<6	<6
Montgomery	41	21	s	<6
Prince George's	51	s	36	<6
Queen Anne's	<6	<6	<6	<6
Saint Mary's	8	<6	<6	<6
Somerset	<6	<6	<6	<6
Talbot	<6	<6	<6	<6
Washington	10	9	<6	<6
Wicomico	<6	<6	<6	<6
Worcester	<6	<6	<6	<6

<6 = Death counts of 0-5 are suppressed per DHMH/CCSC Mortality Data Suppression Policy

s = Death counts are suppressed to prevent disclosure of data in other cell(s). (See Appendix C for methods.)

Source: NCHS Compressed Mortality File in CDC WONDER

Table 73.
Cervical Cancer Age-Adjusted Mortality Rates*
by Jurisdiction and Race, Maryland, 2003-2007


Jurisdiction	Total	Race		
		Whites	Blacks	Other
Maryland	2.2	1.7	3.7	**
Allegany	**	**	**	**
Anne Arundel	2.1	1.6	**	**
Baltimore City	4.5	3.5	5.1	**
Baltimore County	2.0	1.6	4.9	**
Calvert	**	**	**	**
Caroline	**	**	**	**
Carroll	**	**	**	**
Cecil	**	**	**	**
Charles	**	**	**	**
Dorchester	**	**	**	**
Frederick	**	**	**	**
Garrett	**	**	**	**
Harford	2.6	2.9	**	**
Howard	**	**	**	**
Kent	**	**	**	**
Montgomery	1.5	1.0	**	**
Prince George's	2.5	**	3.1	**
Queen Anne's	**	**	**	**
Saint Mary's	**	**	**	**
Somerset	**	**	**	**
Talbot	**	**	**	**
Washington	**	**	**	**
Wicomico	**	**	**	**
Worcester	**	**	**	**

* Rates are per 100,000 and are age-adjusted to 2000 U.S. standard population

** Rates based on death counts of 0-15 are suppressed per DHMH/CCSC Mortality Data
Suppression Policy

Source: NCHS Compressed Mortality File in CDC WONDER


Maryland Cervical Cancer Incidence Rates by Geographical Area: Comparison to U.S. Rate, 2003-2007



Note: Aggregated regional rates are used in comparisons when rates for one or more counties in that region are suppressed due to small numbers of cases or deaths. (See Appendix C for methods.)

Source: MD incidence rates from Maryland Cancer Registry, 2003-2007
U.S. (SEER 17) rate from SEER*Stat Software

Maryland Cervical Cancer Mortality Rates by Geographical Area: Comparison to U.S. Rate, 2003-2007



Appendix A

**Cigarette Restitution Fund
Cancer Report Requirements**

Cigarette Restitution Fund Cancer Report Requirements

The Maryland General Assembly established a Cigarette Restitution Fund (CRF) to provide for the distribution of funds from the tobacco settlement (House Bill 1425, Chapter 17 of the Acts of 2000 and Senate Bill 896, Chapter 18 of the Acts of 2000). The law created a Tobacco Use Prevention and Cessation Program and a Cancer Prevention, Education, Screening and Treatment Program, and provides parameters on how the funds may be spent. One provision of the law requires the Maryland Department of Health and Mental Hygiene (DHMH) to conduct a baseline cancer survey (2000) as well as cancer surveys at least every other year thereafter.

The law requires that the survey include:

- (1) The number and percentage of individuals who have each targeted cancer, both Statewide and in each county;
- (2) The number and percentage of individuals within each minority population who have each targeted cancer, both Statewide and in each county;
- (3) The mortality rate for each targeted cancer, both Statewide and in each county;
- (4) The mortality rate for the different minority populations for each targeted cancer, both Statewide and in each county;
- (5) The number of identifiable cancers with a high incidence in the State for which there are effective methods of prevention and early detection, and treatment after detection;
- (6) Any aspect of targeted and non-targeted cancers that DHMH seeks to measure; and
- (7) Any other factor that DHMH determines to be important for measuring rates of cancer in the State or for evaluating whether the program meets its objectives.

This information is provided in this Cancer Report as follows:

<i>Required Component of the Cancer Report</i>	<i>Location of Information in this Report</i>
1. Number and percentage of individuals having each targeted cancer, both Statewide and in each jurisdiction.	Tables 1, 2, 3, 4, 7, 8, 11, 12, 13, 16, 17, 20, 21, 22, 25, 26, 29, 30, 31, 34, 35, 38, 39, 40, 43, 44, 47, 48, 49, 52, 53, 56, 57, 58, 61, 62, 65, 66, 67, 70, 71
2. Number and percentage of individuals within each minority population having each targeted cancer, both Statewide and in each jurisdiction.	Same as above.
3. Mortality rate for each targeted cancer, both Statewide and in each jurisdiction.	Tables 1, 5, 6, 9, 10, 11, 14, 15, 18, 19, 20, 23, 24, 27, 28, 29, 32, 33, 36, 37, 38, 41, 42, 45, 46, 47, 50, 51, 54, 55, 56, 59, 60, 63, 64, 65, 68, 69, 72, 73
4. Mortality rate for the different minority populations for each targeted cancer, both Statewide and in each county.	Same as above.
5. Number of identifiable cancers with a high incidence in the State for which there are effective methods of prevention and early detection, and treatment after detection.	High incidence and effective prevention: Lung cancer: Tables 11, 12, 13, 16, 17 High incidence and effective detection: Colorectal and breast cancer: Tables 20, 21, 22, 25, 26, 29, 30, 31, 34, 35

<p>6. Other aspects of targeted and non-targeted cancers that DHMH seeks to measure.</p>	<p>For all cancer sites and for each targeted cancer, the report:</p> <ol style="list-style-type: none"> 1. Compares Maryland incidence and mortality rates to that of the U.S. (mortality data are not yet available); 2. Delineates incidence and mortality trends by race; 3. Shows 5-year mortality trends and 5-year combined data; 4. Presents 5-year incidence trends and 5-year combined data; 5. Tracks stage of disease at diagnosis over a 5-year period; 6. Lists appropriate Healthy People 2010 objective(s) showing trend data for each targeted cancer and identifies Maryland's progress in meeting the respective objective(s); 7. Describes the evidence for screening, primary prevention and chemoprevention for each targeted cancer, based on current scientific literature; and 8. Describes the recommended public health intervention for each targeted cancer based on the evidence referenced above. <p>This information is located throughout the report.</p>
<p>7. Other factors that DHMH determines to be important for measuring rates of cancer in the State or for evaluating whether the program meets its objectives.</p>	<p>Same as above.</p>

Appendix B

Cancer Report Format

Cancer Report Format

1. Selection of Targeted Cancers

Under the Cigarette Restitution Fund (CRF) Program, Cancer Prevention, Education, Screening and Treatment (CPEST) Program, the Maryland Department of Health and Mental Hygiene targeted seven cancer sites: lung and bronchus, colon and rectum, female breast, prostate, oral, melanoma of the skin, and cervix. These cancers have been targeted because they can be prevented (lung and bronchus and melanoma of the skin) or detected early and treated (colon and rectum, female breast, cervical, and oral), or are a major cause of cancer death (prostate).

2. Report Format

Information provided in this report focuses on all cancer sites reported in Maryland and the seven specific cancer sites targeted by the CPEST Program. The main body of the 2010 CRF Cancer Report focuses on the most recent data (2007 and 5-year combined data for the period 2003 through 2007).

Section I of the 2010 CRF Cancer Report is an Executive Summary, including an introduction to the report, highlights of major findings for each cancer, and a brief description of major changes to this report from the last (2009) CRF Cancer Report.

Section II of the report describes overall cancer incidence and mortality in Maryland for all cancer sites combined. This section includes graphs comparing long-term trends (1998-2007) in overall cancer incidence and mortality rates for Maryland and the U.S.; 5-year incidence and mortality trends (2003-2007) for all cancer sites (overall and by race); trends in stage for all cancers diagnosed in Maryland (2003-2007); and a comparison of Maryland mortality rates to the Healthy People 2010 target.

Section III presents cancer incidence and mortality data for the seven cancers targeted under the Cigarette Restitution Fund Program. Each chapter includes a comparison of the Maryland 2007 incidence and mortality rates (with 95% confidence intervals [95% C.I.]) and U.S. rates in the overview text and table. Maryland mortality rankings among the 50 states and the District of Columbia, based on 5-year mortality rates, are also described. Graphics are also included in each chapter to depict the following: Trends in cancer incidence and mortality rates for the 5-year period from 2003 to 2007; 5-year trends in cancer incidence and mortality rates by race (gender used for melanoma); 5-year trends in cancer stage at time of diagnosis; and prevalence of cancer screening and cancer-risk behaviors in Maryland compared to Healthy People 2010 targets. Public health evidence and recommended areas for public health intervention are also described for each targeted cancer. The number of new cancer cases, number of cancer deaths, and age-adjusted cancer incidence and mortality rates for each cancer are tabulated by gender, race, and jurisdiction for 2007 and for the 5-year period, 2003-2007. All rates are age-adjusted to the 2000 U.S. standard population. Maps included in each cancer chapter display

Maryland incidence and mortality rates compared to corresponding U.S. rates for the combined years 2003-2007, by geographical area (see Appendix H for map data).

Appendix A describes the legal basis for the Cancer Report and includes a crosswalk between each required component and its location in this report. Appendix C describes the sources of data used to prepare the 2010 Cancer Report and specific data considerations (e.g., data confidentiality and statistical methods). A glossary of terms used in the 2010 Cancer Report is included as Appendix D. Maryland population estimates for 2007, by race and gender, are presented in Appendix E. The population data in these tables can be used as denominators for calculating crude incidence and mortality rates. Appendix F depicts the 2000 U.S. standard population organized by age groupings. Appendix G contains a listing of International Classification of Diseases for Oncology (ICD-O-3) codes for incidence, along with corresponding ICD-10 codes for mortality for the cancer sites included in the report. Appendix H presents age-adjusted incidence and mortality rates with 95% confidence intervals, by Maryland geographical area (state, region, and county). Appendix I tables display trends in cancer incidence and mortality rates, by cancer site and race (gender used for melanoma), over the 5-year period (2003-2007). Appendix J tables show the distribution of cancer stage at diagnosis for all cancer sites and the targeted cancers, by year, from 2003 to 2007.

Appendix C

**Cancer Report Data Sources, References, and
Data Considerations**

2010 Cigarette Restitution Fund (CRF) Cancer Report Data Sources, References, and Data Considerations

I. DATA SOURCES

Data and information presented in the 2010 Cigarette Restitution Fund (CRF) Cancer Report were obtained from a variety of sources, including:

- Maryland Department of Health and Mental Hygiene (DHMH)
 - Center for Cancer Surveillance and Control
 - Office of Health Policy and Planning
 - Center for Health Promotion, Education and Tobacco Use Prevention
- National Cancer Institute (NCI, part of the National Institutes of Health)
- Centers for Disease Control and Prevention (CDC); and
- Office of Disease Prevention and Health Promotion at the U.S. Department of Health and Human Services

These sources and the types of information provided for the 2010 CRF Cancer Report are described in the following sections.

A. Cancer Incidence and Stage Data

1. Maryland Cancer Registry

The Maryland Cancer Registry (MCR), Center for Cancer Surveillance and Control, DHMH, is the source for all Maryland-specific cancer incidence and cancer stage data used in this report. The MCR is a computerized data system that registers (i.e., collects and consolidates reports) all new cases of reportable cancers (excluding non-genital squamous cell or basal cell skin cancer) that are diagnosed or treated in Maryland and reported to the MCR. Incidence rates used in this report were calculated using cases reported to the MCR as of December 1, 2009 for diagnosis year 2007.

The Maryland cancer reporting law and regulations mandate the collection of cancer information from hospitals, radiation therapy centers, diagnostic pathology laboratories licensed in Maryland, freestanding ambulatory care facilities, surgical centers, and physicians whose non-hospitalized cancer patients are not otherwise reported. MCR also participates in data exchange agreements with 13 other states/jurisdictions, including Delaware, Pennsylvania, Virginia, West Virginia, and the District of Columbia. Information on Maryland residents diagnosed or treated for cancer in these jurisdictions is included in this report. **Note: The 2006 case counts presented in this report for Montgomery and Prince George's counties are underreported due to delay in case reporting. Cancers reported to the MCR after the annual cutoff date are not included in the MCR official Maryland case counts and rates. The case undercounts resulted in lower than actual age-adjusted incidence rates for Montgomery and Prince George's counties, for the National Capital geographic region, and to a lesser degree, for Maryland, for 2006 and the 5-year period 2003-2007.**

2. Surveillance, Epidemiology, and End Results Program (SEER)

The Surveillance, Epidemiology, and End Results (SEER) Program, managed by the National Cancer Institute (NCI), is an authoritative source of information on cancer incidence, stage, and survival in the U.S. SEER incidence rates representative of the U.S. are used in the 2010 CRF Cancer Report for comparisons with Maryland incidence rates.

The SEER Program, which began in 1973, collects, analyzes, and publishes cancer incidence and survival data from population-based cancer registries participating in the program. The SEER Program was expanded in 1992 (creating the SEER 13 registry database) and again in 2001 to increase representation of minority and rural low-income populations including Hispanics, American Indian populations, and rural African Americans. Since 2000, SEER incidence data have been collected from 13 SEER registries and four expansion registries throughout the U.S. (SEER 17 registry database) and are estimated to represent approximately 26% of the U.S. population. The SEER database adequately represents cancer incidence in the U.S. population with regard to race, ethnicity, age, gender, poverty, and education, and by collecting data on epidemiologically significant population subgroups.

SEER 17 incidence data are used in this report for comparisons with the most recent Maryland data (2003-2007) because they provide the broadest population coverage that is currently available. For longer-term comparisons that include Maryland data prior to 2000, SEER 13 registry data are used. All SEER 13 and 17 rates were obtained from SEER*Stat (version 6.5.1), a statistical software tool for the analysis of SEER and other cancer-related databases. The SEER Program updates cancer statistics annually in a publication called the SEER Cancer Statistics Review (CSR). SEER data for specific cancers can be seen on the Web at http://seer.cancer.gov/csr/1975_2007/index.html. Additional information about SEER can also be found on the Web site at www.seer.cancer.gov.

The Maryland population estimates for 2007 presented in Appendix E were obtained from SEER*Stat.

B. Cancer Mortality Data

The Maryland and U.S. mortality data presented in this report were obtained from the National Center for Health Statistics (NCHS) Compressed Mortality Files (CMF) in the Centers for Disease Control and Prevention (CDC) Wide-ranging Online Data for Epidemiologic Research (WONDER) system. CDC WONDER is an easy-to-use Web-based system that makes information from CDC available to public health professionals and the public at large. It provides access to a wide array of public health information, including Web resources for Healthy People (HP) 2010 targets (see Section C.4 of this appendix) and cancer mortality data.

The NCHS CMF is a county-level national mortality and population database spanning the years 1979-2007. The number of deaths, crude death rates, and age-adjusted death

rates can be obtained by place of residence (total U.S., state, and county), age group, race, gender, year of death, and underlying cause of death (based on International Classification of Diseases [ICD] code or group of codes). Mortality data presented in this report for the individual years 1999 to 2007 and 5-year combined data for the period 2003-2007 were obtained from the 1999-2007 CMF using ICD Tenth Revision (ICD-10) codes. Mortality rates for 1998, which are used in 10-year trend graphics in this report, were obtained from the 1979-1998 CMF using Ninth Revision (ICD-9) codes. Data was accessed in December 2010.

Beginning with 1999 mortality data, CDC WONDER reports race in four categories (American Indian or Alaska Native, Asian or Pacific Islander, Black or African American, and White), as well as Hispanic ethnicity; for years prior to 1999, race is reported in three categories (Black or African American, White, and Other). The category of “Other” races in this report includes the American Indian or Alaska Native race category and the Asian or Pacific Islander race category.

C. Behavioral and Risk Factor Data

The CRF Cancer Report includes data on the prevalence of cancer screening and prevalence of various risk factors for cancer (e.g., smoking) in Maryland. These data are obtained from several different sources, as described below.

1. Maryland Behavioral Risk Factor Surveillance System (BRFSS)

The Maryland Behavioral Risk Factor Surveillance System (BRFSS) is used for the CRF Cancer Report as a source of data on the prevalence of cancer screening (e.g., mammograms) and cancer risk behaviors (e.g., tobacco use) in Maryland. The BRFSS is an annual telephone survey conducted on a random sample of Maryland adult residents. This survey, managed by the Maryland DHMH Family Health Administration, Office of Health Policy and Planning, provided risk behavior and cancer screening information for this report. Maryland data can be accessed online at <http://www.marylandbrfss.org>. In addition, both Maryland and state-aggregated national data on health risk behavior can be obtained from the CDC BRFSS Web site at <http://www.cdc.gov/brfss>.

2. Maryland Youth Tobacco Survey

Data from the Maryland Youth Tobacco Survey (MYTS) are used in the CRF Cancer Report to monitor trends in tobacco use (as a risk factor for lung cancer) by Maryland youth. The MYTS, managed by the DHMH Family Health Administration, Center for Health Promotion, Education and Tobacco Use Prevention, is administered to gather information regarding attitudes, usage, and exposure to tobacco products among public middle and high school students Statewide and within each of Maryland’s 23 counties and Baltimore City. Survey results are also used in apportioning Local Tobacco Use Prevention and Cessation grants among Maryland’s 24 major political subdivisions. To date, the MYTS has been conducted in 2000, 2002, 2006, and 2008. Published survey reports are available on the DHMH Web site at <http://www.crf.state.md.us/html/stats.cfm>

and http://crf.maryland.gov/tobacco_behaviors.cfm. Additional information can be obtained from the Center for Health Promotion, Education, and Tobacco Use Prevention at 410-767-1362.

3. Maryland Cancer Survey

The Maryland Cancer Survey (MCS) is a biennial survey managed by the DHMH Center for Cancer Surveillance and Control, Surveillance and Evaluation Unit. The purpose of the MCS is to determine cancer screening rates and to measure cancer risk behaviors among persons age 40 years and older living in Maryland, for selected cancers targeted by DHMH. Completed surveys are available for 2002, 2004, 2006, and 2008. MCS data are used in the CRF Cancer Report to supplement BRFSS data on prevalence of cancer screening and cancer risk behaviors among adults age 40 years and older in Maryland.

Some charts in this report include both MCS and Maryland BRFSS data, as a basis for comparison with HP 2010 targets. Caution should be used when comparing results from the MCS and BRFSS. Although they are similar, these surveys have certain design and methodological differences, including targeted age groups, scope and timing of the surveys, and weighting. The MCS reports, including detailed information on the survey methods, are available on the Web at http://fha.maryland.gov/cancer/surv_data-reports.cfm.

4. Healthy People 2010

HP 2010 is a collaboration of local and national governmental agencies and private organizations that have developed prevention-oriented national objectives to improve the health of Americans. The HP initiative is under the Office of Disease Prevention and Health Promotion at the U.S. Department of Health and Human Services (DHHS). The overarching HP 2010 goal for cancer prevention is to “reduce the number of new cases as well as the illness, disability, and death caused by cancer.” To achieve this goal, measurable objectives related to cancer screening and cancer risk behaviors were established, each with a specific quantitative target. Several of these targets are used in the CRF Cancer Report as benchmarks by which Maryland progress can be measured.

In 2006, a Midcourse Review of HP 2010 was completed by DHHS to assess progress toward the original HP 2010 objectives, and to revise those objectives for which new data had become available. DHHS is currently updating all HP goals and objectives as part of HP 2020 initiative; the new HP 2020 objectives are scheduled for release in late 2010. Additional information can be found on the Web at <http://www.healthypeople.gov> and <http://www.healthypeople.gov/data/midcourse>.

II. REFERENCES USED FOR PUBLIC HEALTH EVIDENCE AND PUBLIC HEALTH INTERVENTION SECTIONS

A. National Cancer Institute Physician Data Query (NCI PDQ)

Information provided in the chapters under the sections for "Public Health Evidence" and "Public Health Intervention" was taken primarily from the NCI PDQ[®] Web site. While the United State Preventive Services Task Force (USPSTF) reviews its recommendations every few years, the information presented in the PDQ on cancer prevention and screening is updated more frequently and the date of the most recent revision can be found on each Web page for that topic. Prevention and screening sections from this source provide information for health professionals and the public on various aspects of cancer control such as prevention, screening, treatment, genetics, and clinical trials. For some cancer types, the information is reviewed by a scientific editorial board and is updated as new research becomes available. The PDQ Editorial Board evaluates evidence in two steps: (1) study design, and (2) assessment of the evidence. The first step is to describe the evidence within five domains (see below); the second is an assessment of certainty--to judge the overall "level" of evidence as "solid," "fair," or "inadequate." The Board conducts the same process separately for potential benefits and potential harms of each intervention.

Step 1: Description of the evidence

Step 1 involves evaluating the levels of evidence in five domains.

1. Study Design: study designs in order of strongest evidence to weakest evidence, are described as follows:
 - a. Evidence obtained from at least one randomized controlled trial (this is considered the gold standard for scientific research);
 - b. Evidence obtained from controlled trials without randomization;
 - c. Evidence obtained from well-designed and conducted cohort or case-control studies, preferably from more than one center or research group;
 - d. Evidence obtained from multiple time series with or without intervention; and
 - e. Opinions of respected authorities based on clinical experience, descriptive studies, or reports of expert committees.
2. Internal validity
3. Consistency (coherence)/volume of the evidence
4. Direction and magnitude of effects for health outcomes (both absolute and relative risks, as quantitative as possible, may vary for different populations)
5. External validity

Step 2: Assessment of the evidence

Step 2 is a judgment of the level of certainty (solid, fair, inadequate) and is based on the Board's understanding of the direction and magnitude of the health effects of widespread implementation. The assessment may also include a statement of benefits and a second statement of harms of widespread implementation.

More information about NCI PDQ can be accessed at:

Levels of evidence

<http://www.cancer.gov/cancertopics/pdq/screening/levels-of-evidence>

Prevention and screening/detection

<http://www.cancer.gov/cancertopics/pdq/prevention>

<http://www.cancer.gov/cancertopics/pdq/screening>

The PDQ reference is used throughout the report for consistency in interpreting the results of scientific literature and the PDQ Summary of Evidence is often quoted verbatim and sometimes paraphrased. PDQ definitions are included in Appendix D (Glossary). For additional information, the Web site is <http://www.cancer.gov/cancertopics/pdq>.

B. Maryland Department of Health and Mental Hygiene, Medical Advisory Committees for Breast, Cervical, Colorectal, Oral, and Prostate Cancers

The Center for Cancer Surveillance and Control has convened four Medical Advisory Committees to formulate guidelines for breast, cervical, colorectal, and prostate cancer screening, diagnosis, and treatment. The Office of Oral Health has convened a Medical Advisory Committee to formulate guidelines for oral cancer for screening, diagnosis, and treatment. All guidelines are located at <http://fha.maryland.gov/cancer/guidelines.cfm>.

C. Additional Medical Literature

Lung and Bronchus Cancer

Centers for Disease Control and Prevention. *Best Practices for Comprehensive Tobacco Control Programs – 2007* (October 2007). National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, Atlanta, GA. http://www.cdc.gov/tobacco/stateandcommunity/best_practices/index.htm. Last accessed April 7, 2011.

Screening for Lung Cancer, Topic Page. May 2004. U.S. Preventive Services Task Force. Agency for Healthcare Research and Quality, Rockville, MD. <http://www.uspreventiveservicestaskforce.org/uspstf/uspslung.htm>. Last accessed November 10, 2010.

Colorectal Cancer

Screening for Colorectal Cancer, Topic Page. November 2008. U.S. Preventive Services Task Force. Agency for Healthcare Research and Quality, Rockville, MD. <http://www.uspreventiveservicestaskforce.org/uspstf/uspscolo.htm>. Last accessed November 10, 2010.

Female Breast Cancer

Chemoprevention for Breast Cancer, Topic Page. July 2002. U.S. Preventive Services Task Force. Agency for Healthcare Research and Quality, Rockville, MD.

<http://www.uspreventiveservicestaskforce.org/uspstf/uspssbrpv.htm>. Last accessed November 10, 2010.

Screening for Breast Cancer, Topic Page. November 2009. U.S. Preventive Services Task Force. Agency for Healthcare Research and Quality, Rockville, MD.

<http://www.uspreventiveservicestaskforce.org/uspstf/uspssbrca.htm>. Last accessed November 10, 2010.

Prostate Cancer

Smith RA, Cokkinides V, and Brawley OW. Cancer Screening in the United States, 2008: A Review of Current American Cancer Society Guidelines and Cancer Screening Issues. *CA Cancer J Clin* 2008; 58: 161-179.

<http://caonline.amcancersoc.org/cgi/content/full/58/3/161>. Last accessed November 10, 2010.

Screening for Prostate Cancer, Topic Page. August 2008. U.S. Preventive Services Task Force. Agency for Healthcare Research and Quality, Rockville, MD.

<http://www.uspreventiveservicestaskforce.org/uspstf/uspssprca.htm>. Last accessed November 10, 2010.

Oral Cancer

Screening for Oral Cancer, Topic Page. February 2004. U.S. Preventive Services Task Force. Agency for Healthcare Research and Quality, Rockville, MD.

<http://www.uspreventiveservicestaskforce.org/uspstf/uspssoral.htm>. Last accessed November 10, 2010.

Skin Cancer

Screening for Skin Cancer, Topic Page. February 2009. U.S. Preventive Services Task Force. Agency for Healthcare Research and Quality, Rockville, MD.

<http://www.uspreventiveservicestaskforce.org/uspstf/uspsskca.htm>. Last accessed November 10, 2010.

Cervical Cancer

Screening for Cervical Cancer, Topic Page. January 2003. U.S. Preventive Services Task Force. Agency for Healthcare Research and Quality, Rockville, MD.

<http://www.uspreventiveservicestaskforce.org/uspstf/uspsscerv.htm>. Last accessed November 10, 2010.

CDC. Quadrivalent Human Papillomavirus Vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR* 2007;56 (No. RR-02); March 23, 2007.

CDC. FDA Licensure of Bivalent Human Papillomavirus Vaccine (HPV2, Cervarix) for Use in Females and Updated HPV Vaccination Recommendations from the Advisory Committee on Immunization Practices (ACIP). *MMWR* 2010;59(20); May 28, 2010.

III. DATA CONSIDERATIONS

A. Data Confidentiality

DHMH regards all data reported to, and received and processed by, the MCR as confidential. Data are secured from unauthorized access and disclosure. The MCR manages and releases cancer information in accordance with the laws and regulations established by the State of Maryland, as set forth in the Annotated Code of Maryland, Health-General Article, §§18-203 – 204 and §4-101 et seq., and Code of Maryland Regulations, COMAR 10.14.01 (Cancer Registry).

Because incidence data and mortality data come from different sources, separate suppression procedures were employed. For the number of cancer cases collected by MCR and for incidence rates calculated using case and population data, the following protocols apply: To ensure patient confidentiality and to comply with the *MCR Data Use Policy and Procedures* (July 2008; http://fha.maryland.gov/cancer/mcr_data.cfm), cells with counts of 1-5 cases are suppressed and presented as “<6.” Complementary suppression of case counts in additional cell(s) is used, denoted by “s,” to prevent back-calculation of numbers in those cells with primary suppression. Incidence rates based on 15 or fewer (non-zero) cases are presented with asterisks (**) because the rates are unstable and do not provide reliable information.

Mortality data for the report were extracted from the NCHS CMF in CDC WONDER using its Web-based data query feature (see Section I.B above). ICD-10 codes listed in Appendix G of this report were used for identifying type of cancer for extraction. Data obtained from the NCHS CMF are subject to both CDC WONDER and NCHS data use restrictions, which differ slightly from those of the *MCR Data Use Policy* used for incidence data. To ensure that individual identity is protected in the use and re-release of mortality data from the CMF in CDC WONDER and that reliable mortality rates are presented in this and other CCSC publications, the DHMH Center for Cancer Surveillance and Control (CCSC) developed the *Mortality Data Suppression Policy When Using National Center for Health Statistics (NCHS) Mortality Data in CCSC Publications* (June 2008). In accordance with this policy, the following protocols are applied to mortality data in this report: Death counts of fewer than 6 (i.e., 0-5 deaths) are suppressed, and denoted by “<6.” Complementary suppression of death counts in additional cell(s) is used, as denoted by the letter “s,” to prevent back-calculation of numbers in cells with primary suppression. Age-adjusted mortality rates based on counts less than 16 (i.e., 0-15 deaths) are suppressed (denoted by ** symbol) because the rates are unstable and do not provide reliable information. Although CDC WONDER publishes and annotates as “unreliable” rates based on counts less than 20 deaths, CCSC suppresses death rates based on counts of less than 16 deaths. This threshold is consistent

with the criteria used in both the NCI U.S. Cancer Statistics Review and the *DHMH/MCR Data Use Policy* for incidence rate suppression.

B. Gender

Gender is reported to the MCR as: a) male; b) female; c) hermaphrodite; d) transsexual; and e) unknown (not stated). The totals shown in the count for number of cancer cases may not equal the sum of males and females because of cases in these other gender categories.

C. Rate Analysis

Individual year incidence rates for 2007 presented in this report were calculated using Maryland resident cancer cases diagnosed from January 1 through December 31 of that year, and reported to the MCR as of December 1, 2009. The individual year mortality data (2007) consist of deaths that occurred between January 1 and December 31 of that year. Multiple year incidence rates presented were calculated for 5-year collapsed rates using MCR 2003-2007 data. Corresponding mortality rates were extracted from the NCHS CMF in CDC WONDER as 5-year combined data from 2003-2007.

Age-adjustment, also called age-standardization, is one of the tools used to control for the different and changing age distributions of the population in states, counties, etc., and to enable meaningful comparisons of vital rates over time. Age-adjusted rates do not include cancer cases on which age has not been reported. Federal agencies have adopted the year 2000 U.S. standard population as the standard for age-adjusting incidence and mortality rates. For consistency and ease of comparison, incidence and mortality rates in this report were calculated and age-adjusted using the 2000 U.S. standard population. Additional information on age-adjustment can be found at <http://www.cdc.gov/nchs/data/statnt/statnt20.pdf>.

Incidence and mortality counts and rates are suppressed according to the *DHMH/MCR Data Use Policy* and the *DHMH/CCSC Mortality Data Suppression Policy*, as described in Section III.A above.

The Annual Percent Change (APC) is calculated for incidence and mortality trends and for tracking incidence and mortality rates by race and gender over time. See Appendix D, Glossary, for the definition of APC.

D. Confidence Intervals and Statistical Significance

Age-adjusted rates for specific geographic areas (e.g., U.S., states, regions, counties) can be compared to determine whether differences in incidence or mortality exist between those areas. However, incidence and mortality rates, particularly those based on small numbers of events (cases or deaths) or small population sizes, can be highly variable from year to year. The rate from one year may not be typical of the usual rate for a geographic area when compared to other years. For this reason, two rates cannot simply be compared side-by-side to determine whether they are statistically significantly

different. Confidence intervals are useful in defining a range within which the typical rate for a geographic area can be expected to lie.

A confidence interval is used to describe the range of uncertainty around a point estimate (e.g., an incidence or mortality rate) and serves as an indicator of the precision or stability of a rate. Most confidence intervals are, by convention, calculated at the 95% level; at this level, there is a 95% probability that the interval covers the true value. The smaller the number of events upon which a rate is based, the wider the confidence interval will be.

Confidence intervals for incidence and mortality rates are included in this report to facilitate comparisons between rates, such as the comparison of Maryland rates to U.S. rates. Confidence intervals for Maryland and SEER 17 incidence rates, provided by the MCR, are developed from the SEER*Stat software. Confidence intervals for mortality rates were generated as part of the query of CMF data using CDC WONDER. The following formula can also be used to approximate the 95% confidence interval for age-adjusted rates:

$$\text{Lower limit} = R - [1.96 (R/\sqrt{n})]$$

$$\text{Upper limit} = R + [1.96 (R/\sqrt{n})]$$

R = age-adjusted cancer incidence or mortality rate

n = number of events (cancer cases or deaths)

When the confidence intervals around two rates (e.g., state and county rates) do not overlap, it can be stated with 95% confidence that the two rates are statistically significantly different. For example, Maryland's 2007 colorectal cancer (CRC) incidence rate was 41.6 per 100,000, with a confidence interval of 40.0-43.4. The 2007 U.S. SEER-reported CRC incidence rate was 45.5 per 100,000 population, with a 95% confidence interval of 45.0-46.0. Since these confidence intervals do not overlap, the two rates are considered to be statistically significantly different (i.e., the difference between these rates is more than that expected by chance).

If the two confidence intervals overlap and if the rate for one area is included in the confidence interval of the other rate, then the rates are not statistically significantly different. However, when there is overlap in the confidence intervals for two rates, and the rate for the comparison area is not included in the interval for the rate of interest, the two rates may or may not be statistically significantly different. In this situation, statistical testing methods described by the North American Association of Central Cancer Registries (NAACCR), *Cancer in North America* (May 2010) are used in this report to determine whether the differences between the two rates are statistically significant. An approximate confidence interval for the rate ratio of two age-adjusted rates can be calculated using the following formula:

$$(R_1/R_2)^{1 \pm z/x}$$

where,

R_1 and R_2 are the age-adjusted rates being compared;

SE_1 and SE_2 are the standard errors for the respective rates;

$z = 1.96$ for 95% limits; and

$x = (R_1 - R_2) / \sqrt{(SE_1^2 + SE_2^2)}$

If the confidence interval for the rate ratio includes the value of one, then the two rates are not statistically significantly different (p-value of 0.05).

In this report, when two rates are not statistically significantly different, they are described as being “similar.”

E. National Comparison Data

Maryland (statewide) and county incidence and mortality rates are compared to U.S. SEER incidence rates (see Section I.A) and U.S. mortality rates from NCHS (Section I.B).

Data used for Maryland cancer mortality ranking by site are based on NCHS mortality files extracted from CDC WONDER. Maryland’s mortality ranking among the 50 states and the District of Columbia for all cancer sites combined and for specific targeted cancers is based on a 5-year average (2003-2007) of age-adjusted rates. Because mortality rates describe the cancer burden better than incidence rates, only Maryland rankings for mortality are presented for each targeted cancer.

Maps in this report display comparisons of Maryland incidence and mortality rates, by geographical area, to U.S. rates. For both incidence and mortality rate maps, the 5-year (2003-2007) U.S. rate was used as a basis for comparison with rates for Maryland jurisdictions (counties and regions). A ramp is used for grouping Maryland data into categories in reference to U.S. rates. The ramp groups data into five divisions: >25% above U.S. rate; 10-25% above U.S. rate; between 10% below and 10% above U.S. rate; 10-25% below U.S. rate; and >25% below U.S. rate. Note that 10-25% includes the 10% and 25%, but less than 10% and more than 25% do not include the endpoints of the range. Where 5-year incidence or mortality rates for any given jurisdiction are suppressed due to a small number of cases or deaths, aggregated regional rates for the affected area are used in lieu of county rates as a basis for comparison in maps.

F. Race and Hispanic Ethnicity

The MCR began requiring submission of more detailed data on race and ethnicity in August 1998. Incidence data provided by the MCR for this report include the following race categories: White, Black, and Other. The “Other” race category includes cases reported as American Indian or Alaska Native, Asian or Pacific Islander, and any other

race category except those cases with unknown or missing race. The MCR uses the National Cancer Institute SEER*Stat software to compile incidence data.

Hispanic ethnicity is captured in a separate data field. Data presented in Table 5 are derived using the NAACCR Hispanic Identification Algorithm. This algorithm uses a combination of NAACCR variables to classify cases as Hispanic. In Table 5, “Hispanic” includes people reported to the MCR as Spanish/Hispanic origin plus those with “derived” Hispanic origin. The derivation is an algorithm based on the person’s surname (last or maiden name) and their place of birth, race, and sex.

Mortality data (death counts and rates) in this report were obtained from the NCHS CMF in CDC WONDER. Race data in the CMF are based on information collected on death certificates. As described in Section I.B above, CDC WONDER began reporting race in four categories (White, Black, Asian or Pacific Islander, and Native American or Alaska Native), as well as Hispanic ethnicity, starting with 2006 mortality data. In years prior to 2006, race is reported in three categories (White, Black, and other). The category of “other” races includes the American Indian or Alaska Native race category and the Asian or Pacific Islander race category. NCHS, in collaboration with the Census Bureau, developed a race-bridging methodology for assigning multiple-race groups to single-race categories.

G. Healthy People 2010 Targets

In the CRF Cancer Report, quantitative HP 2010 targets are compared to Maryland data related to cancer risk behaviors and adherence to cancer screening recommendations (see Section I.C.4). Specifically, HP 2010 targets are compared to data from the Maryland BRFSS and the MCS. The data from these Maryland surveys are weighted to the age, race, and gender of Maryland population. Unlike the national data that serve as the basis for HP 2010 targets, Maryland BRFSS and MCS data are not age-adjusted to the 2000 U.S. standard population. The HP 2010 targets in this report have been updated to reflect changes resulting from the HP 2010 Midcourse review completed in 2006.

H. Appendices

Please refer to additional appendices for:

- Cigarette Restitution Fund Cancer Report Requirements (Appendix A)
- Cancer Report Format (Appendix B)
- Glossary (technical terms and definitions; Appendix D)
- Maryland Population Estimates, 2007 (Appendix E)
- U.S. Standard Population, 2000 (Appendix F)
- Definitions of International Classification of Diseases (ICD) Codes Used for Cancer Incidence and Mortality (Appendix G)
- Maryland Cancer Incidence and Mortality Rates by Geographical Area, 2003-2007 (Appendix H)
- Trends in Cancer Incidence and Mortality Rates in Maryland by Cancer Site and Year, 2003-2007 (Appendix I)

- Trends in Cancer Stage of Disease at Diagnosis in Maryland by Cancer Site, Race, and Year, 2003-2007 (Appendix J)

Appendix D

Glossary

Glossary

- **Age-adjustment:** Age is the most important risk factor for the incidence of most cancers. Cancer rates derived from populations that differ in underlying age structure are not comparable. Age-adjustment is a statistical technique that allows for the comparison of rates among populations having different age distributions, by weighting the age-specific rates in each population to one standard population. Additional information on age-adjustment can be found on the following Web sites:
<http://seer.cancer.gov/seerstat/tutorials/aarates/definition.html>
<http://www.cdc.gov/nchs/data/statnt/statnt20.pdf>
- **Annual Percent Change (APC):** APC is a measure of the annual percent increase or decrease in cancer rates over time and is used for analyzing trends. This measure assumes that cancer rates change at a constant percentage of the rate of the previous year. Rates that change at a constant percentage every year change linearly on a log scale. A more detailed description of the method can be found at:
<http://surveillance.cancer.gov/joinpoint/aapc.html>
- **Ascertainment:** Ascertainment refers to the quality assurance procedures that Maryland Cancer Registry staff use to ensure completeness of cancer cases in the registry database. These activities include: a review of disease indices from all reporting hospitals to identify possible missed cases; a random sample of records from reporting facilities; and review of death certificate data to identify cancer cases not previously reported.
- **Cancer:** Cancer is a disease characterized by the uncontrolled, abnormal growth of cells in different parts of the body that can spread to other parts of the body.
- **Chemoprevention:** Chemoprevention is the use of drugs, vitamins, or other agents to try to reduce the risk of cancer or to delay the development or recurrence of cancer.
- **Confidence Interval (CI):** A confidence interval is the range of values for a rate that will include the true value of the rate a given percentage of the time. A 95% CI includes the true value of the rate 95% of the time.
- **Incidence:** Incidence is the number of new cases of a given cancer or other event during a defined period, usually one year. For the purpose of this report, cancer incidence refers to the number of new cases diagnosed during individual calendar year 2007. Cancer incidence data are also presented in aggregated form as the average annual incidence for the 5-year period from 2003 through 2007.
- **International Classification of Diseases for Oncology (ICD-O):** The ICD-O is the classification system used by tumor or cancer registries to code the site and the histology of the cancer, usually from a pathology report.
- **Invasive cancer:** Invasive cancer is a stage of cancer in which cancer cells have spread to healthy tissue adjacent to the tumor. It may still be considered localized if it has not spread

to other parts of the body. Stage data presented in this report involve a diagnosis of invasive cancer: localized, regional, or distant. A diagnosis “in situ” is noninvasive and is not included in the staging data.

- **Mortality:** Mortality refers to the number of deaths during a defined time, usually one year. For the purposes of this report, cancer mortality data are presented for individual calendar year 2007. Data for cancer mortality are also presented in an aggregated form, as the average annual mortality for the 5-year period from 2003 through 2007.
- **Primary prevention:** Primary prevention is preventing cancer before it has developed, such as through avoiding carcinogens (e.g., avoiding tobacco), promoting a healthy lifestyle through exercise and diet, preventing the harmful effects of carcinogens (e.g., using sunscreen), and detecting and removing precancerous lesions (e.g., removing polyps in the colon).
- **Race bridging:** Race bridging refers to the process of making data collected using one set of race categories consistent with data collected using a different set of race categories. This consistency allows estimation and comparison of race-specific statistics at a given point in time or over a period of time. More specifically, race bridging is a method used to make systems sufficiently comparable to permit estimation and analysis of race-specific statistics. Race-bridging algorithms are generally applied to population data, which are used in this report for calculating rates and for describing race categories of Maryland population estimates (see Appendix E).
- **Rate:** A rate is an estimate of the burden of a given disease on a defined population over a specified period of time. A crude rate is calculated by dividing the number of cases or deaths (events) by the population at risk during a given time period. Cancer incidence and mortality rates are usually presented per 100,000 population during a given time period. An incidence rate is the number of new cases during a specific period (usually one year) divided by the population at risk, standardized to a population of 100,000. A mortality rate is the number of deaths for a given period divided by the population at risk per 100,000 population. All rates presented in this report are age-adjusted to the 2000 U.S. standard population.
- **Region:** The following are regional categories in Maryland.

Baltimore Metropolitan Area

Anne Arundel, Baltimore City, Baltimore County, Carroll, Harford, Howard

Note: The Baltimore Metropolitan Area does not include Baltimore City when used in Appendix H and for the incidence and mortality maps.

Eastern Shore Region

Caroline, Cecil, Dorchester, Kent, Queen Anne’s, Somerset, Talbot, Wicomico, Worcester

National Capital Area

Montgomery, Prince George’s

Northwest Region

Allegany, Frederick, Garrett, Washington

Southern Region

Calvert, Charles, Saint Mary's

- **Screening:** Screening is checking for disease when there are no symptoms, resulting in detection of pre-cancer, or cancer in situ or at an early stage.
- **Stage at Diagnosis:** Cancer stage is the extent to which the cancer has spread from the organ of origin at the time of diagnosis. The stage information used in this report is based on the SEER Summary Stage Guidelines:
 1. **In situ:** the cancerous cells have not invaded the tissue basement membrane. In situ cancers are not considered malignant (with the exception of bladder cancers) and are not included in incidence rate calculations.
 2. **Localized:** the tumor is confined to the organ of origin.
 3. **Regional:** the tumor has spread to adjacent organs or tissue. Regional lymph nodes may also be involved.
 4. **Distant:** the tumor has spread beyond the adjacent organs or tissues. Distant lymph nodes, organs and/or tissues may also be involved.
 5. **Unstaged:** the stage of disease at diagnosis was unable to be classified (often due to insufficient information) or was not reported to the cancer registry.

Appendix E

Maryland Population Estimates, 2007

Maryland Population Estimates by Jurisdiction, 2007

	Total		Total		Total		Total		Total		Total		Total		Total	
	All	Genders	Total	Male	Total	Female	Total	White	Total	White	Total	White	Total	Black	Total	Black
								Male		Female		Male		Female		Female
Maryland	5,618,899		2,719,072	2,899,827	3,614,417	1,777,280	1,837,137		1,683,413		786,088		897,325			
Baltimore Metropolitan Area	2,617,290		1,260,432	1,356,858	1,725,165	845,019	880,146		775,769		358,677		417,092			
Anne Arundel County	510,507		253,222	257,285	411,247	204,645	206,602		79,795		39,192		40,603			
Baltimore City	640,150		298,819	341,331	210,491	102,985	107,506		413,017		187,663		225,354			
Baltimore County	785,830		373,628	412,202	550,732	264,323	286,409		197,761		90,851		106,910			
Carroll County	168,786		83,428	85,358	158,733	78,389	80,344		6,799		3,480		3,319			
Harford County	239,406		117,332	122,074	203,065	99,936	103,129		30,079		14,482		15,597			
Howard County	272,611		134,003	138,608	190,897	94,741	96,156		48,318		23,009		25,309			
Eastern Shore Region	435,171		212,494	222,677	355,986	174,271	181,715		72,840		35,062		37,778			
Caroline County	32,797		16,053	16,744	27,553	13,589	13,964		4,790		2,220		2,570			
Cecil County	99,368		49,014	50,354	92,038	45,496	46,542		5,902		2,851		3,051			
Dorchester County	31,845		15,093	16,752	22,515	10,811	11,704		8,947		4,104		4,843			
Kent County	19,879		9,508	10,371	16,458	7,951	8,507		3,221		1,442		1,779			
Queen Anne's County	46,515		23,081	23,434	42,037	20,921	21,116		3,855		1,868		1,987			
Somerset County	26,147		14,046	12,101	14,795	7,565	7,230		11,008		6,311		4,697			
Talbot County	36,132		17,254	18,878	30,546	14,636	15,910		5,147		2,403		2,744			
Wicomico County	93,218		44,521	48,697	68,640	33,006	35,634		22,672		10,535		12,137			
Worcester County	49,270		23,924	25,346	41,404	20,296	21,108		7,298		3,328		3,970			
National Capital Area	1,766,809		849,009	917,800	877,558	434,120	443,438		712,637		329,453		383,184			
Montgomery County	941,491		453,327	488,164	641,965	312,206	329,759		163,108		75,463		87,645			
Prince George's County	825,318		395,682	429,636	235,593	121,914	113,679		549,529		253,990		295,539			
Northwest Region	471,053		235,695	235,358	418,701	205,972	212,729		40,078		23,690		16,388			
Allegany County	72,603		36,708	35,895	67,126	32,645	34,481		4,830		3,736		1,094			
Frederick County	224,147		110,734	113,413	194,276	95,995	98,281		20,716		10,268		10,448			
Garrett County	29,641		14,617	15,024	29,275	14,408	14,867		271		165		106			
Washington County	144,662		73,636	71,026	128,024	62,924	65,100		14,261		9,521		4,740			
Southern Region	328,576		161,442	167,134	237,007	117,898	119,109		82,089		39,206		42,883			
Calvert County	88,145		43,379	44,766	73,652	36,506	37,146		12,850		6,131		6,719			
Charles County	140,169		68,133	72,036	81,134	40,125	41,009		53,965		25,666		28,299			
St Mary's County	100,262		49,930	50,332	82,221	41,267	40,954		15,274		7,409		7,865			

Source: SeerStat static data as of December 1, 2009 (www.seer.cancer.gov). Data are modified vintage 2008 population estimates produced by U.S. Census Bureau and National Center for Health Statistics. Estimates incorporate 2008 bridged single-race estimates for July 1, 2007. (refer to <http://seer.cancer.gov/popdata>)

Appendix F

U.S. Standard Population, 2000

**2000 U.S. Standard Population
(Census P25-1130)**

Age Group	2000 Population
Less than 01 years	3,794,901
01-04 years	15,191,619
05-09 years	19,919,840
10-14 years	20,056,779
15-19 years	19,819,518
20-24 years	18,257,225
25-29 years	17,722,067
30-34 years	19,511,370
35-39 years	22,179,956
40-44 years	22,479,229
45-49 years	19,805,793
50-54 years	17,224,359
55-59 years	13,307,234
60-64 years	10,654,272
65-69 years	9,409,940
70-74 years	8,725,574
75-79 years	7,414,559
80-84 years	4,900,234
85+ years	4,259,173
Total	274,633,642

Source: National Cancer Institute, SEER, 2000

Appendix G

Definitions of International Classification of Diseases (ICD) Codes Used for Cancer Incidence and Mortality

**International Classification of Diseases for Oncology, Third Edition (ICD-O-3) Codes
Used for Cancer Incidence and
International Classification of Diseases, 10th Revision (ICD-10) Codes
Used for Cancer Mortality**

Cancer Site	Incidence (ICD-O-3)		Mortality (ICD-10)
	Topography (Site)	Histology	
All Cancer Sites	C00.0 – C80.9	Includes all invasive cancers of all sites except basal and squamous cell skin cancers, and includes in situ cancer of the urinary bladder	C00 – C97
Lung and Bronchus	C34.0 - C34.9	Excludes codes 9050-9055, 9140, and 9590-9989	C34
Colon and Rectum	C18.0 – C20.9, C26.0	Excludes codes 9050-9055, 9140, and 9590-9989	C18 – C20, C26.0
Female Breast	C50.0 - C50.9 (female only)	Excludes codes 9050-9055, 9140, and 9590-9989	C50 (female only)
Prostate	C61.9	Excludes codes 9050-9055, 9140, and 9590-9990	C61
Oral Cavity and Pharynx	C00.0 - C14.8	Excludes codes 9050-9055, 9140, and 9590-9989	C00 – C14
Melanoma of the Skin	C44.0 - C44.9	Includes only codes 8720-8790	C43
Cervix	C53.0 - C53.9	Excludes codes 9050-9055, 9140, and 9590-9989	C53

Note: Most cancer mortality (ICD-10) codes are similar to cancer incidence (ICD-O-3) topography (site) codes.

Appendix H

Maryland Cancer Incidence and Mortality Rates by Geographical Area, 2003-2007

Appendix H

All Cancer Sites Incidence Age-Adjusted Incidence Rates by Geographical Area, Maryland, 2003-2007

Geographical Area	Incidence Rates*	95% Confidence Interval	
		Lower CI	Upper CI
Maryland	458.9	456.4	461.4
Northwest Region	490.6	481.8	499.6
Allegany	485.9	465.8	506.7
Frederick	519.0	504.7	533.7
Garrett	406.8	377.8	437.5
Washington	483.8	468.3	499.7
Baltimore Metropolitan Area ^	473.0	469.3	476.7
Anne Arundel	469.0	460.4	477.8
Baltimore City	461.4	454.0	468.9
Baltimore County	489.3	482.7	495.8
Carroll	497.4	482.2	513.0
Harford	488.7	475.8	501.8
Howard	431.3	419.0	443.9
National Capital Area †	410.7	406.3	415.2
Montgomery †	410.8	405.0	416.7
Prince George's †	408.7	401.8	415.7
Southern Region	460.2	448.6	472.0
Calvert	479.6	457.6	502.4
Charles	449.3	431.1	468.1
Saint Mary's	459.2	438.6	480.6
Eastern Shore Region	477.9	469.3	486.7
Caroline	490.4	457.4	525.3
Cecil	488.3	468.1	509.1
Dorchester	454.6	425.5	485.4
Kent	507.6	468.7	549.1
Queen Anne's	466.5	439.8	494.5
Somerset	487.3	450.8	526.1
Talbot	486.7	459.5	515.3
Wicomico	467.8	448.5	487.7
Worcester	488.0	464.6	512.3

* Rates are per 100,000 population and are age-adjusted to 2000 U.S. standard population

^ Area rate does not include Baltimore City

† 2003-2007 incidence rates for Montgomery County, Prince George's County, and the National Capital Area are lower than actual due to case underreporting in 2006. (See Appendix C, Section I.A.1.)

Source: Maryland Cancer Registry

Appendix H

Lung and Bronchus Cancer Incidence Age-Adjusted Incidence Rates by Geographical Area, Maryland, 2003-2007

Geographical Area	Incidence Rates*	95% Confidence Interval	
		Lower CI	Upper CI
Maryland	66.6	65.6	67.6
Northwest Region	72.6	69.3	76.2
Allegany	82.1	74.2	90.8
Frederick	74.8	69.3	80.6
Garrett	52.0	42.1	63.6
Washington	70.8	64.9	77.1
Baltimore Metropolitan Area ^	73.4	72.0	74.9
Anne Arundel	72.0	68.6	75.6
Baltimore City	82.2	79.1	85.4
Baltimore County	74.5	72.0	77.1
Carroll	72.5	66.7	78.8
Harford	75.7	70.6	81.0
Howard	51.8	47.4	56.6
National Capital Area †	47.4	45.9	49.0
Montgomery †	42.4	40.6	44.4
Prince George's †	53.9	51.3	56.5
Southern Region	70.4	65.7	75.3
Calvert	76.1	67.2	85.8
Charles	64.5	57.4	72.1
Saint Mary's	73.1	64.8	82.0
Eastern Shore Region	82.3	78.8	85.9
Caroline	92.0	77.9	107.8
Cecil	86.5	78.0	95.6
Dorchester	84.1	72.1	97.8
Kent	80.9	66.1	98.3
Queen Anne's	79.1	68.3	91.2
Somerset	101.6	85.4	120.1
Talbot	70.0	60.4	81.0
Wicomico	86.9	78.7	95.7
Worcester	74.2	65.7	83.7

* Rates are per 100,000 population and are age-adjusted to 2000 U.S. standard population

^ Area rate does not include Baltimore City

† 2003-2007 incidence rates for Montgomery County, Prince George's County, and the National Capital Area are lower than actual due to case underreporting in 2006. (See Appendix C, Section I.A.1.)

Source: Maryland Cancer Registry

Appendix H

Colorectal Cancer Incidence Age-Adjusted Incidence Rates by Geographical Area, Maryland, 2003-2007

Geographical Area	Incidence Rates*	95% Confidence Interval	
		Lower CI	Upper CI
Maryland	46.4	45.6	47.2
Northwest Region	51.1	48.3	54.1
Allegany	58.3	51.7	65.7
Frederick	53.1	48.5	58.0
Garrett	46.4	37.1	57.5
Washington	46.6	41.9	51.7
Baltimore Metropolitan Area ^	46.8	45.6	48.0
Anne Arundel	44.2	41.5	47.0
Baltimore City	49.0	46.6	51.4
Baltimore County	47.9	45.9	50.0
Carroll	50.8	45.9	56.0
Harford	45.6	41.6	49.8
Howard	42.8	38.9	47.0
National Capital Area †	41.1	39.7	42.6
Montgomery †	37.9	36.2	39.8
Prince George's †	45.1	42.8	47.6
Southern Region	54.9	50.8	59.2
Calvert	54.3	46.9	62.5
Charles	60.3	53.4	67.8
Saint Mary's	50.0	43.3	57.4
Eastern Shore Region	49.8	47.1	52.7
Caroline	51.1	40.9	63.1
Cecil	53.1	46.5	60.4
Dorchester	58.2	48.2	69.9
Kent	43.9	33.4	57.1
Queen Anne's	50.2	41.6	60.1
Somerset	51.3	39.9	64.9
Talbot	48.6	40.4	58.1
Wicomico	49.2	43.1	55.9
Worcester	45.8	39.0	53.6

* Rates are per 100,000 population and are age-adjusted to 2000 U.S. standard population

^ Area rate does not include Baltimore City

† 2003-2007 incidence rates for Montgomery County, Prince George's County, and the National Capital Area are lower than actual due to case underreporting in 2006. (See Appendix C, Section I.A.1.)

Source: Maryland Cancer Registry

Appendix H

Female Breast Cancer Incidence Age-Adjusted Incidence Rates by Geographical Area, Maryland, 2003-2007

Geographical Area	Incidence Rates*	95% Confidence Interval	
		Lower CI	Upper CI
Maryland	122.4	120.6	124.1
Northwest Region	126.3	120.2	132.6
Allegany	115.7	102.0	131.0
Frederick	139.5	129.8	149.8
Garrett	125.2	103.5	150.3
Washington	114.9	104.6	126.0
Baltimore Metropolitan Area ^	120.4	117.9	122.9
Anne Arundel	120.2	114.4	126.2
Baltimore City	102.8	98.2	107.5
Baltimore County	130.4	125.8	135.1
Carroll	133.9	123.5	145.0
Harford	113.2	105.1	121.8
Howard	129.6	121.0	138.6
National Capital Area †	122.1	119.0	125.3
Montgomery †	128.1	123.8	132.4
Prince George's †	114.0	109.4	118.7
Southern Region	111.4	104.0	119.1
Calvert	119.8	105.7	135.4
Charles	109.3	98.2	121.4
Saint Mary's	105.9	92.8	120.2
Eastern Shore Region	125.7	119.6	132.1
Caroline	143.5	119.6	171.0
Cecil	118.9	105.7	133.3
Dorchester	108.1	88.9	130.5
Kent	159.0	128.7	194.8
Queen Anne's	101.9	85.3	120.9
Somerset	106.9	83.4	135.2
Talbot	141.3	121.1	164.3
Wicomico	127.3	113.8	142.0
Worcester	139.1	121.6	158.7

* Rates are per 100,000 population and are age-adjusted to 2000 U.S. standard population

^ Area rate does not include Baltimore City

† 2003-2007 incidence rates for Montgomery County, Prince George's County, and the National Capital Area are lower than actual due to case underreporting in 2006. (See Appendix C, Section I.A.1.)

Source: Maryland Cancer Registry

Appendix H

Prostate Cancer Incidence Age-Adjusted Incidence Rates by Geographical Area, Maryland, 2003-2007

Geographical Area	Incidence Rates*	95% Confidence Interval	
		Lower CI	Upper CI
Maryland	157.6	155.4	159.9
Northwest Region	155.1	147.6	162.8
Allegany	133.5	118.4	150.1
Frederick	166.1	153.5	179.4
Garrett	127.0	104.4	153.4
Washington	165.7	152.2	180.0
Baltimore Metropolitan Area ^	152.2	149.0	155.5
Anne Arundel	148.2	141.0	155.7
Baltimore City	164.7	157.8	171.9
Baltimore County	150.8	145.4	156.4
Carroll	139.5	127.5	152.4
Harford	166.3	154.9	178.2
Howard	131.4	121.3	142.1
National Capital Area †	164.1	159.9	168.5
Montgomery †	157.0	151.6	162.6
Prince George's †	173.0	166.1	180.1
Southern Region	149.9	139.8	160.5
Calvert	124.1	107.1	143.0
Charles	168.5	151.1	187.2
Saint Mary's	151.2	133.7	170.3
Eastern Shore Region	144.5	137.6	151.7
Caroline	128.4	104.3	156.5
Cecil	139.7	124.1	156.7
Dorchester	126.4	104.7	151.6
Kent	185.1	152.9	222.6
Queen Anne's	155.0	133.6	179.0
Somerset	117.8	92.1	148.5
Talbot	171.5	148.9	196.9
Wicomico	132.4	117.2	149.0
Worcester	150.1	132.3	170.0

* Rates are per 100,000 population and are age-adjusted to 2000 U.S. standard population

^ Area rate does not include Baltimore City

† 2003-2007 incidence rates for Montgomery County, Prince George's County, and the National Capital Area are lower than actual due to case underreporting in 2006. (See Appendix C, Section I.A.1.)

Source: Maryland Cancer Registry

Appendix H

Oral Cancer Incidence Age-Adjusted Incidence Rates by Geographical Area, Maryland, 2003-2007

Geographical Area	Incidence Rates*	95% Confidence Interval	
		Lower CI	Upper CI
Maryland	9.6	9.3	10.0
Northwest Region	9.4	8.2	10.7
Allegany	10.6	7.7	14.1
Frederick	8.9	7.2	10.9
Garrett	**	**	**
Washington	9.6	7.5	12.1
Baltimore Metropolitan Area ^	10.2	9.6	10.7
Anne Arundel	11.0	9.7	12.4
Baltimore City	10.9	9.8	12.0
Baltimore County	9.7	8.8	10.7
Carroll	9.6	7.6	11.9
Harford	10.8	9.0	12.9
Howard	8.1	6.5	9.9
National Capital Area †	8.3	7.7	8.9
Montgomery †	8.2	7.4	9.0
Prince George's †	8.3	7.3	9.3
Southern Region	11.7	10.0	13.7
Calvert	11.9	8.8	15.7
Charles	10.5	8.0	13.5
Saint Mary's	13.1	9.9	17.0
Eastern Shore Region	10.2	8.9	11.5
Caroline	**	**	**
Cecil	11.5	8.7	15.0
Dorchester	**	**	**
Kent	13.8	8.4	21.9
Queen Anne's	10.7	7.0	15.6
Somerset	**	**	**
Talbot	10.9	7.1	16.2
Wicomico	9.3	6.8	12.6
Worcester	10.2	7.0	14.4

* Rates are per 100,000 population and are age-adjusted to 2000 U.S. standard population

** Rates based on case counts of 1-15 are suppressed per DHMH/MCR Data Use Policy

^ Area rate does not include Baltimore City

† 2003-2007 incidence rates for Montgomery County, Prince George's County, and the National Capital Area are lower than actual due to case underreporting in 2006. (See Appendix C, Section I.A.1.)

Source: Maryland Cancer Registry

Appendix H

Melanoma Incidence Age-Adjusted Incidence Rates by Geographical Area, Maryland, 2003-2007

Geographical Area	Incidence Rates*	95% Confidence Interval	
		Lower CI	Upper CI
Maryland	20.1	19.6	20.6
Northwest Region	21.9	20.1	23.9
Allegany	13.8	10.5	17.9
Frederick	24.1	21.2	27.3
Garrett	13.4	8.3	20.4
Washington	25.1	21.6	28.9
Baltimore Metropolitan Area ^	21.8	21.0	22.6
Anne Arundel	29.3	27.2	31.5
Baltimore City	8.3	7.3	9.4
Baltimore County	22.6	21.2	24.1
Carroll	28.9	25.4	32.8
Harford	29.4	26.4	32.8
Howard	26.6	23.8	29.7
National Capital Area †	13.3	12.5	14.1
Montgomery †	17.6	16.4	18.8
Prince George's †	8.0	7.0	9.0
Southern Region	24.8	22.2	27.5
Calvert	41.5	35.2	48.5
Charles	12.7	10.0	15.9
Saint Mary's	25.4	20.9	30.6
Eastern Shore Region	28.3	26.2	30.5
Caroline	22.7	15.9	31.3
Cecil	23.5	19.3	28.4
Dorchester	15.4	10.2	22.4
Kent	31.2	22.0	43.1
Queen Anne's	37.4	30.0	46.1
Somerset	25.6	17.7	35.9
Talbot	34.9	27.5	43.8
Wicomico	24.3	20.0	29.2
Worcester	39.9	33.2	47.8

* Rates are per 100,000 population and are age-adjusted to 2000 U.S. standard population

^ Area rate does not include Baltimore City

† 2003-2007 incidence rates for Montgomery County, Prince George's County, and the National Capital Area are lower than actual due to case underreporting in 2006. (See Appendix C, Section I.A.1.)

Source: Maryland Cancer Registry

Appendix H

Cervical Cancer Incidence Age-Adjusted Incidence Rates by Geographical Area, Maryland, 2003-2007

Geographical Area	Incidence Rates*	95% Confidence Interval	
		Lower CI	Upper CI
Maryland	7.6	7.2	8.1
Northwest Region	8.0	6.4	9.7
Allegany	11.1	6.8	17.1
Frederick	9.0	6.7	11.9
Garrett	**	**	**
Washington	6.0	3.8	9.1
Baltimore Metropolitan Area ^	7.7	7.0	8.4
Anne Arundel	6.7	5.4	8.2
Baltimore City	10.3	8.9	12.0
Baltimore County	8.0	6.9	9.3
Carroll	5.4	3.4	8.1
Harford	5.7	4.0	7.9
Howard	5.8	4.1	8.0
National Capital Area †	7.5	6.7	8.3
Montgomery †	8.1	7.0	9.3
Prince George's †	6.9	5.8	8.2
Southern Region	7.6	5.8	9.8
Calvert	8.6	5.1	13.7
Charles	6.8	4.2	10.3
Saint Mary's	8.3	5.0	12.8
Eastern Shore Region	7.6	6.1	9.4
Caroline	**	**	**
Cecil	9.7	6.2	14.5
Dorchester	**	**	**
Kent	**	**	**
Queen Anne's	**	**	**
Somerset	**	**	**
Talbot	**	**	**
Wicomico	6.7	3.8	10.9
Worcester	**	**	**

* Rates are per 100,000 population and are age-adjusted to 2000 U.S. standard population

** Rates based on case counts of 1-15 are suppressed per DHMH/MCR Data Use Policy

^ Area rate does not include Baltimore City

† 2003-2007 incidence rates for Montgomery County, Prince George's County, and the National Capital Area are lower than actual due to case underreporting in 2006. (See Appendix C, Section I.A.1.)

Source: Maryland Cancer Registry

Appendix H

All Cancer Sites Mortality Age-Adjusted Mortality Rates by Geographical Area, Maryland, 2003-2007

Geographical Area	Mortality Rates*	95% Confidence Interval	
		Lower CI	Upper CI
Maryland	188.5	186.8	190.1
Northwest Region	189.1	183.6	194.6
Allegany	196.0	183.5	208.6
Frederick	188.5	179.6	197.4
Garrett	172.1	153.1	191.1
Washington	194.8	185.0	204.7
Baltimore Metropolitan Area ^	189.1	186.4	191.8
Anne Arundel	203.1	197.1	209.0
Baltimore City	233.2	227.9	238.5
Baltimore County	193.2	189.2	197.3
Carroll	188.5	178.9	198.2
Harford	193.9	185.4	202.3
Howard	143.4	135.8	151.0
National Capital Area	160.2	157.3	163.0
Montgomery	135.8	132.5	139.2
Prince George's	194.9	189.9	200.0
Southern Region	215.9	207.5	224.2
Calvert	215.0	199.4	230.5
Charles	220.0	206.4	233.6
Saint Mary's	213.0	198.4	227.7
Eastern Shore Region	209.4	203.7	215.1
Caroline	225.6	202.9	248.3
Cecil	216.4	202.6	230.3
Dorchester	202.4	183.0	221.7
Kent	208.2	184.1	232.3
Queen Anne's	206.9	188.7	225.2
Somerset	238.7	212.7	264.7
Talbot	177.3	161.7	193.0
Wicomico	223.3	209.8	236.7
Worcester	200.6	185.9	215.2

* Rates are per 100,000 population and are age-adjusted to 2000 U.S. standard population

^ Area rate does not include Baltimore City

Source: NCHS Compressed Mortality File in CDC WONDER (mortality rates)

Appendix H

Lung and Bronchus Cancer Mortality Age-Adjusted Mortality Rates by Geographical Area, Maryland, 2003-2007

Geographical Area	Mortality Rates*	95% Confidence Interval	
		Lower CI	Upper CI
Maryland	53.5	52.7	54.4
Northwest Region	54.6	51.6	57.6
Allegany	61.6	54.6	68.5
Frederick	49.9	45.3	54.5
Garrett	45.2	36.1	55.9
Washington	59.9	54.4	65.4
Baltimore Metropolitan Area ^	55.4	53.9	56.8
Anne Arundel	61.7	58.4	64.9
Baltimore City	72.4	69.4	75.3
Baltimore County	56.3	54.1	58.5
Carroll	55.4	50.2	60.6
Harford	59.8	55.2	64.4
Howard	34.9	31.1	38.6
National Capital Area	38.3	36.9	39.6
Montgomery	30.6	29.0	32.2
Prince George's	49.0	46.4	51.5
Southern Region	64.3	59.7	68.8
Calvert	60.6	52.3	68.9
Charles	67.0	59.5	74.5
Saint Mary's	64.7	56.6	72.8
Eastern Shore Region	66.2	63.0	69.4
Caroline	75.9	62.8	89.1
Cecil	69.1	61.3	76.9
Dorchester	66.0	55.0	77.0
Kent	57.7	45.5	72.1
Queen Anne's	65.1	55.0	75.3
Somerset	84.4	69.0	99.8
Talbot	52.6	44.0	61.1
Wicomico	75.1	67.3	82.9
Worcester	57.3	49.7	65.0

* Rates are per 100,000 population and are age-adjusted to 2000 U.S. standard population

^ Area rate does not include Baltimore City

Source: NCHS Compressed Mortality File in CDC WONDER (mortality rates)

Appendix H

Colorectal Cancer Mortality Age-Adjusted Mortality Rates by Geographical Area, Maryland, 2003-2007

Geographical Area	Mortality Rates*	95% Confidence Interval	
		Lower CI	Upper CI
Maryland	18.6	18.1	19.1
Northwest Region	18.1	16.4	19.8
Allegany	18.8	15.1	23.2
Frederick	20.0	17.1	22.9
Garrett	13.8	9.0	20.3
Washington	17.1	14.2	20.0
Baltimore Metropolitan Area ^	18.5	17.7	19.4
Anne Arundel	19.6	17.7	21.4
Baltimore City	22.8	21.2	24.5
Baltimore County	19.0	17.8	20.3
Carroll	22.3	19.0	25.7
Harford	16.1	13.7	18.6
Howard	15.2	12.7	17.7
National Capital Area	15.7	14.8	16.6
Montgomery	12.3	11.3	13.3
Prince George's	20.9	19.3	22.6
Southern Region	25.8	22.9	28.8
Calvert	25.7	20.5	31.6
Charles	31.0	25.8	36.3
Saint Mary's	19.8	15.6	24.9
Eastern Shore Region	20.2	18.4	21.9
Caroline	19.2	13.1	27.1
Cecil	21.8	17.6	26.7
Dorchester	25.1	18.6	33.0
Kent	22.1	14.7	32.0
Queen Anne's	22.2	16.6	29.1
Somerset	13.9	8.4	21.7
Talbot	15.9	11.6	21.3
Wicomico	23.8	19.4	28.2
Worcester	16.1	12.3	20.7

* Rates are per 100,000 population and are age-adjusted to 2000 U.S. standard population

^ Area rate does not include Baltimore City

Source: NCHS Compressed Mortality File in CDC WONDER (mortality rates)

Appendix H

Female Breast Cancer Mortality Age-Adjusted Mortality Rates by Geographical Area, Maryland, 2003-2007

Geographical Area	Mortality Rates*	95% Confidence Interval	
		Lower CI	Upper CI
Maryland	25.9	25.1	26.7
Northwest Region	25.8	23.1	28.5
Allegany	25.6	19.8	32.6
Frederick	25.0	20.8	29.2
Garrett	36.7	25.3	51.6
Washington	25.0	20.2	29.7
Baltimore Metropolitan Area ^	24.8	23.5	26.1
Anne Arundel	26.1	23.4	28.9
Baltimore City	31.0	28.5	33.5
Baltimore County	25.4	23.4	27.4
Carroll	25.5	20.8	30.1
Harford	24.9	21.0	28.8
Howard	18.8	15.3	22.2
National Capital Area	24.6	23.2	26.1
Montgomery	20.3	18.6	22.0
Prince George's	30.4	27.9	32.8
Southern Region	29.5	25.5	33.4
Calvert	34.0	26.5	43.1
Charles	29.4	23.6	36.3
Saint Mary's	24.8	18.7	32.4
Eastern Shore Region	25.6	22.9	28.4
Caroline	24.1	15.3	36.1
Cecil	25.1	19.2	32.1
Dorchester	15.4	9.0	24.6
Kent	24.7	15.1	38.1
Queen Anne's	31.2	22.3	42.5
Somerset	34.1	21.6	51.1
Talbot	20.7	13.5	30.3
Wicomico	28.8	22.7	36
Worcester	26.7	19.7	35.4

* Rates are per 100,000 population and are age-adjusted to 2000 U.S. standard population

^ Area rate does not include Baltimore City

Source: NCHS Compressed Mortality File in CDC WONDER (mortality rates)

Appendix H

Prostate Cancer Mortality Age-Adjusted Mortality Rates by Geographical Area, Maryland, 2003-2007

Geographical Area	Mortality Rates*	95% Confidence Interval	
		Lower CI	Upper CI
Maryland	27.3	26.3	28.4
Northwest Region	25.1	21.8	28.4
Allegany	26.0	19.5	34.2
Frederick	25.7	20.4	32.0
Garrett	24.5	14.7	38.2
Washington	24.1	18.9	30.4
Baltimore Metropolitan Area ^	24.9	23.2	26.5
Anne Arundel	25.5	21.8	29.2
Baltimore City	37.3	33.7	40.8
Baltimore County	25.0	22.7	27.3
Carroll	24.9	19.3	31.7
Harford	24.8	19.8	30.7
Howard	24.0	18.7	30.4
National Capital Area	25.9	23.9	27.8
Montgomery	19.8	17.7	21.9
Prince George's	37.0	32.9	41.0
Southern Region	37.1	31	43.2
Calvert	40.1	29.4	53.5
Charles	32.4	23.6	43.3
Saint Mary's	38.9	28.9	51.3
Eastern Shore Region	27.4	24.1	30.7
Caroline	33.7	21.1	51.1
Cecil	29.1	20.8	39.6
Dorchester	**	**	**
Kent	34.1	21.4	51.7
Queen Anne's	18.5	11.0	29.2
Somerset	43.6	27	66.7
Talbot	26.4	18.4	36.7
Wicomico	25.7	18.8	34.3
Worcester	27.9	20.4	37.4

* Rates are per 100,000 population and are age-adjusted to 2000 U.S. standard population

^ Area rate does not include Baltimore City

** Rates based on death counts of 0-15 deaths are suppressed per DHMH/CCSC Mortality

Data Suppression Policy

Source: NCHS Compressed Mortality File in CDC WONDER (mortality rates)

Appendix H

Oral Cancer Mortality Age-Adjusted Mortality Rates by Geographical Area, Maryland, 2003-2007

Geographical Area	Mortality Rates*	95% Confidence Interval	
		Lower CI	Upper CI
Maryland	2.6	2.4	2.8
Northwest Region	2.2	1.6	2.8
Allegany	**	**	**
Frederick	**	**	**
Garrett	**	**	**
Washington	3.2	2.0	4.7
Baltimore Metropolitan Area ^	2.5	2.2	2.8
Anne Arundel	3.0	2.3	3.7
Baltimore City	4.4	3.7	5.1
Baltimore County	2.7	2.2	3.1
Carroll	**	**	**
Harford	2.8	1.9	4.0
Howard	1.9	1.1	2.9
National Capital Area	1.9	1.6	2.2
Montgomery	1.6	1.2	2.0
Prince George's	2.4	1.9	3.0
Southern Region	2.8	1.9	3.9
Calvert	**	**	**
Charles	3.5	2.0	5.7
Saint Mary's	**	**	**
Eastern Shore Region	3.1	2.4	3.9
Caroline	**	**	**
Cecil	4.0	2.4	6.3
Dorchester	**	**	**
Kent	**	**	**
Queen Anne's	**	**	**
Somerset	**	**	**
Talbot	**	**	**
Wicomico	**	**	**
Worcester	**	**	**

* Rates are per 100,000 population and are age-adjusted to 2000 U.S. standard population

^ Area rate does not include Baltimore City

** Rates based on death counts of 0-15 deaths are suppressed per DHMH/CCSC Mortality Data Suppression Policy

Source: NCHS Compressed Mortality File in CDC WONDER (mortality rates)

Appendix H

Melanoma Mortality Age-Adjusted Mortality Rates by Geographical Area, Maryland, 2003-2007

Geographical Area	Mortality Rates*	95% Confidence Interval	
		Lower CI	Upper CI
Maryland	2.7	2.5	2.9
Northwest Region	3.4	2.7	4.2
Allegany	3.9	2.3	6.3
Frederick	3.7	2.6	5.1
Garrett	**	**	**
Washington	3.1	2.0	4.6
Baltimore Metropolitan Area ^	3.1	2.8	3.5
Anne Arundel	3.9	3.1	4.8
Baltimore City	1.8	1.4	2.4
Baltimore County	3.0	2.5	3.5
Carroll	2.9	1.9	4.3
Harford	3.2	2.3	4.5
Howard	2.2	1.4	3.2
National Capital Area	1.9	1.6	2.3
Montgomery	2.2	1.7	2.6
Prince George's	1.7	1.2	2.2
Southern Region	2.8	2.0	3.9
Calvert	**	**	**
Charles	**	**	**
Saint Mary's	**	**	**
Eastern Shore Region	3.9	3.1	4.8
Caroline	**	**	**
Cecil	**	**	**
Dorchester	**	**	**
Kent	**	**	**
Queen Anne's	**	**	**
Somerset	**	**	**
Talbot	**	**	**
Wicomico	4.0	2.4	6.3
Worcester	5.2	3.0	8.3

* Rates are per 100,000 population and are age-adjusted to 2000 U.S. standard population

^ Area rate does not include Baltimore City

** Rates based on death counts of 0-15 deaths are suppressed per DHMH/CCSC Mortality Data Suppression Policy

Source: NCHS Compressed Mortality File in CDC WONDER (mortality rates)

Appendix H

Cervical Cancer Mortality Age-Adjusted Mortality Rates by Geographical Area, Maryland, 2003-2007

Geographical Area	Mortality Rates*	95% Confidence Interval	
		Lower CI	Upper CI
Maryland	2.2	2.0	2.5
Northwest Region	2.3	1.5	3.3
Allegany	**	**	**
Frederick	**	**	**
Garrett	**	**	**
Washington	**	**	**
Baltimore Metropolitan Area ^	1.9	1.5	2.3
Anne Arundel	2.1	1.4	3.1
Baltimore City	4.5	3.6	5.6
Baltimore County	2.0	1.5	2.7
Carroll	**	**	**
Harford	2.6	1.5	4.2
Howard	**	**	**
National Capital Area	1.9	1.5	2.4
Montgomery	1.5	1.1	2.1
Prince George's	2.5	1.9	3.3
Southern Region	**	**	**
Calvert	**	**	**
Charles	**	**	**
Saint Mary's	**	**	**
Eastern Shore Region	1.6	1.0	2.5
Caroline	**	**	**
Cecil	**	**	**
Dorchester	**	**	**
Kent	**	**	**
Queen Anne's	**	**	**
Somerset	**	**	**
Talbot	**	**	**
Wicomico	**	**	**
Worcester	**	**	**

* Rates are per 100,000 population and are age-adjusted to 2000 U.S. standard population

^ Area rate does not include Baltimore City

** Rates based on death counts of 0-15 deaths are suppressed per DHMH/CCSC Mortality Data Suppression Policy

Source: NCHS Compressed Mortality File in CDC WONDER (mortality rates)

Appendix I

Trends in Cancer Incidence and Mortality Rates in Maryland by Cancer Site, Race, and Year, 2003-2007

Appendix I

**Table 1: Cancer Incidence Rates, by Cancer Site and Year
Maryland, 2003-2007**

Cancer Site	2003	2004	2005	2006 †	2007	APC 2003-2007	MD Trend
All Cancer Sites	494.4	462.6	457.4	426.3	455.3	-2.4%	↓
Lung	70.7	69.1	68.0	63.4	62.5	-3.3%	↓
Colorectal	54.6	48.7	46.3	41.3	41.6	-6.8%	↓
Female Breast	133.4	124.2	118.6	112.8	123.2	-2.5%	↓
Prostate	176.7	148.0	147.2	153.9	162.5	-1.3%	↓
Oral	11.7	9.4	8.8	8.9	9.6	-4.4%	↓
Melanoma	19.4	18.7	21.3	19.7	21.2	2.3%	↑
Cervical	9.3	7.5	8.5	6.7	6.4	-8.2%	↓

† 2006 Maryland incidence rates are lower than actual due to case underreporting for Montgomery and

Prince George's counties. (See Appendix C, Section I.A.1.)

Rates are age-adjusted to 2000 U.S. standard population

APC = Annual Percent Change (%)

Source: Maryland Cancer Registry (incidence rates)

**Table 2: Cancer Mortality Rates, by Cancer Site and Year
Maryland, 2003-2007**

Cancer Site	2003	2004	2005	2006	2007	APC 2003-2007	MD Trend
All Cancer Sites	195.7	189.9	190.2	186.7	180.4	-1.8%	↓
Lung	57.3	53.0	54.9	52.6	50.1	-2.7%	↓
Colorectal	19.5	19.1	18.7	18.4	17.5	-2.5%	↓
Female Breast	26.8	27.1	25.8	25.0	24.8	-2.3%	↓
Prostate	29.1	28.8	25.9	26.3	26.6	-2.7%	↓
Oral	2.4	2.5	2.7	2.8	2.5	2.0%	↑
Melanoma	2.5	2.7	2.8	3.0	2.4	0.2%	↑
Cervical	2.1	2.5	2.0	2.2	2.4	1.4%	↑

Rates are age-adjusted to 2000 U.S. standard population

APC = Annual Percent Change (%)

Source: NCHS Compressed Mortality File in CDC WONDER (mortality rates)

Appendix I

**Table 3: Incidence Rates by Race and Year
Maryland, 2003-2007**

Cancer Site	Race	2003	2004	2005	2006 †	2007	APC 2003-2007
All cancer sites	White	489.2	469.8	466.4	434.3	460.5	-2.0%
	Black	495.0	444.4	434.9	395.7	444.0	-3.3%
Lung	White	71.2	71.1	69.5	67.1	64.3	-2.6%
	Black	73.6	67.7	66.2	55.3	60.3	-5.8%
Colorectal	White	51.5	46.1	45.5	40.2	40.6	-5.9%
	Black	62.9	55.8	49.4	42.7	44.8	-9.0%
Female breast	White	136.3	127.4	121.1	115.0	125.4	-2.7%
	Black	118.6	114.0	108.7	109.7	117.2	-0.6%
Prostate	White	150.2	132.0	131.7	137.3	146.5	-0.1%
	Black	241.2	202.7	193.3	186.3	209.0	-3.6%
Oral	White	11.8	9.7	9.1	9.4	10.0	-3.6%
	Black	11.4	8.3	8.4	7.6	8.1	-7.4%
Cervix	White	8.4	6.7	7.8	5.8	6.2	-7.2%
	Black	10.7	10.1	9.1	7.1	7.2	-10.8%

**Table 4: Melanoma Incidence Rates by Gender and Year
Maryland, 2003-2007**

Cancer Site	Gender	2003	2004	2005	2006 †	2007	APC 2003-2007
Melanoma	Male	24.1	24.1	27.9	26.0	27.2	3.2%
	Female	16.0	14.9	16.8	15.3	17.1	1.6%

† 2006 Maryland incidence rates are lower than actual due to case underreporting for Montgomery and Prince George's counties. (See Appendix C, Section I.A.1.)

Rates are age-adjusted to 2000 U.S. standard population

APC = Annual Percent Change (%)

Source: Maryland Cancer Registry (incidence rates)

Appendix I

**Table 5: Mortality Rates by Race and Year
Maryland, 2003-2007**

Cancer Site	Race	2003	2004	2005	2006	2007	APC 2003-2007
All Cancer Sites	White	189.8	185.5	187.6	183.6	176.6	-1.5%
	Black	228.4	218.9	210.4	211.1	207.7	-2.2%
Lung	White	56.5	53.3	55.9	53.7	51.4	-1.8%
	Black	64.3	57.6	55.5	53.2	51.2	-5.2%
Colorectal	White	17.9	17.9	17.5	17.6	15.7	-2.8%
	Black	26.7	25.0	24.9	22.7	24.1	-3.0%
Female Breast	White	24.4	25.6	24.9	23.7	22.8	-2.1%
	Black	34.9	32.9	28.8	30.2	32.4	-2.3%
Prostate	White	24.7	24.1	21.1	21.7	23.0	-2.4%
	Black	53.2	53.7	48.8	51.1	45.3	-3.6%
Oral	White	2.4	2.3	2.5	2.6	2.5	2.1%
	Black	2.9	3.0	3.5	3.7	2.8	1.4%
Cervix	White	1.5	2.2	1.5	1.7	1.7	-0.1%
	Black	3.6	3.9	3.2	3.6	4.3	2.8%

**Table 6: Melanoma Mortality Rates by Gender and Year
Maryland, 2003-2007**

Cancer Site	Gender	2003	2004	2005	2006	2007	APC 2003-2007
Melanoma	Male	3.7	3.9	4.2	4.8	3.5	1.0%
	Female	1.6	1.8	1.8	1.8	1.8	2.4%

Rates are age-adjusted to 2000 U.S. standard population

APC = Annual Percent Change (%)

Source: NCHS Compressed Mortality File in CDC WONDER (mortality rates)

Appendix J

Trends in Cancer Stage of Disease at Diagnosis in Maryland by Cancer Site and Year, 2003-2007

Appendix J

Table 1: All Cancer Sites
Distribution of Cancer Stage at Diagnosis, by Year
Maryland, 2003-2007

Stage					
	2003	2004	2005	2006	2007
	%	%	%	%	%
Local	43.2	42.0	42.5	42.9	45.9
Regional	20.7	19.5	20.1	20.8	21.1
Distant	18.3	19.9	20.2	20.5	20.9
Unstaged	17.8	18.5	17.3	15.8	12.1

Source: Maryland Cancer Registry

Table 2: Lung Cancer
Distribution of Cancer Stage at Diagnosis, by Year
Maryland, 2003-2007

Stage					
	2003	2004	2005	2006	2007
	%	%	%	%	%
Local	19.4	16.8	18.5	17.1	18.7
Regional	26.4	23.1	23.9	23.8	23.7
Distant	39.8	43.1	44.1	45.6	47.8
Unstaged	14.3	17.1	13.5	13.5	9.8

Source: Maryland Cancer Registry

Table 3: Colorectal Cancer
Distribution of Cancer Stage at Diagnosis, by Year
Maryland, 2003-2007

Stage					
	2003	2004	2005	2006	2007
	%	%	%	%	%
Local	31.6	35.0	37.0	35.7	39.3
Regional	37.9	29.2	31.6	33.1	32.8
Distant	17.3	19.0	17.9	17.7	18.1
Unstaged	13.2	16.8	13.5	13.5	9.8

Source: Maryland Cancer Registry

Table 4: Breast Cancer
Distribution of Cancer Stage at Diagnosis, by Year
Maryland, 2003-2007

Stage					
	2003	2004	2005	2006	2007
	%	%	%	%	%
Local	55.6	54.0	54.9	57.1	58.4
Regional	29.3	31.9	31.2	31.9	31.6
Distant	4.5	4.8	4.7	5.0	5.8
Unstaged	10.7	9.3	9.2	6.0	4.2

Source: Maryland Cancer Registry

Appendix J

Table 5: Prostate Cancer
Distribution of Cancer Stage at Diagnosis, by Year
Maryland, 2003-2007

Stage					
	2003	2004	2005	2006	2007
	%	%	%	%	%
Local	73.6	72.8	70.1	64.7	69.1
Regional	6.9	7.8	7.2	8.3	10.0
Distant	2.7	2.9	2.9	2.9	2.7
Unstaged	16.8	16.5	19.8	24.1	18.1

Source: Maryland Cancer Registry

Table 6: Oral Cancer
Distribution of Cancer Stage at Diagnosis, by Year
Maryland, 2003-2007

Stage					
	2003	2004	2005	2006	2007
	%	%	%	%	%
Local	31.9	28.8	28.3	28.1	27.3
Regional	47.4	42.5	44.2	44.4	47.4
Distant	5.4	12.7	15.7	17.9	17.0
Unstaged	15.3	15.9	11.8	9.6	8.4

Source: Maryland Cancer Registry

Table 7: Melanoma
Distribution of Cancer Stage at Diagnosis, by Year
Maryland, 2003-2007

Stage					
	2003	2004	2005	2006	2007
	%	%	%	%	%
Local	56.7	57.5	57.7	59.1	68.4
Regional	7.2	7.9	8.2	9.7	9.2
Distant	3.9	3.3	2.8	3.7	3.6
Unstaged	32.2	31.4	31.3	27.5	18.8

Source: Maryland Cancer Registry

Table 8: Cervical Cancer
Distribution of Cancer Stage at Diagnosis, by Year
Maryland, 2003-2007

Stage					
	2003	2004	2005	2006	2007
	%	%	%	%	%
Local	44.6	38.5	36.6	34.2	38.1
Regional	21.0	32.3	31.1	36.7	34.5
Distant	7.3	10.6	9.8	11.1	16.0
Unstaged	27.2	18.6	22.4	18.1	11.3

Source: Maryland Cancer Registry

For comments or questions about this report contact:

Surveillance and Evaluation Unit
Center for Cancer Surveillance and Control
Maryland Department of Health and Mental Hygiene
Room 406-A
201 West Preston Street
Baltimore, Maryland 21201

410-767-0791
FAX: 410-333-5210